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A B S T R A C T
Background
Iodine is an essential nutrient required for the biosynthesis of thyroid hormones, which are responsible for regulating growth, development
and metabolism. Iodine requirements increase substantially during pregnancy and breastfeeding. If requirements are not met during
these periods, the production of thyroid hormones may decrease and be inadequate for maternal, fetal and infant needs. The provision
of iodine supplements may help meet the increased iodine needs during pregnancy and the postpartum period and prevent or correct
iodine deficiency and its consequences.
Objectives
To assess the benefits and harms of supplementation with iodine, alone or in combination with other vitamins and minerals, for women
in the preconceptional, pregnancy or postpartum period on their and their children's outcomes.
Search methods
We searched Cochrane Pregnancy and Childbirth's Trials Register (14 November 2016), and the WHO International Clinical Trials Registry
Platform (ICTRP) (17 November 2016), contacted experts in the field and searched the reference lists of retrieved studies and other relevant
papers.
Selection criteria
Randomized and quasi-randomized controlled trials with randomisation at either the individual or cluster level comparing injected or
oral iodine supplementation (such as tablets, capsules, drops) during preconception, pregnancy or the postpartum period irrespective of
iodine compound, dose, frequency or duration.
Data collection and analysis
Two review authors independently assessed trial eligibility, risk of bias, extracted data and conducted checks for accuracy. We used the
GRADE approach to assess the quality of the evidence for primary outcomes.
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We anticipated high heterogeneity among trials, and we pooled trial results using random-eAects models and were cautious in our
interpretation of the pooled results.
Main results
We included 14 studies and excluded 48 studies. We identified five ongoing or unpublished studies and two studies are awaiting
classification. Eleven trials involving over 2700 women contributed data for the comparisons in this review (in three trials, the primary or
secondary outcomes were not reported).
Maternal primary outcomes
Iodine supplementation decreased the likelihood of the adverse eAect of postpartum hyperthyroidism by 68% (average risk ratio (RR) 0.32;
95% confidence interval (CI) 0.11 to 0.91, three trials in mild to moderate iodine deficiency settings, 543 women, no statistical heterogeneity,
low-quality evidence) and increased the likelihood of the adverse eAect of digestive intolerance in pregnancy by 15 times (average RR
15.33; 95% CI 2.07 to 113.70, one trial in a mild-deficiency setting, 76 women, very low-quality evidence).
There were no clear diAerences between groups for hypothyroidism in pregnancy or postpartum (pregnancy: average RR 1.90; 95% CI
0.57 to 6.38, one trial, 365 women, low-quality evidence, and postpartum: average RR 0.44; 95% CI 0.06 to 3.42, three trials, 540 women,
no statistical heterogeneity, low-quality evidence), preterm birth (average RR 0.71; 95% CI 0.30 to 1.66, two trials, 376 women, statistical
heterogeneity, low-quality evidence) or the maternal adverse eAects of elevated thyroid peroxidase antibodies (TPO-ab) in pregnancy or
postpartum (average RR 0.95; 95% CI 0.44 to 2.07, one trial, 359 women, low-quality evidence, average RR 1.01; 95% CI 0.78 to 1.30, three
trials, 397 women, no statistical heterogeneity, low-quality evidence), or hyperthyroidism in pregnancy (average RR 1.90; 95% CI 0.57 to
6.38, one trial, 365 women, low-quality evidence). All of the trials contributing data to these outcomes took place in settings with mild to
moderate iodine deficiency.
Infant/child primary outcomes
Compared with those who did not receive iodine, those who received iodine supplements had a 34% lower likelihood of perinatal mortality,
however this diAerence was not statistically significant (average RR 0.66; 95% CI 0.42 to 1.03, two trials, 457 assessments, low-quality
evidence). All of the perinatal deaths occurred in one trial conducted in a severely iodine-deficient setting. There were no clear diAerences
between groups for low birthweight (average RR 0.56; 95% CI 0.26 to 1.23, two trials, 377 infants, no statistical heterogeneity, low-quality
evidence), neonatal hypothyroidism/elevated thyroid-stimulating hormone (TSH) (average RR 0.58; 95% CI 0.11 to 3.12, two trials, 260
infants, very low-quality evidence) or the adverse eAect of elevated neonatal thyroid peroxidase antibodies (TPO-ab) (average RR 0.61; 95%
CI 0.07 to 5.70, one trial, 108 infants, very low-quality evidence). All of the trials contributing data to these outcomes took place in areas with
mild to moderate iodine deficiency. No trials reported on hypothyroidism/elevated TSH or any adverse eAect beyond the neonatal period.
Authors' conclusions
There were insuAicient data to reach any meaningful conclusions on the benefits and harms of routine iodine supplementation in women
before, during or aPer pregnancy. The available evidence suggested that iodine supplementation decreases the likelihood of postpartum
hyperthyroidism and increases the likelihood of the adverse eAect of digestive intolerance in pregnancy - both considered potential
adverse eAects. We considered evidence for these outcomes low or very low quality, however, because of study design limitations and
wide confidence intervals. In addition, due to the small number of trials and included women in our meta-analyses, these findings must
be interpreted with caution. There were no clear eAects on other important maternal or child outcomes though these findings must also
be interpreted cautiously due to limited data and low-quality trials. Additionally, almost all of the evidence came from settings with mild
or moderate iodine deficiency and therefore may not be applicable to settings with severe deficiency.
More high-quality randomised controlled trials are needed on iodine supplementation before, during and aPer pregnancy on maternal
and infant/child outcomes. However, it may be unethical to compare iodine to placebo or no treatment in severe deficiency settings. Trials
may also be unfeasible in settings where pregnant and lactating women commonly take prenatal supplements with iodine. Information
is needed on optimal timing of initiation as well as supplementation regimen and dose. Future trials should consider the outcomes in
this review and follow children beyond the neonatal period. Future trials should employ adequate sample sizes, assess potential adverse
eAects (including the nature and extent of digestive intolerance), and be reported in a way that allows assessment of risk of bias, full data
extraction and analysis by the subgroups specified in this review.
P L A I N   L A N G U A G E   S U M M A R Y
Iodine supplementation for women before, during or a6er pregnancy
What is the issue?
It is estimated that over 1.8 billion people worldwide do not get enough iodine in their diet, putting them at risk of iodine deficiency.
Iodine is an essential nutrient needed in small amounts for the body to make thyroid hormones. The World Health Organization (WHO)
recommends that iodine is added to salt to prevent problems caused by lack of iodine. Women who are pregnant or breastfeeding need
extra iodine, which puts them at greater risk of deficiency. The breast milk contains iodine for the infant.
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Why is this important?
Thyroid function is increased during pregnancy as thyroid hormones produced by the mother (and the baby as the pregnancy progresses)
are essential for growth and development of the baby and to regulate the development of the brain and nervous system. Nervous tissue
begins to develop as early as the second month of pregnancy. If women have too little iodine during pregnancy or infants have too
little during early childhood, the damage may be irreversible. Research has shown that severe iodine deficiency can stunt children's
normal physical growth as well as harm normal mental development, resulting in lower intelligence quotients. Less is known about the
consequences of mild or moderate deficiency. Too much iodine can also cause harm and have negative eAects on mothers and babies, for
example by causing the thyroid to become overactive.
Although salt is the commonly the main source of iodine, expert medical groups recommend that women in many countries take iodine
supplements during and following pregnancy to help ensure their iodine needs are met.
What evidence did we find?
We searched for evidence in November 2016 and identified 14 randomised controlled trials of iodine supplements in the form of tablets,
capsules, drops or injections before, during or aPer pregnancy. Eleven trials with over 2700 women contributed findings to the review. Eight
trials compared iodine with no treatment or a placebo and three trials compared iodine given with other vitamins and minerals against
only the vitamins and minerals.
Women who received iodine supplements were less likely to develop the unwanted eAect of hyperthyroidism (an overactive thyroid gland)
aPer giving birth (three trials involving 543 women) but they were more likely to experience nausea or vomiting during pregnancy (one trial
involving 76 women) when compared to those who did not receive iodine. One trial (365 women) did not find any diAerence in the number
of women with an overactive thyroid gland during pregnancy. The number of women with an underactive thyroid gland (hypothyroidism)
was not clearly diAerent either during pregnancy (one trial involving 365 women) or aPer giving birth (three trials involving 540 women)
when iodine supplements were given. A similar number of women had raised thyroid antibodies during pregnancy (one trial, 359 women)
and aPer giving birth (three trials, 397 women). We found no clear diAerences between women given iodine supplements and those not
when looking at preterm births (two trials, 376 women) or deaths around the time of giving birth (two trials, 457 women), babies born with
a low birthweight (two trials, 377 babies), newborn babies with an underactive thyroid gland (two trials, 260 babies) or with raised thyroid
antibodies (one trial, 108 babies).
The quality of the evidence was low to very low, mostly because few trials looked at each outcome or because of limitations in the study
designs. Most of the findings were from one or two trials and small numbers of women were included. This means we are not confident
in the results.
What does this mean?
The potential benefits and harms of any intervention must be weighed as part of deciding whether to use it. Our Cochrane Review provides
a summary of the evidence but there were not enough data for any meaningful conclusions on the benefits and harms of routine iodine
supplementation in women before, during or aPer pregnancy. The limited information we found suggests there are benefits and risks
of iodine supplementation. More research will clarify the eAects and safety of this intervention. Future research should use randomised
controlled trial designs where practical and ethical, and include the outcomes from this review.
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Summary of findings for the main comparison.   Any supplement containing iodine versus same supplement without iodine or no treatment/placebo
(maternal outcomes)
Any supplement containing iodine versus same supplement without iodine or no treatment/placebo (maternal outcomes)
Population: women during the preconception, pregnancy and postpartum period
Setting: Denmark, Germany, Morocco, New Zealand, Thailand, Zaire
Intervention: any supplement containing iodine
Comparison: same supplement without iodine or no treatment/placebo
Anticipated absolute effects* (95% CI)Outcomes
Risk with same supplement
without iodine or no treat-
ment/placebo
Risk with any sup-
plement containing
iodine
Relative effect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study population
21 per 1000 40 per 1000
(12 to 134)
Moderate
Maternal hypothyroidism - preg-
nancy
21 per 1000 40 per 1000
(12 to 135)
Average RR 1.90
(0.57 to 6.38)
365
(1 RCT)
⊕⊕⊝⊝
Low 1, 2
 
Study population
7 per 1000 4 per 1000
(1 to 34)
Moderate
Maternal hypothyroidism - post-
partum
11 per 1000 5 per 1000
(1 to 37)
Average RR 0.44
(0.06 to 3.42)
540
(3 RCTs)
⊕⊕⊝⊝
Low 2, 3
 
Study populationPreterm birth
111 per 1000 78 per 1000
(33 to 184)
Average RR 0.71
(0.30 to 1.66)
376
(2 RCTs)
⊕⊕⊝⊝
Low 1, 2
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Moderate
122 per 1000 87 per 1000
(37 to 202)
Study population
68 per 1000 65 per 1000
(30 to 142)
Moderate
Maternal adverse effect: elevated
thyroid peroxidase antibodies -
pregnancy
68 per 1000 65 per 1000
(30 to 142)
Average RR 0.95
(0.44 to 2.07)
359
(1 RCT)
⊕⊕⊝⊝
Low 1, 2
 
Study population
301 per 1000 304 per 1000
(235 to 391)
Moderate
Maternal adverse effect: elevated
TPO-ab - postpartum
77 per 1000 78 per 1000
(60 to 100)
Average RR 1.01
(0.78 to 1.30)
397
(3 RCTs)
⊕⊕⊝⊝
Low 1, 4
 
Study population
21 per 1000 40 per 1000
(12 to 134)
Moderate
Maternal adverse effect: hyper-
thyroidism - pregnancy
21 per 1000 40 per 1000
(12 to 135)
Average RR 1.90
(0.57 to 6.38)
365
(1 RCT)
⊕⊕⊝⊝
Low 1, 2
 
Study population
49 per 1000 16 per 1000
(5 to 45)
Moderate
Maternal adverse effect: hyper-
thyroidism - postpartum
6 per 1000 3 per 1000
Average RR 0.32
(0.11 to 1.91)
543
(3 RCTs)
⊕⊕⊝⊝
Low 2, 4
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(1 to 7)
Study population
22 per 1000 333 per 1,000
(45 to 1,000)
Moderate
Maternal adverse effect: digestive
intolerance - pregnancy
25 per 1000 383 per 1000
(52 to 1,000)
Average
RR 15.33
(2.07 to 113.70)
76
(1 RCT)
⊕⊝⊝⊝
Very low 2, 5
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; TPO-ab: thyroid peroxidase antibodies
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1One study with design limitations (high risk for attrition bias).
2 Wide confidence interval.
3Most studies contributing data had design limitations (high risk for attrition bias and unclear for selection bias).
4Most studies contributing data had design limitations (high risk for attrition bias and selection bias).
5One study with high risk of blinding and attrition bias.
 
 
Summary of findings 2.   Any supplement containing iodine versus same supplement without iodine or no treatment/placebo (child outcomes)
Any supplement containing iodine versus same supplement without iodine or no treatment/placebo (child outcomes)
Population: women during the preconception, pregnancy and postpartum period
Setting: Germany, New Zealand, Thailand, Zaire
Intervention: any supplement containing iodine
Comparison: same supplement without iodine or no treatment/placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
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Risk with same supplement
without iodine or no treat-
ment/placebo
Risk with any supplement
containing iodine
Study population
208 per 1000 137 per 1000
(87 to 214)
Moderate
Perinatal mortality
208 per 1000 137 per 1000
(87 to 214)
Average RR 0.66
(0.42 to 1.03)
399
(1 RCT)
⊕⊕⊝⊝
Low 1, 2
 
Study population
90 per 1000 51 per 1000
(24 to 111)
Moderate
Low birthweight
96 per 1000 54 per 1000
(25 to 118)
Average RR 0.56
(0.26 to 1.23)
377
(2 RCTs)
⊕⊕⊝⊝
Low 2, 3
 
Study population
34 per 1000 20 per 1000
(4 to 106)
Moderate
Neonatal hypothy-
roidism or elevated
TSH
34 per 1000 20 per 1000
(4 to 106)
Average RR 0.58
(0.11 to 3.12)
219
(1 RCT)
⊕⊝⊝⊝
Very low 2, 3, 5
 
Study population
43 per 1000 26 per 1000
(3 to 244)
Moderate
Neonatal adverse ef-
fect: elevated TPO-ab
43 per 1000 26 per 1000
(3 to 245)
Average RR 0.61
(0.07 to 5.70)
108
(1 RCT)
⊕⊝⊝⊝
Very low 2, 4, 5
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Child adverse effect:
hyperthyroidism
   
See comments     No trials re-
ported this
outcome
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; TPO-ab: thyroid peroxidase antibodies; TSH: thyroid-stimulating hormone
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1Design limitations (high risk of attrition bias and unclear for selection bias).
2Wide confidence interval.
3One study had design limitations (high risk for attrition bias).
4One study with design limitations (high risk for selection bias).
5Small number of events.
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B A C K G R O U N D
Description of the condition
Iodine is an essential nutrient required for the biosynthesis
of thyroid hormones thyroxine (T4) and triiodothyronine (T3),
which are responsible for regulating growth, development and
metabolism. Very little iodine is required to meet the body's needs,
ranging from 90 µg to 290 µg per day depending on age and
physiological status (IOM 2001). However it can be challenging to
meet these needs given that naturally-occurring iodine is low in
most foods and beverages, with the exception of seafood, including
fish, shellfish and plants from the ocean (Rohner 2014). For many
people, the major source of dietary iodine is added, from salt
fortified with iodine or from dairy products in settings where iodine
is added to animal feed or where iodine-containing antiseptics are
used.
Iodine in preconception, pregnancy and breastfeeding
Throughout pregnancy there are major alterations in thyroid
function as a result of metabolic demands and hormonal changes
(Glinoer 1997). The concentrations of T4 and T3 rise significantly
until approximately mid-gestation and then remain relatively
stable until the end of gestation at term. Iodine requirements
increase substantially during pregnancy; initially as a result of a
50% increase in thyroid hormone production and a 30% to 50%
increase in the renal excretion of iodine (Glinoer 2007), and later
in gestation when iodine passes through the placenta for fetal
production of thyroid hormones (Glinoer 1997). Maternal and fetal
thyroid hormones are essential in regulating the development
of the fetal brain and nervous system including the creation
and growth of nerve cells, the formation of synapses, which are
required for communication between nerve cells, and myelination,
which is the formation of a fat-based layer that allows for fast
communication between nerve cells (Prado 2014). Some of these
events begin in the second month of gestation (Prado 2014), so may
be influenced by iodine status and thyroid hormone production
prior to conception (or prior to knowledge of pregnancy).
During breastfeeding, thyroid hormone production and urinary
iodine excretion return to non-pregnancy levels, but iodine
requirements remain elevated because iodine is concentrated in
the mammary gland for excretion in breast milk (Leung 2011).
Breastmilk iodine content varies with maternal dietary iodine
intake and is lowest in iodine-deficient areas and highest where
additional iodine is routinely provided through supplements or
universal salt iodization (Azizi 2009). As long as maternal iodine
intake is adequate, breast milk can meet infant iodine needs.
Recommended iodine intakes
Minute amounts of iodine are required to meet iodine needs
and prevent deficiency. DiAerent agencies have recommended
diAerent intakes to meet iodine needs of non-pregnant, pregnant
and breastfeeding women, ranging from 150 μg to 290 μg a day.
The International Council for Control of Iodine Deficiency Disorders
(ICCIDD), World Health Organization (WHO), and United Nations
Children's Fund (UNICEF) recommended a daily iodine intake of 250
μg for pregnant women and those breastfeeding their babies (WHO/
UNICEF/ICCIDD 2007). The US Institute of Medicine established a
recommended dietary allowance of 220 μg a day for women during
pregnancy and 290 μg a day whilst breastfeeding (IOM 2001). The
European Food Safety Authority set the adequate intake among
pregnant women and women who are breastfeeding their infants at
200 μg/day (EFSA 2014). All three recommendations suggest 150 μg
a day for non-pregnant adult women though recommended intakes
for the adolescent period diAer.
Both the US Institute of Medicine and the European Commission
Scientific Committee on Food have set tolerable upper intake levels
for iodine, which are the highest levels of daily intake not likely
to pose a risk of adverse health eAects in the general population
(IOM 2001; SCF 2006). These two organizations' recommendations
vary greatly for non-pregnant, pregnant and breastfeeding women
though, with the US Institute of Medicine level at 1100 µg a
day and the European Commission level set at 600 µg a day.
These recommended intakes are not intended for iodine-deficient
populations however, as metabolic adaptations to deficiency could
result in adverse health eAects at lower intakes (Rohner 2014).
Burden of iodine deficiency
It is estimated that over 1.8 billion people worldwide have an
insuAicient iodine intake, putting them at risk of iodine deficiency
(Andersson 2012). Europe is the region with the highest proportion
of individuals with insuAicient intake (44%), whereas Southeast
Asia has the highest number (540 million). Given the elevated
iodine requirements during pregnancy and breastfeeding and the
importance of thyroid hormones for growth and development
of the nervous system, ensuring adequate status in women and
young children is critical. However, as only a limited number of
countries have completed surveys in pregnant women and women
of reproductive age on national or large sub-national levels, there
are insuAicient data to directly estimate the regional or global
prevalence of low iodine intake in these important target groups
(Wong 2011).
Consequences of iodine deficiency
The consequences of iodine deficiency, which result from
inadequate thyroid hormone production and can aAect individuals
of any age, sex, and physiological status, are collectively known
as iodine deficiency disorders (Hetzel 1983; WHO/UNICEF/ICCIDD
2007). They are most serious and may be irreversible if they occur
during pregnancy or early childhood, though the eAects depend on
the timing and severity of iodine deficiency (Zimmermann 2012a).
If the increased iodine requirements during pregnancy are not met,
the concentration of T4 diminishes (hypothyroxinaemia) in both
mother and fetus, which can lead to irreversible brain damage
with intellectual disability and neurologic abnormalities (Glinoer
2007; Williams 2008). Iodine deficiency in pregnancy has been
associated with maternal and fetal goitre and hypothyroidism,
increased pregnancy loss and infant mortality, and impairments
in child development (Dunn 1993; Dunn 2001). Symptoms of
hypothyroidism, or an underactive thyroid, include tiredness,
weakness, poor memory and diAiculty concentrating, weight gain,
feeling cold, dry skin and hair loss (Jameson 2005). Globally, iodine
deficiency is the most common cause of hypothyroidism (Jameson
2005) and the most common preventable cause of impaired brain
development and mental function (WHO/UNICEF 2007).
The eAect of iodine deficiency on child development can manifest
itself as anything from mild intellectual blunting to cretinism,
with a large proportion of the population experiencing intellectual
impairment somewhere in between these extremes (Glinoer 2000).
Endemic cretinism, the most serious iodine deficiency disorder, is
a permanent condition of severely stunted physical and mental
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development that results from an untreated congenital deficiency
of thyroid hormones caused by severe maternal iodine deficiency
(Hetzel 1983). It is still unclear whether mild-to-moderate maternal
iodine deficiency in humans produces changes in cognitive
function. Some evidence suggests that children with chronic severe
iodine deficiency have significantly lower intelligence quotient (IQ)
scores than those with adequate iodine status (Zimmermann 2009).
Some randomised clinical studies conducted in school-age children
indicate that cognitive performance may improve with iodine
supplementation, even in mildly deficient areas (Gordon 2009;
Melse-Boonstra 2010). In the absence of iodine these eAects are
largely preventable by immediate thyroid hormone replacement,
although deficits in memory and IQ may persist over time (Williams
2008). It is also thought that iodine deficiency could be associated
with autism (Sullivan 2008) and with children's attention deficit and
hyperactivity disorder (Vermiglio 2004).
A variety of factors aAect iodine metabolism and thyroid
function and can exacerbate iodine deficiency. Other nutritional
deficiencies, including of selenium and iron, can lead to decreased
thyroid hormone production and cause damage to the thyroid
because key enzymes required for thyroid hormone synthesis and
metabolism depend on these nutrients (Zimmermann 2002). Iron
supplementation has been shown to improve the eAicacy of iodine
supplementation or salt iodization in iodine- and iron-deficient
children (Hess 2002; Zimmermann 2000).
Compounds found naturally in some foods such as cassava,
sorghum, soy and millet, and pollutants in food and water
such as perchlorate and nitrate can also negatively aAect iodine
metabolism and thyroid function (Rohner 2014). Collectively
known as goitrogens, these substances can compete with iodine
for uptake by the thyroid and impair the activity of key enzymes
required to produce thyroid hormones. Infants and young children
appear particularly vulnerable to the eAects of goitrogens, and
eAects are generally only seen where there is pre-existing iodine
deficiency.
Consequences of excess iodine
Excess iodine exposure can also cause serious negative health
eAects, and can occur through ingestion of supplements, water
or foods with high iodine content or via medical treatments or
procedures. Acute iodine poisoning may cause gastrointestinal
or cardiovascular symptoms, or even coma, aPer ingestion of
many grams of iodine (Zimmermann 2008). Excess iodine can
also cause the thyroid to become over or underactive (hyper or
hypothyroidism). Hypothyroidism symptoms are described above.
Symptoms of excess thyroid hormone production as a result of
hyperthyroidism include hyperactivity, irritability, heat intolerance,
palpitations, weakness, fatigue and weight loss (Jameson 2005).
In iodine suAiciency, the thyroid is able to adjust to a wide
range of iodine intakes, so healthy individuals may tolerate up
to 1 mg daily (Zimmermann 2008). In areas of chronic iodine
deficiency however, individuals are less tolerant to high iodine
intake, especially older adults with longstanding goitre. Iodine-
induced hyperthyroidism has been reported in the initial phases of
salt iodization programmes, though it is nearly always temporary
(WHO/UNICEF/ICCIDD 2007). It was estimated that 11 countries
have excessive iodine intakes (up from seven in 2007) as presented
at the Sixty-sixth World Health Assembly in a progress report from
the WHO in 2013.
Indicators of iodine status
Urinary iodine concentration (UIC)
In conditions of iodine suAiciency, over 90% of ingested iodine
is excreted in the urine, whereas in chronic iodine deficiency
the excretion may be less than 20%, making urinary iodine
concentration (UIC) a good indicator of recent iodine intake, or
short-term iodine status (Rohner 2014). UIC has limited utility in
assessing individual intake or status because of large variations
within and between days (WHO 2013). These variations level out in
large population samples though, making UIC a useful population-
level indicator. UIC is not a direct indicator of thyroid function, but
low values suggest a greater risk of developing thyroid disorders
(Rohner 2014).
UIC is commonly collected from school age children and
extrapolated to the general population or other population groups;
however, neither this group nor non-pregnant women serve as an
adequate proxy for pregnant women (Wong 2011). For pregnant
women, a median UIC below 150 μg/L is indicative of insuAicient
iodine intake, 150 μg/L to 249 μg/L adequate iodine intake, 250 μg/
L to 499 μg/L above iodine requirements, and 500 μg/L or higher
concentrations suggest an excessive intake (beyond that needed
for prevention and control of iodine deficiency) (WHO 2013). For
women who are breastfeeding their infants and children under two
years of age, a median UIC of below 100 μg/L indicates insuAicient
iodine intake, and 100 μg/L or more indicates adequate iodine
intake. For these population groups, the category of iodine intake
is not extrapolated to category of iodine status.
Goitre
The development of goitre, or enlargement of the thyroid gland,
begins as an adaptive response when iodine available to the thyroid
is not suAicient for adequate thyroid hormone production (Rohner
2014). Goitre responds slowly to changes in iodine intake and
is therefore an indicator of longer-term iodine status. In areas
of chronic iodine deficiency it can take years for thyroid size to
return to normal, and goitre may never completely disappear
(Zimmermann 2012b).
The presence of goitre can be determined by neck inspection
and palpation or by thyroid ultrasonography (Rohner 2014; WHO/
UNICEF/ICCIDD 2007). This method however has poor sensitivity
and specificity in areas of mild-to-moderate iodine deficiency. In
these settings, assessment of thyroid size by ultrasonography is
preferred and technology is available for use in field settings.
International reference values for thyroid volume using ultrasound
are available only for school age children though (Zimmermann
2004).
Thyroid-stimulating hormone (TSH)
This hormone, also known as thyrotropin, is produced by the
pituitary gland and stimulates thyroid hormone production and
release by the thyroid gland (Rohner 2014). Serum TSH levels
increase in response to low thyroid hormone concentration and
decrease in response to high concentration; it is a very sensitive
indicator of thyroid function and is the primary screening test
for thyroid dysfunction (Jameson 2005). Though TSH levels may
rise in response to iodine deficiency, they are oPen in the normal
range, therefore TSH is not considered a sensitive indicator of
iodine status (Rohner 2014; Zimmermann 2008). TSH is a useful
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indicator of iodine nutrition in neonates though because they have
high thyroidal iodine turnover (Delange 1998). Moderately elevated
levels (higher than 5 mIU/L in whole blood) indicate neonatal
iodine deficiency, which is a direct reflection of iodine deficiency
during pregnancy (WHO/UNICEF/ICCIDD 2007). A prevalence of less
than 3% of infants with moderately elevated TSH is expected in
iodine-suAicient regions (Rohner 2014; WHO/UNICEF/ICCIDD 2007).
Neonatal TSH screening for congenital hypothyroidism is standard
practice in many developed countries (WHO/UNICEF/ICCIDD 2007).
This condition, which has genetic causes, is relatively rare (one
in 4000 births) and indicated by highly elevated TSH levels (20
mIU/L or higher), and requires immediate treatment to prevent
permanent neurological damage.
Because of a physiological surge in newborns, neonatal TSH
assessment must take place at least 48 hours following birth (WHO/
UNICEF/ICCIDD 2007). In some countries elevated neonatal TSH
may be attributed to the use of beta-iodine-containing antiseptics
so results need to be interpreted cautiously in these contexts.
Thyroid hormones
Triiodothyronine (T3) and its prohormone, thyroxine (T4), are
hormones produced and secreted by the thyroid gland (Rohner
2014). T4 is converted to T3, the active hormone, in peripheral
tissues. A very small amount (less than 1%) of T4 and T3 in the
blood is not bound to protein, and therefore biologically active. In
the past, thyroid hormone assessments typically measured total
amounts because the free levels were too low to detect. However,
with the advent of newer techniques, free T4 and free T3, which
better reflect the physiological eAects of thyroid hormones than
total hormone concentrations, are usually measured nowadays.
T3 and T4 levels are direct clinical indicators of thyroid function, but
levels are protected in the early stages of thyroid dysfunction and
changes occur only at later stages (Rohner 2014). Therefore these
thyroid hormones are not good indicators of iodine status, except
in cases of severe iodine deficiency. A diagnosis of subclinical
hypothyroidism is based on elevated TSH with normal T4 and T3
levels. Overt hypothyroidism occurs when thyroid function further
diminishes, as indicated by falling free T4 levels, and the diagnosis
is based on high TSH and low T4. T3 levels are typically maintained
even longer than T4 levels. Some research has shown that neonatal
T4 levels are lower in iodine-deficient compared to iodine-suAicient
areas; however, validated norms have not been established for
comparison.
Thyroglobulin (Tg)
Tg is a protein matrix for thyroid hormone synthesis (Glinoer
1997). Tg levels rise early in pregnancy, and the increase is most
pronounced towards the end of gestation. In newborns, Tg levels
are normally increased in the first few days, possibly in response to
the physiological TSH surge (Pezzino 1981).
Tg is an indirect indicator of thyroid function and Tg levels are
positively correlated with thyroid volume (Rohner 2014). Tg is
elevated in iodine-deficient populations and is also an indirect
indicator of iodine status. Levels respond more quickly (weeks
to months) to iodine repletion than TSH or goitre (Zimmermann
2008). Assays can be performed on samples collected on dried
blood spots and international reference ranges are available for
school-age children (Zimmermann 2004). The presence of anti-Tg
antibodies, however, is reported to complicate interpretation of Tg
values (Rohner 2014).
Complex changes in thyroid physiology can make interpretation of
thyroid function and iodine status in pregnancy and early infancy
diAicult, therefore special considerations should to be taken into
account to avoid misinterpreting results (Laurberg 2007). Though
Stinca and colleagues recently reported that dried blood spot Tg is
a sensitive indicator of iodine status in pregnant women and that Tg
antibodies may not be necessary in this assessment (Stinca 2016).
Description of the intervention
Guidance and recommendations
Since 1993, universal salt iodization, or the addition of iodine to
all salt for human and animal consumption including food industry
salt, has been recommended for preventing and controlling
iodine deficiency (UNICEF/WHO 1994; WHO 2014). As a result
of this long-standing recommendation and the related support
for its implementation, most countries have some form of
salt iodization program in place to prevent and control iodine
deficiency and its consequences (UNICEF 2008). Universal salt
iodization is widely acknowledged as a cost-eAective, feasible, and
sustainable approach to control iodine deficiency, and research
suggests that successful salt iodization programmes can meet
the needs of population groups susceptible to iodine deficiency
and its consequences, specifically pregnant and breastfeeding
women and infants (Zimmermann 2007). However, it has been
recognized that these groups may need to be targeted with other
iodine interventions (Untoro 2007). WHO and UNICEF recommend
considering iodine supplementation in pregnant women, women
breastfeeding their infants and children from six to 23 months
of age, alongside eAorts to scale up salt iodization, in settings
where large proportions of the population do not have access
to iodized salt (WHO/UNICEF 2007). In addition, where pregnant
women are diAicult to reach, WHO and UNICEF recommend that
supplementation be extended to all women of reproductive age.
In some countries, for example the USA, Canadian and Australian
medical bodies have issued specific recommendations for iodine
supplementation in women who are pregnant or breastfeeding
(and women considering becoming pregnant in Australia) (ATA
2006; NHMRC 2010).
Supplement form, dose, and regimen
Oral supplements
Several diAerent types of oral iodine supplements are available for
public health purposes. These can be broadly divided into frequent
low dose (such as daily or weekly), or infrequent high dose (such as
annually or only once). The low-dose formulations usually contain
iodine as potassium iodide and come in the form of tablets or
drops for oral consumption. Many commercially available multiple-
micronutrient supplements including prenatal formulations also
contain iodine, oPen 150 μg for a daily dose (Leung 2009).
High-dose iodine supplements usually come in the form of oral
iodized oil capsules; the iodine is stored mainly in the thyroid gland
and can meet needs for up to a year. The above-mentioned WHO/
UNICEF guidance recommends a single annual dose of 400 mg or a
daily dose of 250 μg for pregnant and breastfeeding women (or 150
μg a day for non-pregnant women) (WHO/UNICEF 2007), whereas
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the USA, Canadian and Australian recommendations suggest 150
μg/day (ATA 2006; NHMRC 2010).
Injectable supplements
Much of the early iodine supplementation research used high-dose
intramuscular iodized oil injections (e.g. Pharoah 1971 and Pretell
1972) and this approach was used in public health programmes
especially in the 1970s and 1980s. This would currently be
considered a medical intervention that should be provided under
medical supervision. Other forms of medical iodine interventions
are available including sodium iodide solution used in intravenous
parenteral nutrition.
How the intervention might work
Iodine requirements increase during pregnancy because of
increased thyroid hormone production and iodine excretion,
and during breastfeeding because iodine is concentrated in the
mammary gland for excretion in breast milk. If maternal iodine
requirements are not met during this period, the production of
thyroid hormones may decrease and be inadequate for maternal,
fetal and infant needs (Glinoer 2007). Consequences may include
maternal or child hypothyroidism or goitre, pregnancy loss, low
birthweight, infant mortality, and developmental delays ranging
from mild intellectual impairment to cretinism.
Additional iodine intake through iodine supplementation may
help meet the increased iodine needs for thyroid hormone
production and transfer to the fetus/infant during pregnancy and
the postpartum period and prevent or correct iodine deficiency
and its consequences. Iodine supplementation prior to conception
could increase iodine stores and thyroid hormone production
before the additional demands of pregnancy. This may be
especially important in severely iodine-deficient areas to allow
time for correction of long-standing deficiency. Even where iodine
deficiency is less severe though, additional iodine intake prior
to pregnancy may be warranted because thyroid hormones are
important for brain and nervous system development events
starting as early as the seventh week of gestation (Prado 2014),
when women may not know or share with others that they are
pregnant.
Previous evidence reviews reported that high-dose iodine
supplementation through intramuscular injection prior to, or early
in pregnancy reduced the incidence of cretinism and improved
child cognitive development scores in severely iodine-deficient
areas (Bougma 2013; Zimmermann 2012a). There is also evidence
of improved birthweight, through oral iodine supplementation,
and decreased child mortality, through injected iodized oil
(Zimmermann 2012a).
From an implementation perspective, pregnant and postpartum
women oPen have contact with the healthcare system, which
generally provides or recommends prenatal and sometimes
postnatal micronutrient supplementation - usually iron and folic
acid. Similarly, where indicated, iodine supplementation could be
integrated into routine antenatal and postnatal care. To reach
women prior to pregnancy, existing contacts with the healthcare
system or other platforms could be used to provide or recommend
iodine supplementation for those planning on becoming pregnant
or to all women of reproductive age, or both, because pregnancies
are oPen unplanned (as is done with folic acid supplementation
recommendations in many settings).
Why it is important to do this review
It is important to assess the eAects and safety of iodine
supplementation in women before or during pregnancy and in the
postpartum period for optimal maternal and child outcomes and to
inform policy making towards the achievement of the WHO global
targets for maternal, infant and young child nutrition by 2025 (WHA
2012).
This review will complement the findings of other existing reviews
assessing the provision of iodine through a variety of interventions.
Mahomed and colleagues conducted one of the first Cochrane
Reviews on the topic (now withdrawn), examining maternal iodine
supplementation in areas of iodine deficiency (Mahomed 2006).
More recently a non-Cochrane review examined the eAect of
prenatal or periconceptional iodine supplementation on child
development, growth and other clinical outcomes (Zhou 2013).
The eAects of iodine supplementation for preventing iodine
deficiency disorders in children (Angermayr 2004) and mortality
and adverse neurodevelopmental outcomes in preterm infants
(Ibrahim 2006) are addressed in other Cochrane Reviews. A review
on salt iodization for prevention of iodine deficiency disorders
is published elsewhere (Aburto 2014) and a Cochrane Review
on fortification of foods and condiments (other than salt) with
iodine for prevention of iodine deficiency disorders (Land 2013)
is being conducted. Furthermore, a review on the eAect of
iodized salt or iodine supplements on prenatal and postnatal
growth (Farebrother 2015) is also underway. Cochrane reviews
have also been conducted on point-of-use fortification of foods
with multiple-micronutrient powders (Suchdev 2015) and multiple-
micronutrient supplementation (Haider 2015) for women during
pregnancy.
O B J E C T I V E S
To assess the benefits and harms of supplementation with iodine,
alone or in combination with other vitamins and minerals, for
women in the preconceptional, pregnancy or postpartum period on
their and their children's outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised and quasi-randomized controlled trials
with randomisation at either the individual or cluster level. We
intended to include eligible cross-over trials (and use only the
results from the first period) however we did not identify any such
studies.
Types of participants
Women who become pregnant, or pregnant or postpartum women
of any chronological age and parity (number of births), regardless
as to the iodine status of the study population or setting. We
included studies that randomised women to receive treatment
starting at any point prior to conception, during pregnancy or
within the first six weeks postpartum. We planned to exclude
studies specifically targeting women screened for and diagnosed
with thyroid disorders (as defined by trial authors) or other health
problems (e.g. thyroid disease, HIV, tuberculosis) however we did
not identify any such studies.
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Types of interventions
Injected or oral iodine supplementation (such as tablets, capsules,
drops) during preconception, pregnancy or the postpartum period
irrespective of compound, dose, frequency or duration.
Specifically, where data were available we planned to assess the
following comparisons:
1. any supplement containing iodine versus same supplement
without iodine or no intervention/placebo;
2. any oral iodine supplement versus same supplement without
iodine or no intervention/placebo;
3. oral iodine-only supplement versus no intervention or placebo;
4. oral iodine supplement with other vitamins and/or minerals
versus only other vitamins and/or minerals (exact same
formulation of other vitamins/minerals, but no iodine);
5. any injected iodine supplement versus same supplement
without iodine or no intervention/placebo;
6. injected iodine-only supplement versus no intervention or
placebo;
7. injected iodine supplement with other vitamins and/or minerals
versus only other vitamins and/or minerals (exact same
formulation of other vitamins/minerals, but no iodine).
We only identified data for comparisons 1 through 6. Because we
did not identify any studies for comparison 7, comparisons 5 and 6
include the exact same data and we have only reported comparison
5. We have summarized comparisons 2, 3, 4 and 5 in comparison
1, and we have summarized comparisons 3 and 4 in comparison 2.
We have summarized comparison 1, the main comparison, in the
'Summary of findings' tables (Summary of findings for the main
comparison and Summary of findings 2).
We included interventions that combined iodine supplementation
with co-interventions (e.g. education), only if the co-interventions
were the same across study arms. We excluded studies that
examined tube feeding, parenteral nutrition, or food-based
interventions (e.g. fortified or bio fortified foods, point-of-use
fortification with micronutrient powders or lipid-based nutrient
supplements).
Types of outcome measures
We included studies which met the above-mentioned criteria
regardless of outcomes reported, though we only extracted the
outcomes described below.
Primary outcomes
Maternal
1. Hypothyroidism (as defined by trial authors)
2. Preterm birth (as defined by trial authors)
3. Adverse eAects
a. Elevated thyroid peroxidase antibodies (TPO-ab) (as defined
by trial authors)
b. Hyperthyroidism (as defined by trial authors)
c. Digestive intolerance (as defined by trial authors)
Infants and children - to 23 months of age
1. Perinatal mortality (including stillbirth/fetal death and neonatal
death, as defined by trial authors)
2. Low birthweight (less than 2500 g)
3. Hypothyroidism or elevated TSH (as defined by trial authors)
4. Adverse eAects
a. Elevated TPO-ab (as defined by trial authors)
b. Hyperthyroidism (as defined by trial authors)
Secondary outcomes
Maternal
1. Spontaneous miscarriage (as defined by trial authors)
2. Thyroid size (assessed by any method)
3. Thyroglobulin (Tg) (μg/L)
4. InsuAicient iodine intake (pregnancy: median urinary iodine
concentration (UIC) less than 150 μg/L, breastfeeding: median
UIC less than 100 μg/L)
5. Excessive iodine intake (pregnancy only: median UIC greater
than or equal to 500 μg/L)
Infants and children - to 23 months of age
1. Small-for-gestational age (as defined by trial authors)
2. Congenital anomalies (including cretinism, as defined by trial
authors)
3. Growth (anthropometric Z scores)
4. Thyroid size (assessed by any method)
5. InsuAicient iodine intake (median UIC less than 100 μg/L)
6. Mental or motor development (as defined by trial authors)
7. Infant death (death in the first year of life)
For relevant maternal outcomes, we included both the pregnancy
and postpartum period. If maternal outcomes were assessed at
multiple time points, unless otherwise specified, we used the
last assessment during pregnancy and the last assessment in the
postpartum period. We planned to include the last assessment
during the intervention period and the last assessment during
the follow-up period though did not because many of the trials
were single dose and therefore this distinction was not relevant,
and also because of the way data were presented in most of the
trials. We did not include any outcomes during the preconception
period. For infant and child outcomes assessed at multiple time
points, where relevant we planned to include the neonatal period
(to 28 days), infancy (under one year), and childhood (beyond one
year). We summarized primary outcomes in 'Summary of findings'
tables (Summary of findings for the main comparison, Summary of
findings 2).
We planned to include any adverse event, such as iodine-induced
hyperthyroidism, in the mother and child as primary outcomes.
None of the trials which reported on hyperthyroidism indicated
whether it was or suspected to be iodine-induced (none of these
trials took place in severely-deficient women so it is unlikely that
the hyperthyroidism would have been caused by the supplemental
iodine). The only other reported outcomes considered by the trial
or review authors to be potentially adverse were elevated TPO-
ab and digestive intolerance. Therefore we replaced any adverse
eAects with hyperthyroidism and elevated TPO-ab (and digestive
intolerance for women), and extracted these outcomes separately
to avoid losing potentially important information.
Urinary and breast milk iodine concentrations are probably the
most common indicators of iodine status; they provide important
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information on the adherence and biological response to the
intervention or potential contamination in the control group.
However these indicators are generally highly skewed and are
typically reported as median with some description of the range. As
we did not have access to primary data, we have presented these
outcomes in Table 1 but they were not included in a meta-analysis
and did not directly inform the conclusions of the review.
Search methods for identification of studies
The following methods section is based on a standard template
used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (14 November 2016).
The Register is a database containing over 22,000 reports of
controlled trials in the field of pregnancy and childbirth. For full
search methods used to populate Pregnancy and Childbirth’s Trials
Register including the detailed search strategies for CENTRAL,
MEDLINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the editorial
information about the Cochrane Pregnancy and Childbirth in the
Cochrane Library and select the ‘Specialized Register ’ section from
the options on the leP side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals plus
monthly BioMed Central email alerts.
Search results are screened by two people and the full text of
all relevant trial reports identified through the searching activities
described above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a
specific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in a more specific search set which has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Studies awaiting classification; Ongoing
studies).
In addition, we searched the WHO International Clinical Trials
Registry Platform (ICTRP) (17 November 2016) for unpublished,
planned and ongoing trials using search terms as described in
Appendix 1.
Searching other resources
We searched through the bibliographies of existing reviews on
similar topics and of retrieved studies. We contacted experts in the
field as well as authors of retrieved studies for lists of other studies
that should be considered for inclusion.
For assistance in identifying ongoing or unpublished studies, we
also contacted the WHO Departments of Reproductive Health
and Research and Nutrition for Health and Development, the
Iodine Global Network, the nutrition section of the United Nations
Children's Fund (UNICEF), the World Food Programme (WFP),
the US Centers for Disease Control and Prevention (CDC), the
Micronutrient Initiative (MI), the Global Alliance for Improved
Nutrition (GAIN), Hellen Keller International (HKI), and Sight and
Life (28 November 2016).
We did not apply any date or language restrictions.
Data collection and analysis
The following methods section is based on a standard template
used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors (KBH and LDR) independently assessed for
inclusion all the potential studies we identified as a result of the
search strategy. We resolved any disagreement through discussion
and, if required, consulted with a third review author (ACW). For
one study (Mohammed 2015), funded by the organization of the
two authors doing the eligibility, another author (JPP) assessed
and determined it was excluded. We included studies published as
abstracts but if we could not assess quality and extract information
(aPer attempting to contact study authors), these studies were
marked as "awaiting classification".
Data extraction and management
We designed a form to extract data and record information
requested from study authors. For eligible studies, data were
extracted once using the agreed form by three review authors (KBH,
BAP and CMYY). Two review authors (KBH and BAP) entered the
data into Review Manager 5 (RevMan 5) soPware (RevMan 2014). We
resolved discrepancies through discussion or, if required, consulted
a third person.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a). We resolved
any disagreement by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in suAicient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random number
table; computer random number generator);
Iodine supplementation for women during the preconception, pregnancy and postpartum period (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
14
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• high risk of bias (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number);• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We described for each included study the method used to conceal
allocation to interventions prior to assignment and assess whether
intervention allocation could have been foreseen in advance of, or
during recruitment, or changed aPer assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively-numbered sealed opaque envelopes);• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that the
lack of blinding would be unlikely to aAect results. Where relevant,
we planned to assess blinding separately for diAerent outcomes or
classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. Where relevant, we planned to assess blinding
separately for diAerent outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomised participants),
reasons for attrition or exclusion where reported, and whether
missing data were balanced across groups or were related to
outcomes. Where suAicient information was reported, or could be
supplied by the trial authors, we planned to re-include missing data
in the analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome
data were less than 20% and were balanced across groups);• high risk of bias (e.g. numbers or reasons for missing
data imbalanced across groups; ‘as-treated’ analysis done
with substantial departure of intervention received from that
assigned at randomisation);• unclear risk of bias (e.g. level of missing data was unclear).
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it was clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review were reported);• high risk of bias (where not all the study’s pre-specified
outcomes were reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest were
reported incompletely and so could not be used; study failed to
include results of a key outcome that would have been expected
to have been reported);• unclear risk of bias.
(6) Other bias (checking for bias due to problems not covered by
(1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;• high risk of other bias;• unclear whether there was risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at
high risk of bias, according to the criteria given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
With reference to (1) to (6) above, we assessed the likely magnitude
and direction of the bias and whether we considered it was likely
to impact on the findings. We planned to explore the impact of the
level of bias through undertaking sensitivity analyses however we
considered only one trial at low overall risk of bias therefore this
analysis would not have been meaningful.
Assessing the quality of the evidence using GRADE
We assessed the overall quality of the evidence for primary
outcomes using the GRADE approach as outlined in the GRADE
handbook in order to assess the quality of the body of evidence
relating to the primary outcomes for any supplement containing
iodine versus same supplement without iodine or no intervention/
placebo. Two review authors independently assessed the quality of
the evidence for each of the maternal and child primary outcomes.
Maternal outcomes
1. Hypothyroidism (as defined by trial authors)
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2. Preterm birth (as defined by trial authors)
3. Adverse eAects
a. Elevated thyroid peroxidase antibodies (TPO-ab) (as defined
by trial authors)
b. Hyperthyroidism (as defined by trial authors)
c. Digestive intolerance (as defined by trial authors)
Infant/child outcomes
1. Perinatal mortality (including stillbirth/fetal death and neonatal
death, as defined by trial authors)
2. Low birthweight (less than 2500 g)
3. Hypothyroidism or elevated TSH (as defined by trial authors)
4. Adverse eAects
a. Elevated TPO-ab (as defined by trial authors)
b. Hyperthyroidism (as defined by trial authors)
We used the GRADEpro Guideline Development Tool to import data
from RevMan 5 (RevMan 2014) in order to create 'Summary of
findings' tables (Summary of findings for the main comparison;
Summary of findings 2). We produced a summary of the
intervention eAect and a measure of quality for each of the
above outcomes using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of eAect,
imprecision, indirectness and publication bias) to assess the
quality of the body of evidence for each outcome. The evidence can
be downgraded from 'high quality' by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of eAect estimates or potential publication bias.
Measures of treatment e<ect
Dichotomous data
For dichotomous data, we have presented results as summary risk
ratio (RR) with 95% confidence intervals (CI).
Continuous data
For continuous data, we used the mean diAerence (MD) if outcomes
were measured in the same way between trials. We planned to use
the standardized mean diAerence to combine trials that measured
the same outcome, but used diAerent methods.
Where trials reported median, we included this information in
additional tables and a narrative summary of the findings.
Unit of analysis issues
Cluster-randomized trials
We included cluster-randomized trials in the analyses along
with individually-randomized trials. Cluster-randomized trials are
labelled with a (C). We had planned to adjust their standard errors
and determine eAective sample size using the methods described
in the Cochrane Handbook for Systematic Reviews of Interventions
using an estimate of the intra cluster correlation co-eAicient (ICC)
derived from the trial (if possible), from a similar trial or from a
study of a similar population to take into account the design eAect
(Higgins 2011b). If we used ICCs from other sources, we planned
to report this and conduct sensitivity analyses to investigate the
eAect of variation in the ICC. However we identified only two
cluster-randomized trials. In one, family was the unit of allocation,
and it was not possible to know if there was more than one
pregnant women per family and therefore any clustering eAect
(Pharoah 1971 (C)). Therefore we did not adjust data from this
trial for clustering. In the other cluster-randomized study, the
reported analysis accounted for clustering therefore no additional
adjustments were necessary (Bouhouch 2014 (C)).
We synthesized the relevant information from the cluster-
randomized and individually-randomized trials.
We considered it reasonable to combine the results from both
if there was little heterogeneity between the study designs and
the interaction between the eAect of intervention and the choice
of randomisation unit was considered to be unlikely. We also
acknowledged heterogeneity in the randomisation unit.
Cross-over trials
We planned to include cross-over trials which would be otherwise
eligible for inclusion and use only data from the first period (if the
data were presented in this way) and anticipated that additional
methods for 'Risk of bias' assessment and analysis would not be
needed. We did not identify any eligible cross-over trials though.
Other unit of analysis issues
For studies with more than two intervention groups (multi-arm
studies, e.g. using diAerent doses), we included only directly
relevant arms. For studies with more than one relevant arm we
combined the arms into a single pair-wise comparison (Higgins
2011) and included the disaggregated data in the corresponding
subgroup category. To avoid double counting participants, if the
control group was shared by diAerent study arms, we divided the
control group (events and total population) over the number of
relevant subgroup categories.
For studies that included non-pregnant women, we only included
those who became pregnant.
If a study examined supplementing both the mother and infant,
and was otherwise eligible, we included that study arm and the
maternal data but excluded the infant data, as it would have been
aAected by the infant intervention.
We included all relevant details in the Characteristics of included
studies tables.
Dealing with missing data
For included studies, we noted levels of attrition in the
Characteristics of included studies tables.
For all outcomes, we carried out analyses, as far as possible,
on an intention-to-treat basis, that is, we attempted to include
all participants randomised to each group in the analyses, and
all participants were analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each trial was
the number randomised minus any participants whose outcomes
were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau2, I2 (Higgins 2003) and Chi2 statistics (Deeks 2011). We
considered heterogeneity as substantial if an I2 statistic was greater
Iodine supplementation for women during the preconception, pregnancy and postpartum period (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
16
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
than 30% and either the Tau2 was greater than zero, or there was
a low P value (less than 0.10) in the Chi2 test for heterogeneity. We
planned to explore any identified substantial heterogeneity (above
30%) by pre-specified subgroup analysis.
Assessment of reporting biases
We planned to investigate reporting biases (such as publication
bias) using funnel plots if there were 10 or more studies in the meta-
analysis. We planned to assess funnel plot asymmetry visually and
if asymmetry was suggested by a visual assessment, we planned to
perform exploratory analyses to investigate it. However there were
no meta-analyses with 10 or more studies so we were unable to
assess reporting bias.
Data synthesis
We carried out statistical analysis using the RevMan 5 soPware
(RevMan 2014). We intended to use fixed-eAect meta-analysis
for combining data where it would be reasonable to assume
that studies were estimating the same underlying treatment
eAect: that is, where trials were examining the same intervention,
and we judged the trials’ populations and methods suAiciently
similar. Since we identified both clinical heterogeneity (suAicient
to expect that the underlying treatment eAects diAered between
trials) or substantial statistical heterogeneity, or both, we used
random-eAects meta-analysis to produce overall summaries if
we considered an average treatment eAect across trials to be
clinically meaningful. We treated the random-eAects summary as
the average of the range of possible treatment eAects and we have
discussed the clinical implications of treatment eAects diAering
between trials. If the average treatment eAect was not clinically
meaningful, we did not combine trials.
As we used random-eAects analyses, we have presented the results
as the average treatment eAect with 95% CIs, and the estimates of
Tau2 and I2.
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we planned to attempt to
investigate it using subgroup analyses and sensitivity analyses. We
considered whether an overall summary was meaningful and, if it
was, used random-eAects analysis to produce it.
We planned to carry out the following subgroup analyses, when
information was available, and using only information reported by
the trial.
1. By period of supplementation: only before pregnancy versus
only during pregnancy versus only during the postpartum
period versus mixed.
2. By supplementation regimen: daily versus weekly versus annual
or single dose.
3. By access to iodized salt: less than 50% versus 50% to 69% versus
greater than or equal to 70% versus not reported.
4. By iodine status of the participants at the start of the
intervention: adequate versus mild or moderate deficiency
versus severe deficiency versus unknown (as defined by trial
authors, or following WHO-recommended criteria).
5. By breastfeeding status: yes at any time versus never versus
mixed/not reported. Note: this factor is not related to pregnancy
outcomes therefore this analysis was performed only on
maternal postpartum and child outcomes.
We planned to include only the primary outcomes in subgroup
analyses.
If we found substantial heterogeneity for any primary outcome,
we planned to assess subgroup diAerences by interaction tests
available within RevMan 5 (RevMan 2014). We planned to report the
results of subgroup analyses quoting the Chi2 statistic and P value,
and the interaction test I2 value.
We decided to add subgroups for a given outcome only where
there were at least four studies as we considered anything less to
be insuAicient to conduct meaningful analysis by the covariate.
However no outcome with statistical heterogeneity included data
from four or more trials, so we did not perform any subgroup
analyses.
Sensitivity analysis
We planned to conduct sensitivity analysis based on the risk of bias
of the studies. We considered a study to be of high quality if it was
graded as 'low risk of bias' in both randomisation and allocation
concealment and in either blinding or loss to follow-up. However
we only considered one trial at low risk of bias therefore did not
conduct this sensitivity analysis. We planned to conduct other
sensitivity analyses based on the studies included, for example, if
we identified and included any cluster-randomized trials we would
carry out sensitivity analysis using a range of ICC values.
We planned to carried out sensitivity analysis for primary outcomes
only.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies tables.
Results of the search
The search of Cochrane Pregnancy and Childbirth's Trials Register
retrieved 43 reports and the additional search strategy identified
another 53 reports. See: Figure 1 which shows the process for
assessing and selecting the studies (Moher 2009). We have included
14 and excluded 48 trials; five are ongoing or have not yet
been published and two are awaiting classification. Eleven trials
involving over 2000 women contributed data for the comparisons
in this review (three trials did not report any primary or secondary
outcomes (Kämpe 1990; Mulrine 2010; Silva 1981).
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Figure 1.   Study flow diagram
 
Included studies
Design
Most of the included studies were randomised controlled trials,
except for four which were quasi-randomized (Kevany 1969;
Liesenkotter 1996; Pharoah 1971 (C); Silva 1981). Individuals were
the unit of allocation for all except for two cluster-randomized
trials which allocated clinic days (Bouhouch 2014 (C)) and families
(Pharoah 1971 (C)). The Bouhouch 2014 (C) analysis adjusted for
clustering. Seven of the trials were reportedly double-blinded
(Bouhouch 2014 (C); Glinoer 1993; Mulrine 2010; Nohr 2000;
Pharoah 1971 (C); Zhou 2015; Gowachirapant 2014). Samples sizes
were generally small (eight trials were 120 or less) and ranged from
54 to 671. Two trials which recruited families or communities did
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not specify how many pregnant women, or women who became
pregnant, were initially included (Kevany 1969; Pharoah 1971 (C)).
One trial stopped at a sample size of 59 women (planned n =
1098) and was unblinded (Zhou 2015). Three trials were assessed
as eligible for inclusion but did not contribute data because they
did not report on any prespecified primary or secondary outcomes
(Kämpe 1990; Mulrine 2010; Silva 1981).
Settings
Six trials were conducted in Europe, in Belgium (Glinoer 1993),
Denmark (Nohr 2000; Pedersen 1993), France (Brucker-Davis 2013),
Germany (Liesenkotter 1996) and Sweden (Kämpe 1990). The
other trials took place in Australia (Zhou 2015), Chile (Silva 1981),
Morocco (Bouhouch 2014 (C)), New Zealand (Mulrine 2010), Papua
New Guinea (Pharoah 1971 (C)), Peru (Kevany 1969), Thailand
(Gowachirapant 2014), and Zaire (Thilly 1978). The trials which
reported when the research took place did so from 1966 through
2011.
Participants
Most of the trials recruited women during pregnancy through
antenatal care contacts at clinics or hospitals (Brucker-Davis 2013;
Glinoer 1993; Kämpe 1990; Liesenkotter 1996; Nohr 2000; Pedersen
1993; Silva 1981; Thilly 1978; Zhou 2015; Gowachirapant 2014). Two
trials recruited postpartum women at the infant's first vaccination
visit (Bouhouch 2014 (C)) or via advertisements (Mulrine 2010). Two
included entire families or communities and as a result, pregnant
or non-pregnant women who later became pregnant were included
(Kevany 1969; Pharoah 1971 (C)).
Average age of participants, where reported, ranged from 23 to
32 years. Information on socioeconomic status was generally not
reported. Five trials reported on anthropometric nutritional status
at baseline, though diAerent indicators were used. Women in the
Danish trials were pregnant and average weight ranged from 62 kg
to 68 kg (Nohr 2000; Pedersen 1993), body mass index (kg/m2) of
postpartum women in the Moroccan trial was 25.6 (Bouhouch 2014
(C)) and of pregnant women in the French trial was 22 (Brucker-
Davis 2013). In the Thai trial, 14% to 17% of pregnant women were
overweight or obese (Gowachirapant 2014).
Information on baseline iodine status of the participants or the
study area was provided in all but one trial (Kämpe 1990). Where
mean UIC was reported, it ranged from 30 µg/L to approximately
130 µg/L and women had insuAicient iodine intake, as indicated by
median UIC below 150 μg/L for pregnant women or below 100 μg/L
for breastfeeding women (Bouhouch 2014 (C); Brucker-Davis 2013;
Glinoer 1993; Liesenkotter 1996; Mulrine 2010; Nohr 2000; Pedersen
1993; Silva 1981; Gowachirapant 2014; Zhou 2015). Three trials only
reported goitre prevalence which ranged from 20% to 70% (Kevany
1969; Pharoah 1971 (C); Thilly 1978). One study area was reported
as high in endemic cretinism (Pharoah 1971 (C)).
Only four trials reported information on household coverage
of iodized salt. Coverage was above 80% in the three trials
that used participant-reported information (Brucker-Davis 2013;
Mulrine 2010; Gowachirapant 2014). Bouhouch 2014 (C) collected
and analysed household salt samples in a sub-sample and found
that 57% contained some iodine (6% with "adequate" or at least 15
ppm iodine and 51% with iodine less than 15 ppm).
Two trials screened women for thyroid peroxidase antibodies (TPO-
ab) and recruited only women with elevated levels (Kämpe 1990;
Nohr 2000).
Interventions
Seven trials included iodine supplementation during pregnancy
only (Glinoer 1993; Nohr 2000; Pharoah 1971 (C); Silva 1981; Thilly
1978; Zhou 2015; Gowachirapant 2014), three included iodine
supplementation only during the postpartum period (Bouhouch
2014 (C); Kämpe 1990; Mulrine 2010) and four gave iodine to
the same women in both pregnancy and the postpartum period
(Brucker-Davis 2013; Liesenkotter 1996; Nohr 2000; Pedersen 1993).
Two trials provided iodine supplementation to women who later
became pregnant (Kevany 1969; Pharoah 1971 (C)).
Most of the included trials used daily oral iodine supplementation,
mainly in the form of tablets (Brucker-Davis 2013; Liesenkotter
1996; Mulrine 2010; Nohr 2000; Zhou 2015; Gowachirapant 2014)
though one used capsules (Kämpe 1990), two used drops (Pedersen
1993; Silva 1981) and one trial reported using a daily supplement
but did not specify the form (Glinoer 1993). The daily iodine
dose ranged from 75 µg to 300 µg and the duration ranged from
approximately one to 17 months. Where the iodine compound was
reported, it was mostly potassium iodide (Glinoer 1993; Kämpe
1990; Liesenkotter 1996; Pedersen 1993; Silva 1981; Gowachirapant
2014) though one trial used potassium iodate (Mulrine 2010). One
trial used a single high dose oral iodine supplement, in the form of
two soP gel capsules containing iodized poppyseed oil with 400 mg
iodine (Bouhouch 2014 (C)).
The three earliest trials, which took place in the 1960s and
1970s, used single high-dose intramuscular injections of iodized oil
(Kevany 1969; Pharoah 1971 (C); Thilly 1978). One trial repeated
this intervention in the same communities three years later (Kevany
1969). The iodine dose in these trials ranged from 475 mg to 1600
mg, though in one study adult women with nodular goitre were
given a lower dose of 95 mg (Kevany 1969). Thilly 1978 specified that
the iodine was slowly resorbable.
Most of the included trials used iodine-only supplementation,
except for three which provided the same additional vitamins and
minerals to the intervention and control groups, either as part of
the supplement containing iodine (Brucker-Davis 2013; Nohr 2000)
or as a separate supplement (Gowachirapant 2014).
Comparisons
Most studies had two trial arms comparing an iodine intervention
with a no-iodine comparison in the same population group
though two trials also included an additional intervention arm
(one included two diAerent iodine doses (Mulrine 2010) and
one included iodine in pregnancy only and in pregnancy and
postpartum (Nohr 2000)). Two trials also had a third arm with
thyroxine (or thyroxine and iodine) supplementation (Glinoer 1993;
Kämpe 1990) however these arms were not eligible and therefore
were not included in this review.
Seven trials reported use of a placebo comparison group
(Bouhouch 2014 (C); Glinoer 1993; Kevany 1969; Mulrine 2010;
Pharoah 1971 (C); Zhou 2015; Gowachirapant 2014), four used no
intervention (Kämpe 1990; Liesenkotter 1996; Pedersen 1993; Silva
1981), and two used other micronutrients (Brucker-Davis 2013;
Nohr 2000). For one study, we found conflicting information about
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the control supplement composition as some reports stated it was
a placebo and some stated it included vitamins (Thilly 1978). For
the purposes of this review, we have considered the control for this
trial as placebo.
Comparison 1
Eleven studies compared the eAects of any supplement containing
iodine versus same supplement without iodine or no treatment/
placebo (Bouhouch 2014 (C); Brucker-Davis 2013; Glinoer 1993;
Kevany 1969; Liesenkotter 1996; Nohr 2000; Pedersen 1993;
Pharoah 1971 (C); Thilly 1978; Zhou 2015; Gowachirapant 2014).
Three trials were otherwise eligible but did not contribute any data
for this comparison (Kämpe 1990; Mulrine 2010; Silva 1981).
Comparison 2
Eight trials compared the eAects of any oral iodine supplement
versus the same supplement without iodine or no treatment/
placebo (Bouhouch 2014 (C); Brucker-Davis 2013; Glinoer 1993;
Liesenkotter 1996; Nohr 2000; Pedersen 1993; Zhou 2015;
Gowachirapant 2014). Three trials were otherwise eligible but did
not contribute any data for this comparison (Kämpe 1990; Mulrine
2010; Silva 1981).
Comparison 3
Five trials compared an oral iodine-only supplement versus
no intervention or placebo (Bouhouch 2014 (C); Glinoer 1993;
Liesenkotter 1996; Pedersen 1993; Zhou 2015). Three trials were
otherwise eligible but did not contribute any data for this
comparison (Kämpe 1990; Mulrine 2010; Silva 1981).
Comparison 4
Three trials compared the eAects of oral iodine supplements with
other vitamins and/or minerals versus only other vitamins and/or
minerals (exact same formulation of other vitamins/minerals, but
no iodine) (Brucker-Davis 2013; Nohr 2000; Gowachirapant 2014).
Comparison 5
Three trials compared the eAects of any injected iodine supplement
versus same supplement without iodine or no treatment/placebo
(Kevany 1969; Pharoah 1971 (C); Thilly 1978).
Comparison 6
Three trials compared the eAects of any injected iodine-only
supplement versus no intervention or placebo (Kevany 1969;
Pharoah 1971 (C); Thilly 1978).
Comparison 7
No studies compared an injected iodine supplement with other
vitamins and/or minerals versus only other vitamins and/or
minerals (exact same formulation of other vitamins/minerals, but
no iodine). Because of this, the trials (and data) are the same for
comparisons 5 and 6, therefore we have only reported comparison
5.
See Characteristics of included studies for a detailed description of
the trials.
Excluded studies
We excluded 48 trials. The main reason for excluding studies
was that they were not randomised or quasi-randomized trials.
Some randomised trials, or trials where it was unclear whether
randomisation was used, were excluded because they compared
diAerent iodine doses (without a placebo or a no treatment control)
or assessed iodized salt (Antonangeli 2002; Mohammed 2015;
Romano 1991; Santiago 2013; Troshina 2010).
See the Characteristics of excluded studies tables for detailed
descriptions of the excluded studies and the reasons for exclusion.
Risk of bias in included studies
Allocation
Random sequence generation
We considered five trials at low risk of selection bias for random
sequence generation (Bouhouch 2014 (C); Brucker-Davis 2013;
Thilly 1978; Zhou 2015; Gowachirapant 2014). Four we deemed
high risk because they used quasi-randomization (Kevany 1969;
Liesenkotter 1996; Pharoah 1971 (C); Silva 1981). The remaining
trials were reportedly randomised but did not provide adequate
information on how random sequences were generated, therefore
we considered risk of bias in this domain unclear.
Allocation concealment
We considered three trials at low risk of selection bias for allocation
concealment because clinic days were the unit of randomisation
or were used to assign individuals (and study staA could not
have reasonably influenced the day women showed up for clinic)
(Bouhouch 2014 (C); Liesenkotter 1996) or because randomisation
was performed centrally (Zhou 2015). We considered three trials
at high risk because they used alternation to assign individuals,
or families, to groups (Kevany 1969; Pharoah 1971 (C); Silva 1981).
The remaining trials did not adequately report the methods used to
conceal allocation so we considered the risk to be unclear.
Blinding
Blinding of participants and sta4
We considered four trials at low risk of performance bias because a
placebo was used for the control group and staA and participants
were reportedly blinded to group assignment (Bouhouch 2014 (C);
Mulrine 2010; Thilly 1978; Gowachirapant 2014). We determined six
trials high risk because no blinding was reported and the control
group did not receive any intervention (Kämpe 1990; Liesenkotter
1996; Pedersen 1993; Silva 1981) or because it was described as an
"open study" (Brucker-Davis 2013) or unblinded during the study
due to ethical consideration to placebo group (Zhou 2015). It was
not possible to assess risk of bias in this domain for the other four
trials due to lack of information reported (Glinoer 1993; Kevany
1969; Nohr 2000; Pharoah 1971 (C)).
Blinding of outcome assessors
Risk of detection bias was mostly unclear because study authors
did not adequately report this information, with the exception of
two trials which we considered low risk because they specified
that outcome assessors were blinded to group assignment
(Pharoah 1971 (C); Gowachirapant 2014) and two trials which were
considered high risk because they were described as an "open
study" (Brucker-Davis 2013) or because the trial was unblinded
mid-way through (Zhou 2015).
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Incomplete outcome data
Two trials were at low risk of attrition bias because of low (less than
20%) and balanced incomplete outcome data (Nohr 2000, Zhou
2015). We determined seven trials to be a high risk because of high
or imbalanced incomplete outcome data, or both (Bouhouch 2014
(C); Brucker-Davis 2013; Mulrine 2010; Pharoah 1971 (C); Silva 1981;
Thilly 1978; Gowachirapant 2014). For the remaining studies, lack
of detailed information on attrition precluded judgement (Glinoer
1993; Kämpe 1990; Kevany 1969; Liesenkotter 1996; Pedersen
1993).
Selective reporting
For most of the included trials, we did not have access to the study
protocol or clinical trial registration which stated the pre-specified
outcomes, therefore the risk of reporting bias due to selective
reporting was unclear. In two cases we did have access to the
trial registry and were able to determine the trial to be low (Zhou
2015) or high (Bouhouch 2014 (C)) risk of reporting bias, based on
the information provided in the registries and the publications. In
another case, we found the risk of bias to be high because baseline
information was only provided for those who completed the study
(Brucker-Davis 2013).
Other potential sources of bias
Most of the included trials appeared to be free of other potential
sources of bias, though this could not be confirmed, therefore we
considered this risk of bias unclear. We did however consider the
risk to be high in two trials which provided iodine to women before
they became pregnant, potentially aAecting their probability of
becoming pregnant and therefore leading to diAerences between
groups and bias (Kevany 1969; Pharoah 1971 (C)).
We have included full details of 'Risk of bias’ assessments in the
Characteristics of included studies tables. We have also included
figures which summarize our 'Risk of bias’ assessments (Figure 2;
Figure 3), which we used to judge study quality in the 'Summary of
findings' tables (see Summary of findings for the main comparison;
Summary of findings 2).
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study
 
 
Iodine supplementation for women during the preconception, pregnancy and postpartum period (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
22
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 3.   (Continued)
 
E<ects of interventions
See: Summary of findings for the main comparison Any
supplement containing iodine versus same supplement without
iodine or no treatment/placebo (maternal outcomes); Summary
of findings 2 Any supplement containing iodine versus same
supplement without iodine or no treatment/placebo (child
outcomes)
In this review we included 14 trials involving 3154 women, though
one trial did not report the number of women randomised (Pharoah
1971 (C)). Three trials involving 417 women (Kämpe 1990; Mulrine
2010; Silva 1981) did not contribute data because they did not
report any primary or secondary outcomes. We have organized
the summary results by comparison, by primary and secondary
outcomes and by maternal and child outcomes.
See Data and analyses for detailed results on primary and
secondary outcomes. We have set out below five out of the seven
prespecified comparisons. None of the included trials included
an assessment of comparison 7, which meant that the originally-
planned comparisons 5 and 6 were the exact same and therefore
we have not reported the results from comparison 6 separately.
For each of the comparisons and outcomes with data, we
have indicated the number of studies, the number of studies
contributing data and the total number of women or children
included in that analysis (instead of the number randomised in case
of attrition).
(1) Any supplement containing iodine versus same supplement
without iodine or no treatment/placebo (11 trials, 2737
participants)
Eleven trials contributed data involving 2737 women (Bouhouch
2014 (C); Brucker-Davis 2013; Glinoer 1993; Kevany 1969;
Liesenkotter 1996; Nohr 2000; Pedersen 1993; Pharoah 1971
(C); Thilly 1978; Zhou 2015; Gowachirapant 2014). None were
considered high quality. Three other trials did not contribute any
data to our analyses (Kämpe 1990; Mulrine 2010; Silva 1981).
Maternal primary outcomes
Hypothyroidism - pregnancy (as defined by trial authors)
Data from one trial (Gowachirapant 2014) involving 365 women
showed no diAerence in risk of hypothyroidism in pregnancy
between women who received and did not receive iodine
supplementation (risk ratio (average RR) 1.90; 95% confidence
interval (CI) 0.57 to 6.38, low-quality evidence) (Analysis 1.1).
Hypothyroidism - postpartum (as defined by trial authors)
Among 540 women in three trials (Bouhouch 2014 (C);
Liesenkotter 1996; Gowachirapant 2014), those who received
iodine supplementation were as likely to be diagnosed with
hypothyroidism in the postpartum period as those who did not
receive any iodine (average RR 0.44; 95% CI 0.06 to 3.42, low-quality
evidence) (Analysis 1.2). We did not find evidence of statistical
heterogeneity (I2 = 0%, Tau2 = 0.00 and Chi2 test for heterogeneity
P = 0.41).
Preterm birth (as defined by trial authors)
Two trials (Zhou 2015; Gowachirapant 2014) involving 376 pregnant
women reported on preterm birth, and showed no diAerence
between groups (average RR 0.71; 95% CI 0.30 to 1.66, low-quality
evidence) (Analysis 1.3). We identified substantial heterogeneity
for this outcome though (I2 = 32%, Tau2 = 0.13 and Chi2 test for
heterogeneity P = 0.23).
Maternal adverse e<ect: elevated thyroid peroxidase antibodies (TPO-
ab) - pregnancy (as defined by trial authors)
One trial with 359 women reported on elevated TPO-ab in
pregnancy (Gowachirapant 2014) and found no diAerence in risk
between the iodine and control groups (average RR 0.95; 95% CI
0.44 to 2.07, low-quality evidence) (Analysis 1.4).
Maternal adverse e<ect: elevated TPO-ab - postpartum (as defined by
trial authors)
This outcome was reported in three trials with 397 women
(Liesenkotter 1996; Pedersen 1993; Gowachirapant 2014). Findings
show no diAerence in the likelihood between the group that
received iodine and the group that did not (average RR 1.01; 95%
CI 0.78 to 1.30, low-quality evidence) (Analysis 1.5). We did not find
any evidence of statistical heterogeneity for this analysis (I2 = 0%,
Tau2 = 0.00 and Chi2 test for heterogeneity P = 0.63).
Maternal adverse e<ect: hyperthyroidism - pregnancy (as defined by
trial authors)
One trial with 365 women reported on this outcome
(Gowachirapant 2014) and found no diAerence between groups
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(average RR 1.90; 95% CI 0.57 to 6.38, low-quality evidence)
(Analysis 1.6).
Maternal adverse e<ect: hyperthyroidism - postpartum (as defined by
trial authors)
Data from three studies involving 543 women (Bouhouch 2014 (C);
Liesenkotter 1996; Gowachirapant 2014) showed that 1.6% of those
who received iodine supplementation and 4.9% of those who did
not had hyperthyroidism in the postpartum period (average RR
0.32; 95% CI 0.11 to 0.91, low-quality evidence) (Analysis 1.7). There
was no statistical heterogeneity (I2 = 0%, Tau2 = 0.00 and Chi2 test
for heterogeneity P = 0.67).
Maternal adverse e<ect: digestive intolerance - pregnancy (as defined
by trial authors)
One trial with 76 women reported on this outcome (Brucker-Davis
2013) and found a higher likelihood of digestive intolerance in the
iodine group whereby 33.3% of women who received iodine and
2.2% of those who did not dropped out of the study due to nausea
or vomiting (average RR 15.33; 95% CI 2.70 to 113.7, very low-quality
evidence) (Analysis 1.8).
Infant/child primary outcomes
Perinatal mortality (including stillbirth/fetal death and neonatal
death, as defined by trial authors)
Two trials with 457 assessments (Thilly 1978; Zhou 2015) reported
on this outcome, though all of the deaths occurred in one trial
(Thilly 1978). In this trial there was lower perinatal mortality in
the group that received iodine supplementation compared to the
control group, however the diAerence did not reach statistical
significance (average RR 0.66; 95% CI 0.42 to 1.03, low-quality
evidence) (Analysis 1.9).
Low birthweight (less than 2500 g)
Two trials with 377 infants reported on this outcome (Zhou 2015;
Gowachirapant 2014) and showed no diAerence between groups
(average RR 0.56; 95% CI 0.26 to 1.23, low-quality evidence)
(Analysis 1.10). There was no evidence of statistical heterogeneity
(I2 = 0%, Tau2 = 0.00 and Chi2 test for heterogeneity P = 0.62).
Neonatal hypothyroidism or elevated thyroid-stimulating hormone
(TSH) (as defined by trial authors)
This outcome was reported in two trials (Zhou 2015; Gowachirapant
2014) with 260 infant assessments, although all of the cases
occurred in one trial (Gowachirapant 2014). The average RR for
neonatal elevated TSH in this trial was 0.58 (95% CI 0.11 to 3.12, very
low-quality evidence) (Analysis 1.11).
Neonatal adverse e<ect - elevated TPO-ab (as defined by trial authors)
One study with 108 assessments (Liesenkotter 1996) reported on
this outcome and showed no diAerence between infants whose
mothers received iodine and those who did not (average RR 0.61;
95% CI 0.07 to 5.70, very low-quality evidence) (Analysis 1.12). In
this trial, all of the neonates with elevated TPO-ab were born to
women with elevated TPO-ab at baseline.
Neonatal adverse e<ect - hyperthyroidism (as defined by trial authors)
No trials reported this outcome.
Maternal secondary outcomes
Spontaneous miscarriage (as defined by trial authors)
Three trials (Brucker-Davis 2013; Zhou 2015; Gowachirapant 2014)
with information on 645 pregnancies showed a similar likelihood
of spontaneous miscarriage (average RR 1.31; 95% CI 0.64 to 2.69)
and no evidence of statistical heterogeneity (I2 = 0%, Tau2 = 0.00 and
Chi2 test for heterogeneity P = 0.64) (Analysis 1.13).
Maternal goitre - pregnancy (assessed by any method)
Two studies (Glinoer 1993; Gowachirapant 2014) with 486 women
showed no diAerence in likelihood of goitre in pregnancy (average
RR 1.00; 95% CI 0.33 to 3.06) however we found significant
heterogeneity for this outcome (I2 = 53%, Tau2 = 0.35 and Chi2 test
for heterogeneity P = 0.14) (Analysis 1.14).
Maternal goitre - postpartum (assessed by any method)
Postpartum goitre was reported in two trials (Liesenkotter 1996;
Gowachirapant 2014). Data from 370 women showed no evidence
of diAerence (average RR 1.17; 95% CI 0.64 to 2.16) though we did
identify substantial heterogeneity (I2 = 33%, Tau2 = 0.10 and Chi2
test for heterogeneity P = 0.22) (Analysis 1.15).
Maternal thyroid volume - pregnancy (in mL) (assessed by any
method)
This outcome was reported in three trials with 496 participants, all
of which reported median thyroid volume so no meta-analysis was
performed (Brucker-Davis 2013; Pedersen 1993; Gowachirapant
2014). In two trials, findings showed lower median thyroid volume
in the iodine compared to the no-iodine groups (Brucker-Davis
2013; Pedersen 1993) (Table 2). Gowachirapant 2014, however,
found similar thyroid volumes in both groups.
Maternal thyroid volume - postpartum (in mL) (assessed by any
method)
Four trials with 457 women reported on this outcome (Brucker-
Davis 2013; Liesenkotter 1996; Pedersen 1993; Gowachirapant
2014) and most used median thyroid volume, so we did not
perform a meta-analysis. Three of the studies showed similar
postpartum thyroid volumes between the iodine and no iodine
groups (Liesenkotter 1996; Pedersen 1993; Gowachirapant 2014).
(Table 3). One trial, however, reported a lower median thyroid
volume (by 1.2 mL) in the iodine group (Brucker-Davis 2013).
Maternal thyroglobulin (Tg) - pregnancy (in μg/L)
This outcome was reported in four studies with 562 women
(Brucker-Davis 2013; Nohr 2000; Pedersen 1993; Gowachirapant
2014) all of which reported median Tg, so we did not perform a
meta-analysis. In all four trials, median Tg in pregnancy was lower in
the group which received iodine compared to the no-iodine group;
the diAerence ranged from 2.1 µg/L to 7.5 µg/L (Table 4).
Maternal Tg - postpartum (in μg/L)
Four trials involving 457 women (Brucker-Davis 2013; Liesenkotter
1996; Pedersen 1993; Gowachirapant 2014) reported this outcome,
mostly as median Tg, therefore we did not perform a meta-analysis.
All four trials showed that women who received iodine had lower
postpartum Tg levels compared to those who did not (Table 5). The
diAerence between groups ranged from 1.57 µg/L to 11.6 µg/L.
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Insu<icient iodine intake - pregnancy (median urinary iodine
concentration (UIC) less than 150 μg/L)
Two studies with 432 participants reported on this outcome
(Brucker-Davis 2013; Gowachirapant 2014). Results show that
women who received iodine supplements had a lower likelihood of
insuAicient iodine intake in pregnancy compared to those who did
not receive any iodine. In the iodine group, 33.3% of women had
inadequate iodine intake in pregnancy compared to 53.2% in the
control group (average RR 0.64; 95% CI 0.51 to 0.80) (Analysis 1.16).
There was no evidence of statistical heterogeneity for this outcome
(I2 = 0%, Tau2 = 0.00 and Chi2 test for heterogeneity P = 0.56).
Insu<icient iodine intake - postpartum (breastfeeding: median UIC
less than 100 μg/L)
Results from two trials (Bouhouch 2014 (C); Gowachirapant
2014) involving 425 women showed that iodine supplementation
reduced the likelihood of having insuAicient iodine intake in the
postpartum period (average RR 0.81; 95% CI 0.70 to 0.93), with no
evidence of statistical heterogeneity (I2 = 0%, Tau2 = 0.00 and Chi2
test for heterogeneity P = 0.90) (Analysis 1.17).
Excessive iodine intake (pregnancy only: median UIC greater than or
equal to 500 μg/L)
One trial (Gowachirapant 2014) with 356 women reported that 7.0%
of women who received iodine supplements and 1.6% of women
who did not had excessive iodine intake during pregnancy (average
RR 4.33; 95% CI 1.24 to 15.07) (Analysis 1.18).
Infant/child secondary outcomes
Small-for-gestational age (as defined by trial authors)
This outcome was reported in two trials (Zhou 2015; Gowachirapant
2014) with 377 infants that showed no evidence of diAerence
between groups (average RR 1.26; 95% CI 0.77 to 2.05) (Analysis
1.19). There was no substantial heterogeneity (I2 = 0%, Tau2 = 0.00
and Chi2 test for heterogeneity P = 0.83).
Congenital anomalies (including cretinism, as defined by trial authors)
Two trials (Pharoah 1971 (C); Zhou 2015), which assessed 875
children, showed a lower frequency of congenital anomalies in the
iodine group compared to the control group, 1.7% versus 6.4%,
respectively, though all of the cases came from one trial (Pharoah
1971 (C)) (average RR 0.27; 95% CI 0.12 to 0.60) (Analysis 1.20).
In six out of seven cases in the iodine group and five out of 26
cases in the control group, the mothers received the treatment
during pregnancy. The other mothers received treatment before
pregnancy.
Growth (anthropometric Z scores)
No trials reported on this outcome.
Neonatal goitre (assessed by any method)
This outcome was reported in three trials (Glinoer 1993; Kevany
1969; Liesenkotter 1996) that assessed 684 neonates. Findings
showed a lower likelihood of enlarged thyroid gland in the
neonates in the iodine group compared to the control group
(average RR 0.11; 95% CI 0.02 to 0.56) (Analysis 1.21) with no
evidence of statistical heterogeneity (I2 = 0%, Tau2 = 0.00 and Chi2
test for heterogeneity P = 0.76).
Neonatal thyroid volume (in mL) (assessed by any method)
Three trials with assessments of 359 neonates (Glinoer 1993;
Liesenkotter 1996; Gowachirapant 2014) showed lower thyroid
volume in the iodine compared to the control group. The MD was
-0.34 mL (95% CI -0.58 to -0.11) though there was evidence of
statistical heterogeneity (I2 = 93%, Tau2 = 0.04 and Chi2 test for
heterogeneity P < 0.00001) (Analysis 1.22).
Insu<icient neonatal iodine intake (median UIC less than 100 μg/L)
One trial (Gowachirapant 2014), which assessed 159 neonates,
found a higher likelihood of insuAicient iodine intake in the iodine
compared to the control group (average RR 2.14; 95% CI 1.04 to
4.37) (Analysis 1.23).
Neonatal mental or motor development (as defined by trial authors)
One study (Gowachirapant 2014) reported scores from the Neonatal
Behavioral Assessment Scales in median and IQR for 149 neonates
(Table 6). Out of the eight sub-scales, three showed higher median
scores in the iodine group compared to the control group, one
showed a higher score in the control group, and three showed equal
scores in both groups.
Child mental or motor development (as defined by trial authors)
Data from two trials (Kevany 1969; Thilly 1978), which measured
174 children, showed a higher IQ score in the group whose mothers
received iodine compared to those who did not. The MD was 11.21
points (95% CI 7.96 to 14.46) (Analysis 1.24) with no statistical
heterogeneity (I2 = 0%, Tau2 = 0.00; Chi2 test for heterogeneity P =
0.70). These findings were combined using MD because the same
instrument, the Brunet-Lézine scale, was used in both trials.
One trial (Zhou 2015) reported on child cognitive, language
development, motor, social-emotional and adaptive behaviour
scores for 53 children at 18 months of age assessed by the Bayley
scales of infant and toddler development (Bayley-Ⅲ). Scores were
similar in both groups (Analysis 1.25; Analysis 1.26; Analysis 1.27;
Analysis 1.28; Analysis 1.29). The same trial also reported moderate
and severe developmental delays based on the cognitive, language
and motor scores and found no significant diAerences between
groups (Analysis 1.30; Analysis 1.31; Analysis 1.32; Analysis 1.33;
Analysis 1.34; Analysis 1.35).
Infant death (death in the first year of life)
No trials reported on this outcome.
Other outcomes
We also extracted data on urinary and breast milk iodine
concentration following supplementation (Table 1). Average UIC
was generally higher in the intervention than the control groups,
however this was not the case for all studies and in some cases
depended on the timing of assessment (e.g. higher in the iodine
group during pregnancy but not postpartum Brucker-Davis 2013
and Pedersen 1993) and the group assessed (e.g. higher among
intervention women but lower among intervention neonates,
compared to controls (Gowachirapant 2014)). With the exception
of one trial (Zhou 2015), in each study where breast milk iodine
concentration was assessed, levels were higher in the iodine
compared to the control groups (Bouhouch 2014 (C); Glinoer 1993;
Pedersen 1993).
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(2) Any oral iodine supplement versus same supplement
without iodine or no treatment/placebo (eight trials, 1274
participants)
Eight trials involving 1274 women were included in this comparison
(Bouhouch 2014 (C); Brucker-Davis 2013; Glinoer 1993; Liesenkotter
1996; Nohr 2000; Pedersen 1993; Zhou 2015; Gowachirapant 2014).
None were considered high quality. Three other trials did not
contribute any data to our analyses (Kämpe 1990; Mulrine 2010;
Silva 1981).
Maternal primary outcomes
Hypothyroidism - pregnancy (as defined by trial authors)
Data from one trial (Gowachirapant 2014) involving 365 women
showed no diAerence in risk of hypothyroidism in pregnancy
between women who received and did not receive iodine
supplementation (average RR 1.90; 95% CI 0.57 to 6.38) (Analysis
2.1).
Hypothyroidism - postpartum (as defined by trial authors)
Among 540 women in three trials (Bouhouch 2014 (C);
Liesenkotter 1996; Gowachirapant 2014), those who received oral
iodine supplementation were as likely to be diagnosed with
hypothyroidism in the postpartum period compared to those who
did not receive any iodine (average RR 0.44; 95% CI 0.06 to 3.42)
(Analysis 2.2). We did not find evidence of statistical heterogeneity
(I2 = 0%, Tau2 = 0.00 and Chi2 test for heterogeneity P = 0.41).
Preterm birth (as defined by trial authors)
Two trials (Zhou 2015; Gowachirapant 2014) involving 376 women
reported on preterm birth, and showed no diAerence between
groups (average RR 0.71; 95% CI 0.30 to 1.66) though there was
statistical heterogeneity ((I2 = 32%, Tau2 = 0.13 and Chi2 test for
heterogeneity P = 0.23) (Analysis 2.3).
Maternal adverse e<ect: elevated TPO-ab - pregnancy (as defined by
trial authors)
One trial with 359 women reported on elevated thyroid peroxidase
antibodies in pregnancy (Gowachirapant 2014) and found no
diAerence in risk between the oral iodine and control groups
(average RR 0.95; 95% CI 0.44 to 2.07) (Analysis 2.4).
Maternal adverse e<ect: elevated TPO-ab - postpartum (as defined by
trial authors)
This outcome was reported in three trials with 397 women
(Liesenkotter 1996; Pedersen 1993; Gowachirapant 2014). Findings
show no diAerence in the likelihood between the group which
received oral iodine and the group which did not receive any iodine
(average RR 1.01; 95% CI 0.78 to 1.30) (Analysis 2.5). We did not find
any evidence of statistical heterogeneity for this analysis (I2 = 0%,
Tau2 = 0.00 and Chi2 test for heterogeneity P = 0.63).
Maternal adverse e<ect: hyperthyroidism - pregnancy (as defined by
trial authors)
One trial with 365 women reported on this outcome
(Gowachirapant 2014) and found no diAerence between groups
(average RR 1.90; 95% CI 0.57 to 6.38) (Analysis 2.6).
Maternal adverse e<ect: hyperthyroidism - postpartum (as defined by
trial authors)
Data from three studies involving 543 women (Bouhouch 2014 (C);
Liesenkotter 1996; Gowachirapant 2014) showed that 1.6% of those
who received oral iodine supplementation and 4.9% of those who
did not had hyperthyroidism in the postpartum period (average RR
0.32, 95% CI 0.11 to 0.91) (Analysis 2.7). There was no statistical
heterogeneity (I2 = 0%, Tau2 = 0.00 and Chi2 test for heterogeneity
P = 0.67).
Maternal adverse e<ect: digestive intolerance - pregnancy (as defined
by trial authors)
One trial with 76 women reported on this outcome (Brucker-Davis
2013) and found a higher likelihood of digestive intolerance in the
group which received oral iodine supplementation compared to
those who did not. One-third of women (33.3%) in the iodine group
and 2.2% of women in the control group dropped out of the study
due to nausea or vomiting (average RR 15.33; 95% CI 2.70 to 113.70)
(Analysis 2.8).
Infant/child primary outcomes
Perinatal mortality (including stillbirth/fetal death and neonatal
death, as defined by trial authors)
One trial with 58 assessments (Zhou 2015) reported no events in
either group (Analysis 2.9).
Low birthweight (less than 2500 g)
Two trials with 377 infants reported on this outcome
(Gowachirapant 2014) and showed no diAerence between groups
(average RR 0.56; 95% CI 0.26 to 1.23) (Analysis 2.10).
Neonatal hypothyroidism or elevated TSH (as defined by trial authors)
This outcome was reported in two trials (Zhou 2015; Gowachirapant
2014) with 260 infant assessments. All of the cases though occurred
in one trial (Gowachirapant 2014); the average RR for neonatal
elevated TSH in this trial was 0.58 (95% CI 0.11 to 3.12) (Analysis
2.11).
Neonatal adverse e<ect - elevated TPO-ab (as defined by trial authors)
One study with 108 assessments (Liesenkotter 1996) reported on
this outcome and showed no diAerence between infants whose
mothers received oral iodine and those who did not (average RR
0.61; 95% CI 0.07 to 5.70) (Analysis 2.12). In this trial, all of the
neonates with elevated TPO-ab were born to women with elevated
TPO-ab at baseline.
Neonatal adverse e<ect - hyperthyroidism (as defined by trial authors)
No trials reported this outcome.
Maternal secondary outcomes
Spontaneous miscarriage (as defined by trial authors)
Three trials (Brucker-Davis 2013; Zhou 2015; Gowachirapant 2014)
with information on 645 pregnancies showed a similar likelihood
of spontaneous miscarriage (average RR 1.31; 95% CI 0.64 to 2.69)
and no evidence of statistical heterogeneity (I2 = 0%, Tau2 = 0.00 and
Chi2 test for heterogeneity P = 0.64)) (Analysis 2.13).
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Maternal goitre - pregnancy (assessed by any method)
Two studies (Glinoer 1993; Gowachirapant 2014) with 486 women
showed no diAerence in likelihood of goitre in pregnancy (average
RR 1.00; 95% CI 0.33 to 3.06) however we found significant
heterogeneity for this outcome (I2 = 53%, Tau2 = 0.35 and Chi2 test
for heterogeneity P = 0.14) (Analysis 2.14).
Maternal goitre - postpartum (assessed by any method)
Postpartum enlarged thyroid gland or goitre was reported in two
trials (Liesenkotter 1996; Gowachirapant 2014). Data from 370
women showed no evidence of diAerence (average RR 1.17; 95% CI
0.64 to 2.16) though we did identify substantial heterogeneity (I2 =
33%, Tau2 = 0.10 and Chi2 test for heterogeneity P = 0.22) (Analysis
2.15).
Maternal thyroid volume - pregnancy (in mL) (assessed by any
method)
This outcome was reported in three trials with 496 participants, all
of which reported median thyroid volume so no meta-analyses was
performed (Brucker-Davis 2013; Pedersen 1993; Gowachirapant
2014). In two trials, findings showed lower median thyroid
volume in the oral iodine compared to the no iodine groups
(Brucker-Davis 2013; Pedersen 1993) (Table 2). Zimmermann and
colleagues however found similar thyroid volumes in both groups
(Gowachirapant 2014).
Maternal thyroid volume - postpartum (in mL) (assessed by any
method)
Four trials with 457 women reported on this outcome (Brucker-
Davis 2013; Liesenkotter 1996; Pedersen 1993; Gowachirapant
2014) and most used median thyroid volume so we did not perform
a meta-analysis. Three of the studies showed similar postpartum
thyroid volumes between the oral iodine and no iodine groups
(Liesenkotter 1996; Pedersen 1993; Gowachirapant 2014). (Table 3).
One trial however reported a lower median thyroid volume (by 1.2
mL) in the iodine group (Brucker-Davis 2013).
Maternal Tg - pregnancy (in μg/L)
This outcome was reported in four studies with 562 women
(Brucker-Davis 2013; Nohr 2000; Pedersen 1993; Gowachirapant
2014) all of which reported median Tg so we did not perform a meta-
analysis. In all four trials, median Tg in pregnancy was lower in the
group which received oral iodine compared to the no iodine group;
the diAerence ranged from 2.1 to 7.5 µg/L (Table 4).
Maternal Tg - postpartum (in μg/L)
Four trials involving 457 women (Brucker-Davis 2013; Liesenkotter
1996; Pedersen 1993; Gowachirapant 2014 reported this outcome,
mostly as median Tg therefore we did not perform a meta-
analysis. All four trials showed that women who received oral iodine
supplements had lower postpartum Tg levels compared to those
who did not (Table 5). The diAerence between groups ranged from
1.57 to 11.6 µg/L.
Insu<icient iodine intake - pregnancy (median UIC less than 150 μg/L)
Two studies with 432 participants reported on this outcome
(Brucker-Davis 2013; Gowachirapant 2014). Results show that
women who received oral iodine supplements had a lower
likelihood of insuAicient iodine intake in pregnancy compared to
the comparison group; 33.3% of women in the iodine group had
inadequate iodine intake compared to 53.2% in the control group
(average RR 0.64; 95% CI 0.51 to 0.80) (Analysis 2.16). There was no
evidence of statistical heterogeneity for this outcome (I2 = 0%, Tau2
= 0.00 and Chi2 test for heterogeneity P = 0.56).
Insu<icient iodine intake - postpartum (breastfeeding: median UIC
less than 100 μg/L)
Results from two trials (Bouhouch 2014 (C); Gowachirapant 2014)
involving 425 women show that iodine supplementation reduced
the likelihood of having insuAicient iodine intake in the postpartum
period (average RR 0.81; 95% CI 0.70 to 0.93) with no evidence
of statistical heterogeneity (I2 = 0%, Tau2 = 0.00 and Chi2 test for
heterogeneity P = 0.90) (Analysis 2.17).
Excessive iodine intake (pregnancy only: median UIC greater than or
equal to 500 μg/L)
One trial (Gowachirapant 2014) with 356 women showed that 7.0%
of women who oral received iodine supplements and 1.6% of
women who did not had excessive iodine intake during pregnancy
(average RR 4.33; 95% CI 1.24 to 15.07) (Analysis 2.18).
Infant/child secondary outcomes
Small-for-gestational age (as defined by trial authors)
This outcome was reported in two trials (Zhou 2015; Gowachirapant
2014) with 377 infants which showed no evidence of diAerence
between groups (average RR 1.26, 95% CI 0.77 to 2.05). There was
no evidence of statistical heterogeneity (I2 = 0%, Tau2 = 0.00 and Chi2
test for heterogeneity P = 0.83) (Analysis 2.19).
Congenital anomalies (including cretinism, as defined by trial authors)
One trial with 57 infants (Zhou 2015) reported this outcome, with
no cases of congenital anomalies in either group (Analysis 2.20).
Growth (anthropometric Z scores)
No trials reported on this outcome.
Neonatal goitre (assessed by any method)
This outcome was reported in two trials (Glinoer 1993; Liesenkotter
1996) which assessed 228 neonates. Findings showed a lower
likelihood of enlarged thyroid gland in the neonate following oral
iodine supplementation in the mother (average RR 0.11; 95% CI 0.02
to 0.56), with no evidence of statistical heterogeneity (I2 = 0%, Tau2
= 0.00 and Chi2 test for heterogeneity P = 0.76) (Analysis 2.21).
Neonatal thyroid volume (in mL) (assessed by any method)
Three trials with assessments of 359 neonates (Glinoer 1993;
Liesenkotter 1996; Gowachirapant 2014) showed lower thyroid
volume in the oral iodine compared to the control group. The MD
was -0.34 mL (95% CI -0.58 to -0.11) though there was evidence
of statistical heterogeneity (I2 = 93%, Tau2 = 0.04 and Chi2 test for
heterogeneity P = 0.00001) (Analysis 2.22).
Insu<icient neonatal iodine intake (median UIC less than 100 μg/L)
One trial (Gowachirapant 2014) which assessed 159 neonates found
a higher likelihood of insuAicient iodine intake in the oral iodine
compared to the control group (average RR 2.14; 95% CI 1.04 to
4.37) (Analysis 2.23).
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Neonatal mental or motor development (as defined by trial authors)
One study (Gowachirapant 2014) reported scores from the Neonatal
Behavioral Assessment Scales in median and IQR for 149 neonates
(Table 6). Out of the eight sub-scales, three showed higher median
scores in the oral iodine group compared to the control group, one
showed a higher score in the control group, and three showed equal
scores in both groups.
Child mental or motor development (as defined by trial authors)
One trial (Zhou 2015) reported on child cognitive, language
development, motor, social-emotional and adoptive behaviour
scores for 53 children at 18 months of age assessed by the Bayley
scales of infant and toddler development (Bayley-Ⅲ). Scores were
similar in both groups (Analysis 2.24; Analysis 2.25; Analysis 2.26;
Analysis 2.27; Analysis 2.28). This trial also reported moderate and
severe developmental delays based on the cognitive, language and
motor scores and found no significant diAerences between groups
(Analysis 2.29; Analysis 2.30; Analysis 2.31; Analysis 2.32; Analysis
2.33; Analysis 2.34).
Infant death (death in the first year of life)
No trials reported on this outcome.
(3) Oral iodine-only supplement versus no intervention or
placebo (five trials, 580 participants)
Five studies involving 580 women were included in this comparison
(Bouhouch 2014 (C); Glinoer 1993; Liesenkotter 1996; Pedersen
1993; Zhou 2015), all of which contributed data. None were
assessed as high quality.
Maternal primary outcomes
Hypothyroidism - pregnancy (as defined by trial authors)
No trials reported on this outcome.
Hypothyroidism - postpartum (as defined by trial authors)
Among 340 women in three trials (Bouhouch 2014 (C);
Liesenkotter 1996; Pedersen 1993), those who received oral
iodine-only supplementation were as likely to be diagnosed with
hypothyroidism in the postpartum period as those who did not
receive any iodine (average RR 0.91; 95% CI 0.10 to 8.60) (Analysis
3.1). We did not find evidence of statistical heterogeneity (I2 = 0%,
Tau2 = 0.00 and Chi2 test for heterogeneity P = 0.32).
Preterm birth (as defined by trial authors)
One trial with 58 assessments (Zhou 2015) showed no diAerence
in the likelihood of preterm birth for women who received oral
supplements with iodine only compared to those who received no
iodine (average RR 1.25; 95% CI 0.37 to 4.19) (Analysis 3.2).
Maternal adverse e<ect: elevated TPO-ab - pregnancy (as defined by
trial authors)
No trial reported on this outcome.
Maternal adverse e<ect: elevated TPO-ab - postpartum (as defined by
trial authors)
This outcome was reported in two trials with 162 women
(Liesenkotter 1996; Pedersen 1993). Findings showed no diAerence
between the group which received oral iodine-only and the group
which did not receive any iodine (average RR 0.62; 95% CI 0.15
to 2.51) (Analysis 3.3). We did not find any evidence of statistical
heterogeneity for this analysis (I2 = 0%, Tau2 = 0.00 and Chi2 test for
heterogeneity P = 0.52).
Maternal adverse e<ect: hyperthyroidism - pregnancy (as defined by
trial authors)
No trial reported on this outcome.
Maternal adverse e<ect: hyperthyroidism - postpartum (as defined by
trial authors)
Two trials involving 286 women (Bouhouch 2014 (C); Liesenkotter
1996) reported postpartum hyperthyroidism. This event occurred
only in one trial though (Bouhouch 2014 (C)) and there was
no diAerence in the likelihood of postpartum hyperthyroidism
between groups (average RR 0.29; 95% CI 0.01 to 7.06) (Analysis 3.4).
Maternal adverse e<ect: digestive intolerance - pregnancy (as defined
by trial authors)
No trial reported on this outcome.
Infant/child primary outcomes
Perinatal mortality (including stillbirth/fetal death and neonatal
death, as defined by trial authors)
One trial with 58 assessments (Zhou 2015) reported no events in
either group (Analysis 3.5).
Low birthweight (less than 2500 g)
One trial (Zhou 2015) reported this outcome with 58 neonates,
showing no diAerence between groups (average RR 0.33; 95% CI
0.04 to 3.02) (Analysis 3.6).
Neonatal hypothyroidism or elevated TSH (as defined by trial authors)
One trial with 41 assessments (Zhou 2015) reported on this
outcome and showed no events in either group (Analysis 3.7),
Neonatal adverse e<ect - elevated TPO-ab (as defined by trial authors)
One study with 108 assessments (Liesenkotter 1996) reported on
this outcome and showed no diAerence between groups (average
RR 0.61; 95% CI 0.07 to 5.70) (Analysis 3.8).
Neonatal adverse e<ect - hyperthyroidism (as defined by trial authors)
No trials reported this outcome.
Maternal secondary outcomes
Spontaneous miscarriage (as defined by trial authors)
This outcome was reported in one trial with 58 pregnant
women (Zhou 2015), which showed no diAerence in likelihood
of spontaneous miscarriage between the oral iodine-only and no
iodine groups (average RR 3.00; 95% CI 0.13 to 70.74) (Analysis 3.9).
Maternal goitre - pregnancy (assessed by any method)
One study involving 120 women (Glinoer 1993) reported on goitre
in pregnancy and found no diAerence between groups (average RR
0.60; 95% CI 0.23 to 1.55) (Analysis 3.10).
Maternal thyroid size - goitre postpartum (assessed by any method)
Postpartum goitre was reported in one trial (Liesenkotter 1996).
Data from 108 women showed no evidence of diAerence between
groups (average RR 1.01; 95% CI 0.73 to 1.39) (Analysis 3.11).
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Maternal thyroid volume - pregnancy (in mL) (assessed by any
method)
One trial with 54 women (Pedersen 1993) reported on this outcome.
Median thyroid volume in the oral iodine-only group was lower, by
1.3 mL, than in the no-iodine group (Table 2).
Maternal thyroid volume - postpartum (in mL) (assessed by any
method)
Two trials including 157 women reported on this outcome
(Liesenkotter 1996; Pedersen 1993). Findings show similar median
thyroid volume in the iodine-only supplementation group and the
no-iodine group (Table 3).
Maternal Tg - pregnancy (μg/L)
This outcome was reported in one trial with 54 women (Pedersen
1993) which showed 45% lower postpartum Tg levels in the iodine-
only group compared to the group that received no iodine (Table 4).
Maternal Tg - postpartum (μg/L)
Two trials involving 157 women (Liesenkotter 1996; Pedersen
1993) reported on this outcome. We did not perform a meta-
analysis because one trial reported median Tg. Results from
these studies show lower postpartum Tg levels in the iodine-only
supplementation group compared to the no-iodine group (Table 5).
In one trial mean Tg was 5.2 μg/L lower (Liesenkotter 1996) and in
the other median Tg was 5.6 μg/L lower (Pedersen 1993).
Insu<icient iodine intake - pregnancy (median UIC less than 150 μg/L)
No trial reported on this outcome.
Insu<icient iodine intake - postpartum (breastfeeding: median UIC
less than 100 μg/L)
Results from one trial (Bouhouch 2014 (C)) with 175 women show
that those who received oral iodine-only supplements were less
likely to have inadequate iodine intake in the postpartum period
compared to those who received no iodine (average RR 0.81; 95%
CI 0.69 to 0.96) (Analysis 3.12).
Excessive iodine intake (pregnancy only: median UIC greater than or
equal to 500 μg/L)
No trial reported on this outcome.
Infant/child secondary outcomes
Small-for-gestational age (as defined by trial authors)
One trial with 58 neonates (Zhou 2015) reported this outcome
(average RR 1.50; 95% CI 0.27 to 8.32) (Analysis 3.13).
Congenital anomalies (including cretinism, as defined by trial authors)
One trial with 57 infants (Zhou 2015) reported on congenital
anomalies and showed no cases in either group (Analysis 3.14).
Growth (anthropometric Z scores)
No trial reported on this outcome.
Neonatal goitre (assessed by any method)
Two trials with 228 neonates (Glinoer 1993; Liesenkotter 1996)
reported on this outcome and showed a lower likelihood of
neonatal goitre in the oral iodine-only supplementation group
compared to the control group (average RR 0.11; 95% CI 0.02
to 0.56) (Analysis 3.15). We found no evidence of statistical
heterogeneity (I2 = 0%, Tau2 = 0.00 and Chi2 test for heterogeneity
P = 0.76).
Neonatal thyroid volume (in mL) (assessed by any method)
This outcome was reported in two studies with 228 assessments
(Glinoer 1993; Liesenkotter 1996) which showed a lower neonatal
thyroid volume, by 0.53 mL, in the oral iodine-only group in
comparison to the control group (95% CI -1.02 to -0.03) (Analysis
3.16). However there was significant statistical heterogeneity (I2 =
91%, Tau2 = 0.12 and Chi2 test for heterogeneity P = 0.0007).
Insu<icient neonatal iodine intake (median UIC less than 100 μg/L)
No trial reported on this outcome.
Child mental or motor development (as defined by trial authors)
One trial (Zhou 2015) reported on child cognitive, language
development, motor, social-emotional and adaptive behaviour
scores at 18 months of age for 53 children assessed by the Bayley
scales of infant and toddler development (Bayley-Ⅲ). Scores were
similar in both groups (Analysis 3.17; Analysis 3.18; Analysis 3.19;
Analysis 3.20; Analysis 3.21). The same trial also reported moderate
and severe developmental delays based on the cognitive, language
and motor scores and found no significant diAerences between
groups (Analysis 3.22; Analysis 3.23; Analysis 3.24; Analysis 3.25;
Analysis 3.26; Analysis 3.27).
Infant death (death in the first year of life)
No trial reported on this outcome.
(4) Oral iodine supplement with other vitamins and/or
minerals versus only other vitamins and/or minerals (exact
same formulation of other vitamins/minerals, but no iodine)
(three trials, 694 participants)
Three studies involving 694 women were included in this
comparison (Brucker-Davis 2013; Nohr 2000; Gowachirapant 2014);
all three contributed data. None were assessed as high quality.
Maternal primary outcomes
Hypothyroidism - pregnancy (as defined by trial authors)
Data from one trial (Gowachirapant 2014) involving 365 women
showed no diAerence in risk of hypothyroidism in pregnancy
between women who received supplements containing iodine and
other vitamins/minerals and those who received only the other
vitamins/minerals (average RR 1.90; 95% CI 0.57 to 6.38) (Analysis
4.1).
Hypothyroidism - postpartum (as defined by trial authors)
One study (Gowachirapant 2014) with 254 women reported on this
outcome and found no evidence of diAerence in the likelihood of
postpartum hypothyroidism between groups (average RR 0.97; 95%
CI 0.06 to 15.32) (Analysis 4.2).
Preterm birth (as defined by trial authors)
Only one trial (Gowachirapant 2014) involving 318 women reported
on preterm birth, and showed no diAerence between groups
(average RR 0.51; 95% CI 0.23 to 1.14) (Analysis 4.3).
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Maternal adverse e<ect: elevated TPO-ab - pregnancy (as defined by
trial authors)
One trial (Gowachirapant 2014) involving 359 women showed no
diAerence between groups (average RR 0.95; 95% CI 0.44 to 2.07)
(Analysis 4.4).
Maternal adverse e<ect: elevated TPO-ab - postpartum (as defined by
trial authors)
This outcome was reported in one trial (Gowachirapant 2014) with
235 women, which showed no diAerence between groups (average
RR 1.03; 95% CI 0.79 to 1.33) (Analysis 4.5).
Maternal adverse e<ect: hyperthyroidism - pregnancy (as defined by
trial authors)
One trial with 365 women reported on this outcome
(Gowachirapant 2014) and found no diAerence between groups
(average RR 1.90; 95% CI 0.57 to 6.38) (Analysis 4.6).
Maternal adverse e<ect: hyperthyroidism - postpartum (as defined by
trial authors)
This outcome was reported in one trial involving 257 women
(Gowachirapant 2014) (average RR 0.35; 95% CI 0.12 to 1.06)
(Analysis 4.7).
Maternal adverse e<ect: digestive intolerance - pregnancy (as defined
by trial authors)
One trial with 76 women reported on this outcome (Brucker-
Davis 2013) and found a higher likelihood of digestive intolerance
in the group that received oral iodine supplementation with
other micronutrients compared to those who received only other
micronutrients. One third of women (33.3%) in the iodine group
and 2.2% of women in the control group dropped out of the study
due to nausea or vomiting (average RR 15.33, 95% CI 2.07 to 113.70;
participants = 76) (Analysis 4.8).
Infant/child primary outcomes
Perinatal mortality (including stillbirth/fetal death and neonatal
death, as defined by trial authors)
No trial reported on this outcome.
Low birthweight (less than 2500 g)
One study with 319 infants reported on this outcome
(Gowachirapant 2014) and showed no diAerence between groups
(average RR 0.61; 95% CI 0.27 to 1.39) (Analysis 4.9).
Neonatal hypothyroidism or elevated TSH (as defined by trial authors)
This outcome was reported in one trial (Gowachirapant 2014) with
219 infant assessments; the average RR for neonatal elevated TSH
was 0.58 (95% CI 0.11 to 3.12) (Analysis 4.10).
Neonatal adverse e<ect - elevated TPO-ab (as defined by trial authors)
No trials reported this outcome.
Neonatal adverse e<ect - hyperthyroidism (as defined by trial authors)
No trials reported this outcome.
Maternal secondary outcomes
Spontaneous miscarriage (as defined by trial authors)
Two trials (Brucker-Davis 2013; Gowachirapant 2014) with
information on 587 pregnancies showed a similar likelihood of
spontaneous miscarriage (average RR 1.26; 95% CI 0.60 to 2.62) and
no evidence of statistical heterogeneity (I2 = 0%, Tau2 = 0.00 and Chi2
test for heterogeneity P = 0.43) (Analysis 4.11).
Maternal goitre - pregnancy (assessed by any method)
One trial with 366 women (Gowachirapant 2014) showed no
diAerence between groups (average RR 1.89; 95% CI 0.56 to 6.34)
(Analysis 4.12).
Maternal goitre - postpartum (assessed by any method)
This outcome was reported in one study (Gowachirapant 2014)
involving 262 women. Results showed no diAerence between
women who received oral iodine with other micronutrients and
those who received only other micronutrients (average RR 2.06;
95% CI 0.64 to 6.68) (Analysis 4.13).
Maternal thyroid volume - pregnancy (in mL) (assessed by any
method)
Two trials (Brucker-Davis 2013; Gowachirapant 2014) with 442
participants reported median prenatal thyroid volume so we did
not perform a meta-analysis. Values were similar in both groups
in one trial (Gowachirapant 2014) and 0.4 mL lower in the group
receiving iodine with other micronutrients compared to the no-
iodine group in the other trial (Brucker-Davis 2013) (Table 2).
Maternal thyroid volume - postpartum (in mL) (assessed by any
method)
Two trials (Brucker-Davis 2013; Gowachirapant 2014) with 300
women reported median postpartum thyroid volume, so we did not
perform a meta-analysis for this outcome. Findings showed similar
values in both groups in one trial (Gowachirapant 2014) and 1.2 mL
lower thyroid volume in the group that received iodine with other
micronutrients compared to the no-iodine group in the other trial
(Brucker-Davis 2013)(Table 3).
Maternal Tg - pregnancy (μg/L)
This outcome was reported in three studies (Brucker-Davis 2013;
Nohr 2000; Gowachirapant 2014) with 508 women. All three
trials reported median Tg therefore we did not perform a meta-
analysis. In each of these trials, prenatal Tg concentrations were
lower in women who received iodine supplements with other
micronutrients compared to those who received no iodine (Table
4). DiAerences ranged from 2.1 μg/L to 5.3 μg/L.
Maternal Tg - postpartum (μg/L)
Two trials involving 300 women (Brucker-Davis 2013;
Gowachirapant 2014) reported median postpartum Tg. In both of
these studies, Tg concentrations were lower in the group receiving
iodine plus other micronutrients than in the no-iodine group (Table
5), in one study by 1.57 μg/L (Gowachirapant 2014) and in another
by 11.6 μg/L (Brucker-Davis 2013).
Insu<icient iodine intake - pregnancy (median UIC less than 150 μg/L)
Two studies with 432 participants reported on this outcome
(Brucker-Davis 2013; Gowachirapant 2014). Results show
that women who received iodine supplements with other
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micronutrients had a lower likelihood of insuAicient iodine
intake in pregnancy compared to those who received only other
micronutrients (average RR 0.64; 95% CI 0.51 to 0.80) (Analysis 4.14).
There was no evidence of statistical heterogeneity for this outcome
(I2 = 0%, Tau2 = 0.00 and Chi2 test for heterogeneity P = 0.56).
Insu<icient iodine intake - postpartum (breastfeeding: median UIC
less than 100 μg/L)
Findings from one trial (Gowachirapant 2014) with 250 women
showed no clear diAerence of having insuAicient iodine intake
postpartum (average RR 0.80; 95% CI 0.61 to 1.04) (Analysis 4.15).
Excessive iodine intake (pregnancy only: median UIC greater than or
equal to 500 μg/L)
One study with 356 women reported on this outcome
(Gowachirapant 2014) and found a greater likelihood of excessive
iodine intake in pregnancy in women who received iodine and other
vitamins/minerals compared to those who received only other
vitamins/minerals (average RR 4.33; 95% CI 1.24 to 15.07) (Analysis
4.16).
Infant/child secondary outcomes
Small-for-gestational age (as defined by trial authors)
This outcome was reported in one trial (Gowachirapant 2014) with
319 assessments which showed no evidence of diAerence between
groups (average RR 1.24; 95% CI 0.74 to 2.06) (Analysis 4.17).
Congenital anomalies (including cretinism, as defined by trial authors)
No trials reported on this outcome.
Growth (anthropometric Z scores)
No trials reported on this outcome.
Neonatal goitre (assessed by any method)
No trials reported on this outcome.
Neonatal thyroid volume (in mL) (assessed by any method)
This outcome was reported in one trial (Gowachirapant 2014)
which assessed 131 neonates and found a trend towards lower
thyroid volume in the group whose mothers received iodine with
other micronutrients compared to those who received only other
micronutrients (MD -0.09; 95% CI -0.18 to -0.00) (Analysis 4.18).
Insu<icient neonatal iodine intake (median UIC less than 100 μg/L)
One trial (Gowachirapant 2014), which assessed 159 neonates,
found a higher likelihood of insuAicient iodine intake in the iodine
compared to the control group (average RR 2.14; 95% CI 1.04 to
4.37) (Analysis 4.19).
Neonatal mental or motor development (as defined by trial authors)
One study (Gowachirapant 2014) reported scores from the Neonatal
Behavioral Assessment Scales for 149 neonates in median and IQR
(Table 6). Out of the eight sub-scales, three showed higher median
scores in the oral iodine group compared to the control group, one
showed a higher score in the control group, and three showed equal
scores in both groups.
Infant death (death in the first year of life)
No trials reported on this outcome.
(5) Any injected iodine supplement versus same supplement
without iodine or no treatment/placebo (three trials,1463
participants)
Three trials were included in this comparison (Kevany 1969;
Pharoah 1971 (C); Thilly 1978), all of which contributed data. One
trial did not report the number of women randomised (Pharoah
1971 (C)). None of the studies were assessed as high quality.
Maternal primary outcomes
None of the trials reported on this review's maternal primary
outcomes (hypothyroidism during pregnancy or postpartum;
preterm birth or any adverse eAect in pregnancy or postpartum).
Infant/child primary outcomes
Perinatal mortality (including stillbirth/fetal death and neonatal
death, as defined by trial authors)
One trial with 399 assessments (Thilly 1978) reported on this
outcome and found a trend towards lower perinatal mortality in
the injected-iodine compared to the control group (average RR 0.66;
95% CI 0.42 to 1.03) (Analysis 5.1).
No trials reported on this review's other infant primary outcomes
(low birthweight, hypothyroidism or elevated TSH or any adverse
eAect).
Maternal secondary outcomes
No trials reported on the prespecified maternal secondary
outcomes (spontaneous miscarriage, maternal goitre during
pregnancy or postpartum, thyroid volume - pregnancy or
postpartum, Tg - pregnancy or postpartum, insuAicient or excessive
iodine intake during pregnancy or postpartum).
Infant/child secondary outcomes
Congenital anomalies (including cretinism, as defined by trial authors)
One study (Pharoah 1971 (C)), which assessed 818 children, showed
a lower frequency of congenital anomalies in the injected iodine
group compared to the control group (average RR 0.27; 95% CI 0.12
to 0.60) (Analysis 5.2).
Neonatal goitre (assessed by any method)
One trial with 465 neonates (Kevany 1969) reported on this
outcome; no events were found in either group (Analysis 5.3).
Mental or motor development (as defined by trial authors)
Data from two trials (Kevany 1969; Thilly 1978), which measured
174 children, showed a higher IQ score, by 11.21 points on average,
in the injected iodine compared to the control group (95% CI 7.96
to 14.46), with no statistical heterogeneity (I2 = 0%, Tau2 = 0.00; Chi2
test for heterogeneity P = 0.70) (Analysis 5.4).
No trials reported on any of the other infant/child prespecified
secondary outcomes (growth, small-for-gestational age, thyroid
volume, insuAicient neonatal iodine intake or infant death).
(6) Injected iodine-only supplement versus no intervention or
placebo (three trials)
All of the trials included in comparison 5 reported using injected
iodine-only supplements (Kevany 1969; Pharoah 1971 (C); Thilly
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1978). Therefore the findings for comparison 6 are the same as for
comparison 5 and are not repeated here.
(7) Injected iodine supplement with other vitamins and/or
minerals versus only other vitamins and/or minerals (exact
same formulation of other vitamins/minerals, but no iodine)
(no trials)
No studies were included in this comparison.
D I S C U S S I O N
Summary of main results
This review evaluates the eAects of oral or injected
iodine supplementation alone or in combination with other
micronutrients prior to, during, or following pregnancy. It includes
14 trials, though only 11 (with over 2700 women) contributed data.
Eight of these 11 trials compared iodine alone versus no treatment
or placebo (five oral and three injected) and three compared iodine
with other vitamins/minerals compared to only other vitamins/
minerals (all oral). We did not identify any studies that used
injected iodine with other vitamins/minerals compared to only
other vitamins/minerals.
We have summarized the primary outcome findings along with an
overall assessment of quality of evidence in 'Summary of findings'
tables (Summary of findings for the main comparison; Summary of
findings 2).
In comparison to the group that received no iodine, those
who received iodine had a lower likelihood of postpartum
hyperthyroidism (1.6% versus 4.9% in three trials, low-quality
evidence) and a higher likelihood of digestive intolerance in
pregnancy (33.3% versus 2.2% in one trial, very low-quality
evidence). Both hyperthyroidism and digestive intolerance were
considered potential adverse eAects. Those who received iodine
supplementation also had a lower likelihood of perinatal mortality
(11.9% versus 18.2% in two trials, low-quality evidence), though
this finding was not statistically significant. For the remaining
primary outcomes, there were no clear diAerences between groups.
For secondary outcomes, in comparison to the group which
received no iodine, those who received iodine supplementation
had lower likelihood of insuAicient iodine intake in pregnancy (two
trials) and the postpartum period (two trials), greater likelihood of
excessive iodine intake in pregnancy (one trial), lower likelihood
of congenital anomalies (two trials), lower likelihood of neonatal
goitre (three trials), lower neonatal thyroid volume (three trials),
higher likelihood of neonatal insuAicient iodine intake (one trial)
and higher child mental development score (two trials).
No trials reported on infant/child growth or infant death and we
found evidence of no eAect for the remaining secondary outcomes.
Our findings, both those showing an eAect and those showing no
eAect, must be interpreted with caution due to the low number of
studies contributing data and small sample sizes.
Overall completeness and applicability of evidence
This review included data from 11 randomised or quasi-
randomized controlled trials that have taken place in 13 countries
since the 1960s. We consider this evidence base to be limited,
both in the number of trials and included women and in the
outcomes of interest reported. The majority of primary outcomes
were reported in only one or two trials. Where we identified
substantial statistical heterogeneity, we were unable to perform
any of the planned subgroup analyses because of insuAicient data.
None of the included trials were assessed as high quality and the
quality of evidence for all of the primary outcomes was considered
low or very low.
Iodine supplementation in women who may become pregnant, and
pregnant or breastfeeding women generally aims to prevent and/
or treat iodine deficiency and its consequences, both in the woman
and her child. Our review has shown that iodine supplementation
may decrease the risk of postpartum hyperthyroidism and increase
the likelihood of experiencing nausea or vomiting in pregnancy.
Evidence for these outcomes came from trials which took place in
areas with mild to moderate iodine deficiency. These findings must
be interpreted cautiously; the postpartum findings were driven
by findings from one study and the digestive intolerance results
came from one trial. There was an indication of decreased risk of
perinatal mortality, though the diAerence between groups was not
statistically significant and all of the events occurred in one trial
which took place in a setting with severe iodine deficiency.
We have also demonstrated that iodine supplementation may
aAect indicators of iodine intake and iodine or thyroid status in
women and their children - mostly positively with the exception
of an increased risk of excessive intake in pregnancy and higher
likelihood of insuAicient neonatal intake. We also identified
evidence for prevention of cretinism in a severely iodine-deficient
area and mixed findings on mental development indicators, with
positive eAects in studies that took place in settings with severe
deficiency. We had planned on performing subgroup analyses,
including by baseline iodine status, however we did not identify
enough trials to perform these additional analyses for any of the
included outcomes.
The importance of routine iodine supplementation for important
outcomes in pregnancy and postpartum and in children under
two still needs to be demonstrated. To our knowledge there are
five planned, ongoing or unpublished trials which may be eligible
for inclusion in this review, in addition to data not yet published
for the Indian component of the Gowachirapant 2014 trial (see
Characteristics of ongoing studies). We expect that when reported,
these trials will help fill some of the evidence gaps identified in
this review. This review should be updated to incorporate the new
findings once they are published.
Quality of the evidence
The overall risk of bias was unclear in most of the trials. Methods
for sequence generation and allocation concealment were either
not specified or considered at high risk of selection bias for
most trials. Similarly, most trials did not describe blinding of
personnel, participants and outcome assessors or the methods
were considered at high risk of performance or detection bias. For
most of the outcomes however, lack of blinding would be unlikely
to influence results, though we cannot rule out this possibility.
All but two studies were considered at either high risk of attrition
bias due to incomplete outcome data or unclear risk because this
information was not provided. For reporting and other bias, we
generally did not have enough information to classify trials as high
or low risk.
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We assessed the quality of the evidence using GRADE and judged
the evidence for comparison 1, any supplement containing iodine
compared with same supplement without iodine or no treatment/
placebo, for maternal primary outcomes (Summary of findings
for the main comparison), and child primary outcomes (Summary
of findings 2) (no outcomes beyond the neonatal period were
reported in the included trials). For maternal outcomes, the quality
of evidence was judged as low for maternal hypothyroidism
during pregnancy, postpartum, preterm, elevated TPO-ab during
pregnancy and postpartum, hyperthyroidism during pregnancy
and postpartum. Digestive intolerance was judged as very low-
quality evidence. For child outcomes, the quality of evidence
was judged as low to very low for perinatal mortality, low
birthweight, neonatal hypothyroidism or elevated TSH, and
neonatal elevated TPO-ab. The main reasons for downgrading were
design limitations, wide confidence intervals and small event size.
Potential biases in the review process
We aimed to minimize bias at each stage of the review process. Two
review authors independently assessed eligibility for inclusion,
carried out data extraction and assessed risk of bias. However
we recognize that this type of review requires many subjective
judgements and others undertaking the same review may have
made diAerent decisions, particularly regarding eligibility and risk
of bias.
We attempted to use a systematic and transparent process to
assess the quality of the evidence relating to specific outcomes
and produce 'Summary of findings' tables. Two review authors
independently assessed the evidence for each quality domain for
each outcome. Any disagreements were discussed and we involved
a third review author where necessary. We planned to use funnel
plots to assess publication bias but we were not able to do this
for any of the outcomes due to the limited number of studies
contributing data. We also relied mostly on published literature and
did not systematically search for grey literature.
Agreements and disagreements with other studies or
reviews
Zhou and colleagues conducted a systematic review on the
eAects of iodine supplementation during pregnancy or the
periconceptional period on child growth and development as
well as pregnancy outcomes and thyroid function, and included
randomised or quasi-randomized controlled trials (Zhou 2013). Our
findings are consistent with the authors' conclusions that there was
a lack of high-quality evidence on the eAect of supplementation on
child growth and cognition.
Taylor and colleagues undertook a systematic review on the impact
of iodine supplementation in settings with mild-to-moderate
iodine deficiency (Taylor 2013). They included observational
studies and randomised controlled trials of maternal iodine
supplementation in pregnancy. Of the trials, they found that most
showed a positive impact on maternal Tg levels and maternal
thyroid volume, no evidence of negative eAect on maternal TPO-
ab, and lower thyroid volume in neonates of women who received
iodine. We found similar results, with the exception of maternal
thyroid volume, where our findings were mixed.
Zimmermann and colleagues conducted a narrative systematic
review/systematic literature search on the eAects of iodine
deficiency in pregnancy and infancy, and included trials on
supplementation before and during pregnancy (Zimmermann
2012a). The authors concluded that in moderate to severely iodine-
deficient areas, iodine supplementation prevented cretinism,
increased birthweight, reduced perinatal and infant death and
improved child cognition. They also concluded that mild deficiency
could impair thyroid function but that eAects on child cognitive or
neurologic function were uncertain. This review reached diAerent
conclusions to ours, however this may be explained by its design;
it did not specify criteria for study inclusion and included non-
randomized trials as well as studies with diAerent comparisons.
An additional review and meta-analysis looked at iodine and
mental development of young children and included randomised
and non-randomized supplementation trials (in mothers or infants,
or both) and prospective cohort studies stratified by mother or
infant iodine status (Bougma 2013). Findings showed a positive
impact of iodine, regardless as to the study design, ranging from 6.9
to 10.2 IQ points, whereas our findings on child development were
mixed.
Angermayr and Clar conducted a Cochrane Review on the eAects of
iodine supplementation for preventing iodine deficiency disorders
in children and found that most trials resulted in increased
urinary iodine excretion, an overall tendency towards reduction of
goitre and mixed results for cognitive, psychomotor and physical
development (Angermayr 2004). Less than 2% of children studied
showed adverse eAects and these eAects were largely minor and
transient. Most trials included in this review used iodized oil and
most were considered low quality.
In the Cochrane Review on iodine supplementation for preventing
mortality and adverse neurodevelopmental outcomes in preterm
infants, Ibrahim and colleagues found only one eligible trial to
include (Ibrahim 2006). This trial was underpowered for mortality
and did not assess neurodevelopment. It showed no eAect of iodine
on T3, T4 or thyrotropin or the incidence of chronic lung disease.
Our review did not include any of these outcomes.
Aburto and colleagues performed a review on the eAect and safety
of salt iodization for prevention of iodine deficiency disorders,
which included over 80 studies of various designs (Aburto 2014).
Findings showed that iodized salt increased intelligence quotient
and urinary iodine excretion and reduced the risk of goitre,
cretinism, low intelligence and low urinary iodine excretion.
There was no eAect found on hypothyroidism, considered by
authors as a potential adverse eAect, and inconsistent results for
hyperthyroidism.
A Cochrane Review on point-of-use fortification of foods with
multiple-micronutrient powders for women during pregnancy
identified one eligible trial that included iodine in the formulation,
along with six other nutrients (Suchdev 2015). The comparison
was tablets with the same formulation, therefore the findings are
not relevant for discussion here. Similarly, the Haider and Bhutta
Cochrane Review on multiple-micronutrient supplementation for
women during pregnancy included trials that compared multiple-
micronutrient supplements with supplements containing iron and
folic acid, iron only, or placebo (Haider 2015).
Some of our findings were unexpected. The evidence that iodine
supplementation reduced the likelihood of hyperthyroidism in the
postpartum period came mainly from one trial, which took place
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in women with mild iodine deficiency in Thailand (Gowachirapant
2014). We are not certain of a mechanism to explain this
relationship. It is possible that iodine supplementation helped
to prevent postpartum thyroiditis, a feature of which is oPen
hyperthyroidism (Stagnaro-Green 2012). Other available evidence
however suggests that iodine has no eAect on or aggravates
postpartum thyroiditis. We also found, with data from the same
trial, that iodine supplementation increased the likelihood of
insuAicient iodine intake in neonates (as indicated by UIC)
(Gowachirapant 2014). This finding is also unexpected and we are
not aware of a plausible explanation.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Overall, there were insuAicient data for any meaningful conclusions
on the benefits and harms of routine iodine supplementation in
women before, during or aPer pregnancy. Based on the information
available for our primary outcomes, we found evidence of benefit
(reduced likelihood of postpartum hyperthyroidism) and harm
(increased likelihood of digestive intolerance) in settings with
mild to moderate iodine deficiency. We also found eAects, mostly
positive, on some indicators of iodine intake and iodine or thyroid
status. All of our findings must be interpreted with caution due
to the small number of trials and included women and low (or
very low) quality of the evidence. We did not identify any trials
that reported on growth (using anthropometric Z scores) or infant
death, and no trials reported on elevated thyroid-stimulating
hormone/hypothyroidism or adverse eAects in children beyond the
neonatal period.
Medical bodies in several countries have concluded that the
potential benefits of iodine supplementation in pregnancy and
breastfeeding (and in some countries in women before pregnancy)
outweigh the potential harms. In many countries, especially in
high-resource settings, it is common practice for women to take
multiple-micronutrient supplements during and aPer pregnancy
and these supplements oPen contain iodine.
Decisions on recommending or taking iodine supplements should
be informed by the likelihood and severity of potential benefits as
well as harms, and are influenced by values and preferences. For
some, knowledge that iodine supplements during these periods
can help ensure adequate intake may be suAicient, given the
scientific basis behind the recommended intakes. Others may want
more direct evidence on functional outcomes. Though we were
unable to explore the role of the women's initial iodine status in our
review, it is an important factor to consider. This information would
generally not be available for individuals but may be known for the
population.
Implications for research
This review highlights the need for additional high-quality
randomised controlled trials of iodine supplementation before,
during and aPer pregnancy on maternal and infant/child outcomes.
However given the body of evidence including and beyond this
review, it may be unethical to compare iodine to placebo or no
treatment in severe deficiency settings. Such trials may also be
unfeasible in any setting where pregnant and lactating women
commonly take prenatal supplements with iodine. Information
is also needed on optimal timing of initiation as well as
supplementation regimen and dose. We recommend future trials
include the outcomes from this review, especially the primary
outcomes, and follow children beyond the neonatal period. All
trials should assess potential adverse eAects, including the nature
and extent of digestive intolerance. Future research should be
reported in a way that allows assessment of risk of bias, full data
extraction and analysis by the subgroups specified in this review.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods • Study design: double-blind cluster-randomized, placebo-controlled trial with 2 arms• Unit of allocation: clinic (cluster)• Time period of recruitment and data collection: Morocco: recruitment went from 25 February-10
August 2010 and data collection went from 25 February 2010–6 August 2011
Participants • Description: 239 healthy postpartum women–infant pairs at their first vaccination visit• Location/setting: the provincial hospital of Amizmiz, the Atlas Mountains of southern Morocco• How participants were recruited and selected: women attending the clinic (cluster) on the same
day were enrolled into the same group. Randomization was done by vaccination clinic dates• Inclusion criteria: with no history of major medical illnesses or thyroid dysfunction, taking no long-
term medications; no history of iodine supplementation during pregnancy or lactation; infant born full
term; infant birthweight 2500 g or greater; breastfeeding mother; and infant 8 weeks of age or younger• Exclusion criteria:• Sample size: 239• Age: at baseline, the median age was 26 years (IQR 22–32)• Socioeconomic status: most women were reported to be illiterate• Nutritional status: at baseline, median maternal weight was 63 kg (56–69), height 155 cm (152–161),
and BMI 25.6 kg/m2 (23.1–28.2)• Baseline iodine status of participants/area: national median UIC in children is 69 μg/L• Baseline coverage of iodized salt: national mandatory salt iodization but poor compliance by salt
industry and lack of enforcement. No baseline data available for study but participants brought in salt
sample at 3 or 6 month visit – 68 samples available: 4 out of 68 (6%) were adequately iodized, 35 out
of 68 (51%) were inadequately iodized and 29 out of 68 (43%) had no measurable iodine. (Adequate
salt iodization: at least 15 ppm)• Breastfeeding practices (if applicable): a total of 95.8% (228/238) of the women were exclusively
breastfeeding at baseline and the rate reduced to 66.3% at 6 months postpartum
Interventions Experimental intervention: women received one dose of 400 mg of oral iodine as 2 soP-gel capsules
of iodized poppyseed oil (each containing 200 mg of iodine; Lipiodol®, Guerbet, Paris, France) and the
infant received placebo. This was considered the "indirect infant supplementation" group.
• Total number randomised: n = 121• Timing: first visit (infant immunization visit, before 8 weeks of age or younger), and at 9 months of age• Form: 2 soP-gel capsules for women, for oral intake• Frequency and duration: once• Iodine compound: potassium iodate• Iodine dose: 400 mg elemental iodine in a single dose• Other nutrients: none• Adherence: not specified
Control/comparison intervention: placebo
• Total number randomised: n = 118• Description: women received placebo (2 oral placebo capsules) and the infant received about 100 mg
of oral iodine, which was given as half of the contents of a soP-gel capsule of iodized poppyseed oil
(containing 200 mg of iodine; Lipiodol®, Guerbet, Paris, France). The supplements were provided at
baseline to the women and after 9 months for the infants only. This was considered the "direct infant
supplementation" group• Adherence: not specified
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Co-intervention(s): none reported
Outcomes • Postpartum: maternal UIC, breast milk iodine concentration, maternal TSH and T4, weight and
height, subclinical hypothyroidism, overt hypothyroidism, hypothyroxinaemia• Infant/child: infant UIC, infant TSH and T4, infant growth
Notes • Because 1 study arm (the control group) received an infant intervention (direct iodine supplementa-
tion to the infant), we did not include any infant data from this trial• 241 mother-infant pairs were recruited. 2 were excluded before randomisation because the infants
were older than 8 weeks at enrolment into the study• The analysis in this report adjusts for clustering, therefore no additional adjustments were required
for this review• Source of funding: ETH Zurich, Switzerland and the Medicor Foundation, Vaduz, Lichtenstein. Guerbet
(Paris, France) provided the iodized oil supplements and Burgerstein (Rapperswil, Switzerland) pro-
vided the placebo capsules free of charge
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomly assigned (using block randomisation) numbers to vaccination clin-
ic dates and mother-infant pairs attending the clinic on the same day were en-
rolled into the same group. The randomisation was done by computer-gener-
ated random numbers (study author communication)
Allocation concealment
(selection bias)
Low risk Randomization at cluster level is unlikely to produce selection bias
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk "Randomization was masked so that the participants, the investigators, and
the sponsor did not know which supplement was administered to which
groups."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information reported to determine
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Loss to follow-up greater than 20% (9-month outcome data for 75% (91/121) in
iodine group and 70% (83/118) in the control group)
Selective reporting (re-
porting bias)
High risk Primary outcomes described in the report are different from those in the clini-
cal trial registration
Other bias Unclear risk The study appears to be free of other sources of bias
Bouhouch 2014 (C)  (Continued)
 
 
Methods • Study design: randomised controlled trial with 2 arms• Unit of allocation: individual• Time period of recruitment and data collection: recruitment took place from July 2007-July 2008
Participants • Description: pregnant women in their first trimester• Location/setting: Nice, France• How participants were recruited and selected: women presenting at their first obstetrical visit
Brucker-Davis 2013 
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• Inclusion criteria: no personal history of thyroid disease, seen before 12 weeks of amenorrhoea, sin-
gleton pregnancy, normal thyroid tests on a systematic screening: FT4 higher than12 pmol/L (10th
percentile for first trimester in this population), TSH lower than 2.5 mIU/L, and TPO-ab below 100 UI/
mL• Exclusion criteria: iodine supplementation before inclusion in this study and UIE ≥ 400 μg/L• Sample size: 111• Age: control: 27 (18–39) years; treated population: 28 (21–37) years• Socioeconomic status: not specified• Nutritional status: BMI control: 22.3 (16.0–39.5) kg/m2; BMI treated population: 21.9 (17.9–30.8) kg/
m2• Baseline iodine status of participants/area: area of mild iodine deficiency. Baseline UIE control: 103
(14-355) μg/L; treated population: 111 (28-399) μg/L• Baseline coverage of iodized salt: 84% of women reported to consume iodized salt, no significant
differences between groups• Breastfeeding practices: not specified• Other important information about participants or setting: none
Interventions Experimental intervention: daily iodine-containing multiple-micronutrient supplements
• Total number randomised: n = 53• Timing:day of enrolment (in first trimester) until 3-months postpartum• Form: tablet• Frequency and duration: daily• Iodine compound: Oligobs Maxiode ®, 150 µg of iodine, Laboratoire CCD, Paris, France• Iodine dose: 150 μg/d• Other nutrients: 1.8 mg vitamin B1, 1.6 mg vitamin B2, 2 mg vitamin B6, 100 μg inositol, 400 μg (0.4
mg) folic acid, 3 μg vitamin B12, 5 μg vitamin D3, 15 mg zinc, 0.5 mg copper, 25 μg selenium• Adherence: assessed by the hospital pharmacist based on the number of pills brought back at each
visit. "good compliance established by pharmacist records"
Control/comparison intervention: multiple-micronutrient supplement without iodine
• Total number randomised: n = 58• Description: daily multiple-micronutrient supplement (Oligobs Grossesse ®, Laboratoire CCD) but
without iodine from the day of enrolment until the 3-month postpartum visit• Adherence: same as experimental intervention
Co-intervention(s): all women received a document from a dietician on how to optimize their dietary
iodine intake
Outcomes • Pregnancy, postpartum: maternal thyroid tests (including FT4, total T4, TBG, TSH, FT3, reverse T3,
Tg, anti-Tg antibodies, anti-TPO antibodies) and UIE at baseline and 2nd and 3rd trimester and 3
months postpartum. Thyroid volume was also assessed at baseline, 3rd trimester and 3 months post-
partum• Infant/child: not reported
Notes • Of 111 women included, 86 were followed until delivery• 1 woman in the iodine group was excluded soon after inclusion because her UIE was > 400 μg/L• Source of funding: French Ministry of Health, Direction of Clinical Research of Nice University Hospital.
Pharmaceutical Laboratory CCD (Paris, France) provided free supplement
Risk of bias
Bias Authors' judgement Support for judgement
Brucker-Davis 2013  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk The table of randomisation was obtained by a method of drawing of lots by
blocks, using tables of permutation
Allocation concealment
(selection bias)
Unclear risk Method of allocation concealment not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk "This was an open study."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The study was open
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 24 women did not complete the study (20 intervention group and 4 control
group). Loss to follow-up was unbalanced. In the iodine group, out of 53 ran-
domised there were 4 miscarriages, 1 induced abortion (for trisomy 18), 10
cases of digestive intolerance (nausea/vomiting), 3 cases of consent withdraw-
al and 2 missed data collection. In the control group, out of 58 randomised,
there were 3 miscarriages and 1 case of digestive intolerance
Selective reporting (re-
porting bias)
High risk Baseline information was only provided for those who completed the study
Other bias Unclear risk The study appears to be free of other sources of bias
Brucker-Davis 2013  (Continued)
 
 
Methods • Study design: double-blind randomised controlled trial with 3 arms• Unit of allocation: individual• Time period of recruitment and data collection: screening went from June 1990-December 1992
Participants • Description: pregnant women (mean 10.7, SEM 0.3 weeks' gestation)• Location/setting: prenatal clinic in Brussels, Belgium• How participants were recruited and selected: women visiting the prenatal clinic for the first time
were screened and only those with excessive thyroidal stimulation (see below criteria) were selected• Inclusion criteria: no known thyroid disease, less than 16 weeks' gestational age and biochemical
evidence of excessive thyroidal stimulation (elevated serum Tg level (> 20 μg/L) with either 1 or both
of low normal free T, index (< 1.23) as calculated from the T4/TBG ratio, and elevated molar ratio T3/
T4 (> 25 x 10-3)• Exclusion criteria: women with abnormal serum TSH level (< 0.2 or > 4.0 mu/L) and/or positive thyroid
antibodies• Sample size: 180 (120 in the iodine and control groups)• Age: not specified• Socioeconomic status: not specified• Nutritional status: not specified• Baseline iodine status of participants/area: baseline median UIC 36 μg/L• Baseline coverage of iodized salt: report describes it being typical of most Western European coun-
tries at the time, with no systematic addition of iodine to the diet• Breastfeeding practices: not specified• Other important information about participants or setting: none
Interventions Experimental intervention 1: oral iodine supplementation
Glinoer 1993 
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• Total number randomised: n = 60• Timing: from day of enrolment until day of delivery• Form: tablets from Christiaens-Pharma• Frequency and duration: daily• Iodine compound: potassium iodide (KI)• Iodine dose: 131 μg KI μg/day, corresponding to 100 μg/day elemental iodine per day• Other nutrients: no other nutrients• Adherence: not specified
Experimental intervention 2: oral iodine and L-thyroxine (L-T4) supplementation
• Total number randomised: n = 60• Timing: from day of enrolment until day of delivery• Form: tablets from Christiaens-Pharma• Frequency and duration: daily• Iodine compound: potassium iodide (KI)• Iodine dose: 131 μg KI/day, corresponding to 100 μg/day elemental iodine• Other nutrients: 100 μg L-T4 per day• Adherence: not specified
Control/comparison intervention: placebo
• Total number randomised: n = 60• Description: daily tablets from day of enrolment until day of delivery• Adherence: not specified
Co-intervention(s): none reported
Outcomes • Pregnancy: maternal total T3 and T4, TBG, free T4, TG, TSH, UIC, and thyroid volume were assessed
at baseline. Serum and urine determinations were repeated in the 2nd and 3rd trimesters• Postpartum: 2-6 days after delivery the same tests were repeated and a second ultrasound was per-
formed. Iodine was determined in breast milk• Infant/child: thyroid function parameters were determined in the neonates on cord blood, and thy-
roid ultrasound was performed at the age of 3-6 days
Notes • The iodine and L-T4 arm of the trial was not eligible for inclusion in this review. Only data from the
iodine and control arms were included• The researchers quoted: “It is important to recognize that the women investigated here do not rep-
resent an average pregnant woman, but are a highly selected group, corresponding to the extreme
fringe of the normal population”. They selected 9% (180/2000) of the women screened for the study,
based on the inclusion/exclusion criteria• A diffuse goitre (TV > 23 mL) was present in 10% of the cases, with TV ranging between 23-64 mL; a
goitre (n = 17) have not been included in the above calculations. Researchers said the number of cases
was too small in each group to allow statistical analysis• Source of funding: Fonds de la Recherche Scientifique Medicale Belge (contract 3.4531.91 to DG),
Solvay Duphar Gynaecology (Brussels, Belgium) and E. Merck Co (Darmstadt, Germany)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The report does not provide sufficient information on random sequence gen-
eration to determine risk: "women were subdivided into 3 equal groups"
Allocation concealment
(selection bias)
Unclear risk Insufficient information about allocation concealment to permit judgement of
‘Low risk’ or ‘High risk’.
Glinoer 1993  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Described as a double-blind randomised trial however there is insufficient in-
formation to determine who was blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to determine who was blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to make judgement
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to make judgement
Other bias Unclear risk The study appears to be free of other sources of bias
Glinoer 1993  (Continued)
 
 
Methods • Study design: randomised double-blind controlled trial with 2 arms• Unit of allocation: individual• Time period of recruitment and data collection: Thailand: October 2008-June 2013
Participants • Description: pregnant women in the first trimester• Location/setting: Ramathibodi Hospital of Mahidol University in Bangkok, Thailand• How participants were recruited and selected: recruited among those who registered at the Ra-
mathibodi Hospital• Inclusion criteria: singleton pregnancy, 18-40 years of age, gestational age ≤ 14 weeks, non-lactating,
generally healthy (no history of thyroid disorders), and not taking any iodine supplement• Exclusion criteria: TSH > 6.0 mIU/L at screening• Sample size: 511 women enrolled and randomised in Thailand• Age: not reported• Socioeconomic status: not reported• Nutritional status: 4% obese and 10%-13% overweight• Baseline iodine status of participants/area: described by authors as mild deficiency (UIC 110-112
µg/L)• Baseline coverage of iodized salt: 88%-89% purchased iodized salt for the household• Breastfeeding practices: not reported• Other important information about participants or setting: at baseline, 40% (placebo group) and
47% (iodine group) were uniparous, 4.7% has subclinical hyperthyroidism and 8.6% had subclinical
hypothyroidism
Interventions Experimental intervention: oral iodine supplementation
• Total number randomised: n = 262• Timing: starting in the first trimester• Form: oral iodine tablets• Frequency and duration: daily until delivery• Iodine compound: potassium iodide• Iodine dose: 200 µg elemental iodine• Other nutrients: see co-interventions below
Gowachirapant 2014 
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• Adherence: not reported (assessed by counting the tablets returned after delivery; good compliance
was defined as taking 80% of prescribed treatment)
Control/comparison intervention: placebo
• Total number randomised: n = 249• Description: identical tablet• Adherence: not reported
Co-intervention(s): multiple vitamin-mineral tablets without iodine, also until delivery
Outcomes • Pregnancy: thyroid function (TSH, free and total T4 and T3, Tg, thyroid antibodies), UIC and thyroid
gland volume in the 2nd and 3rd trimester• Postpartum: thyroid function, UIC and thyroid gland volume 6 weeks postpartum• Infant/child: birth characteristics (from hospital records) and thyroid gland volume at delivery and
6 weeks of age, thyroid function (TSH only?) at delivery from cord blood, spot UIC at 6 weeks of age,
Neonatal behavioural assessment scales at 6 weeks of age (Table 6)
Notes • Trial was also conducted in India but we have not yet located any reports with those data
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “women were allocated to two treatment groups by simple randomisation.”
Allocation concealment
(selection bias)
Unclear risk Allocation concealment method was not clear
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Subjects, caregivers and investigators were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Loss to follow-up was 19%-20% at the first follow-up visit (second trimester)
and > 20% for all subsequent visits, with 58%-59% having 6 weeks' postpartum
data (though loss was balanced between the groups and for similar reasons)
Selective reporting (re-
porting bias)
Unclear risk Unclear. More data were collected (through 24 months of age and in India) but
to date only this PhD thesis has been published
Other bias Unclear risk Appears to be free of other sources of bias
Gowachirapant 2014  (Continued)
 
 
Methods • Study design: quasi-randomized trial• Unit of allocation: appears to be individual• Time period of recruitment and data collection: unclear about recruitment period but injections
were given in the first week of October 1966, and repeated in the original and additional cohort at 3
years after first injection. Data were collected for up to 7 years (as reported in the 1994 study)
Kevany 1969 
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Participants • Description: women of childbearing age• Location/setting: 3 central sierra villages, Tapo, Huasahuasi and Ataquero in the Province of Tarma,
Peru, a mountainous region with an altitude of ˜3000 m. Tarma, a nearby town equipped with labo-
ratory and hospital facilities, served as headquarters for the field work and more detailed laboratory
work was carried out in Lima, about 5 hours away by automobile.• How participants were recruited and selected: women of childbearing age 16-45 years of age from
3 central sierra villages• Inclusion criteria: not specified• Exclusion criteria: not specified• Sample size: 792 (this number is given in the 1972 paper, though it is not clear if it is the number that
were randomised)• Age: between 16-45 years• Socioeconomic status: not specified• Nutritional status: not specified• Baseline iodine status of participants/area: mean UIE in the 3 villages = 17 μg/100 mL – including
pregnant/and non-pregnant cohort; (in the 1969 paper, it was reported as mean UIE (μg/24 hour): 17.2
± 1.1 (for 159 subjects which would include non-pregnant cohort)• Baseline coverage of iodized salt: report specifies that salt iodization had not been implemented in
these areas• Breastfeeding practices: not specified• Other important information about participants or setting: none
Interventions Experimental intervention: injected iodized oil
• Total number randomised: n = 390• Timing: at baseline and after 3 years• Form: intramuscular injection• Frequency and duration: 2 times (baseline and after 3 years) single dose• Iodine compound: iodine• Iodine dose: 2 mL iodized oil containing 950 mg iodine. Adult women with nodular disease were given
0.2 mL (95 mg iodine)• Other nutrients: no other nutrients• Adherence: not specified
Control/comparison intervention: placebo
• Total number randomised: n = 402• Description: intramuscular placebo injection of non-iodized poppy-seed oil (Ethiodol) at baseline and
after 3 years• Adherence: not specified
Co-intervention(s): none reported
Outcomes • Pregnancy: maternal thyroid hormone concentrations in the last 5 months of pregnancy, blood and
urine samples during pregnancy• Postpartum: iodine content in breast milk, iodine content in breast milk at 19th month post-injection
(initial injection), blood and urine sample at the time of delivery and postpartum (not stated when
postpartum)• Infant/child: clinical evaluation, goitre, body weight, stature or supine length, sitting height or crown-
rump length, head and chest circumference, upper arm circumference, triceps, subscapular and waist
skinfold thickness and bi-acromial and bi-ilio cristal diameters, bone maturation by radiologic tests,
bone age, motor and neuropsychological by Gesell test, neuropsychological development was mea-
sured by the Stanford-Binet and the Brunet-Lezine tests, audiometry, voice, buccofacial praxis, artic-
ulation praxis and verbal expression and comprehension tests, EEG, UIE, other blood and urine tests
Kevany 1969  (Continued)
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Notes • The 1972 report is mainly concerned with the evaluation of children who were born into the iodine
programme and have been followed up to 5 years after the injection of their mothers. The 1994 report
provides additional details about maternal blood and urine sample as well as infant neurodevelop-
mental outcomes.• From the 1969 study, description of follow-up for the entire cohort (i.e. all children, women, men). It
is not entirely clear whether childbearing women received follow-up at these specified time points
regardless of conception date. Follow-ups were performed on:• Goitre: at 6, 12, and 18 months after injection (examiners were ignorant of both the prior estimated
gland size and the type of injection. The size of goitre and presence of nodularity were recorded)• Clinical assessment: made by members of the same team throughout the program, looking out for
any side effects, especially thyrotoxicosis• I131 scans – unclear about timing• Thyroid function – unclear about timing• UIE – at 6, 9, 13, 15, and 19 months after injection (in a subgroup)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk "In other groups (excluding schoolchildren), random injection of placebo and
iodine was accomplished by consecutive alternation of iodine and placebo in-
jection."
Allocation concealment
(selection bias)
High risk Alternate allocation evident
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not described in sufficient detail to make judgement
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Goitre: “Examiners were ignorant of both the prior estimated gland size and
the type of injection”, but unclear about other outcomes such as child devel-
opment
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether all pregnancies and births were captured: “As many pregnan-
cies as possible occurring in both the treatment and placebo groups were fol-
lowed throughout gestation”
Only a subgroup of individuals received thyroid function tests, I131 and UIE.
No clear description of how these subjects were selected. Also, unclear how
many childbearing women continued in the study at subsequent follow-up
time points as Table 3 (p 423) refers to entire cohort
Selective reporting (re-
porting bias)
Unclear risk As above for incomplete outcome data
In addition, in the 1994 paper it was mentioned, “Accordingly, in a recalcula-
tion of results, only the children of mothers who had UIE or T4 levels that were
verified and found to be consistent with a definition of iodine deficient or nor-
mal were included" (Table 2)
Other bias High risk This trial recruited women and provided the intervention before they became
pregnant. The intervention may have affected their probability of becoming
pregnant, potentially leading to differences between groups and introducing
bias
Kevany 1969  (Continued)
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Methods • Study design: randomised trial with 3 arms• Unit of allocation: individual• Time period of recruitment and data collection: screening took place during 1984-1985
Participants • Description: pregnant women• Location/setting: Sweden• How participants were recruited and selected: women screened for rubella and TPO-ab• Inclusion criteria: pregnant women in the first trimester screened for rubella antibodies and TPO-ab
titer of 1:1600 or greater• Exclusion criteria: history of Graves' disease or receiving L-T4 medication• Sample size: 58• Age: not specified• Socioeconomic status: not specified• Nutritional status: not specified• Baseline iodine status of participants/area: not available• Baseline coverage of iodized salt: not available• Breastfeeding practices: not specified• Other important information about participants or setting: no
Interventions Experimental intervention 1: potassium iodide
• Total number randomised: n = 20• Timing: from 1-40 weeks postpartum• Form: oral• Frequency and duration: daily• Iodine compound: potassium iodide• Iodine dose: 0.15 mg iodide (as potassium iodide)• Other nutrients: no other nutrients• Adherence: not specified
Experimental intervention 2: L-thyroxine (L-T4)
• Total number randomised: n = 18• Timing: from 1-40 weeks postpartum• Form (injected/oral, tablet, drops etc): oral• Frequency and duration (daily until birth, single dose, etc): daily• Iodine compound: no iodine• Iodine dose (specify if compound or elemental iodine): not applicable• Other nutrients: L-thyroxine (L-T4)• Adherence: not specified
Control/comparison intervention: no intervention
• Total number randomised: n = 18• Description: no intervention• Adherence: not applicable
Co-intervention(s): in women with severe symptoms during the hypothyroid phase, L-T4 supplemen-
tation was provided (n = 6 in the iodine group and n = 4 in the control group). This generally occurred at
the beginning of week 20 postpartum
Outcomes • Pregnancy:• Postpartum: thyroid hormones (TSH, T4, T3) and antibodies (TPO-ab) at 8 time points in the first year
postpartum
Kämpe 1990 
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• Infant/child
Notes • To help ensure adherence and the study assessments, a physician regularly called participants by
phone• Source of funding: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method for sequence generation not specified (“women were randomly divid-
ed into three groups”)
Allocation concealment
(selection bias)
Unclear risk Allocation concealment method not specified
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control group received no intervention therefore blinding was not possible
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Report does not describe whether assessors were blinded to group assignment
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to make judgement. Data were not reported in a way
that showed the numbers for each postpartum assessment for each outcome
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to make judgement
Other bias Unclear risk The study appears to be free of other sources of bias
Kämpe 1990  (Continued)
 
 
Methods • Study design: quasi-randomized trial with 2 arms (iodine supplementation and no intervention).
Women were assigned to a trial arm according to which day of the week (Monday or Tuesday) they
first attended the hospital for antenatal care• Unit of allocation: individual• Time period of recruitment and data collection: not specified
Participants • Description: pregnant women• Location/setting: Benjamin Franklin Hospital at the Free University in Berlin, Germany• How participants were recruited and selected: women consulting the pregnancy care unit of the
hospital• Inclusion criteria: pregnant women with a mean 11.2 weeks' gestation and with no clinical evidence
of autoimmune thyroid disease• Exclusion criteria: history of Graves' disease or receiving L-T4 medication• Sample size: 108• Age: mean age of participants 32.4 (21-40) years• Socioeconomic status: not specified• Nutritional status: not specified
Liesenkotter 1996 
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• Baseline iodine status of participants/area: described as "moderate deficiency". Overall median
UIC was 64 µg/L, with no statistically significant difference between groups. 42% had goitre at baseline
(according to author definition of thyroid volume > 18 mL based on German population normal ranges)• Baseline coverage of iodized salt: not available• Breastfeeding practices: not specified• Other important information about participants or setting: none
Interventions Experimental intervention: iodine
• Total number randomised: n = 228• Timing: throughout pregnancy and postpartum• Form (injected/oral, tablet, drops etc): oral• Frequency and duration (daily until birth, single dose, etc): daily• Iodine compound: potassium iodine• Iodine dose (specify if compound or elemental iodine): 300 µg elemental iodine• Other nutrients: no other nutrients• Adherence: not specified
Control/comparison intervention: no iodine
• Total number randomised: n = 70• Description: no iodine supplementation• Adherence: not specified
Co-intervention(s): none reported
Outcomes • Pregnancy: urinary iodine, blood (thyroid peroxidase antibodies, TSH, T3, T4, TBG, Tg) and thyroid
volume at the beginning of pregnancy (mean 11.2 weeks of gestation)• Postpartum: urinary iodine, blood (TPO-ab, TSH, T3, T4, TBG, Tg) and thyroid volume at mean 11 days
(range 2-21) postpartum• Infant/child: infant urinary iodine and TPO-ab in blood at 5 days of age, thyroid volume at 2 weeks
of age
Notes • More women in the control group than the intervention group were TPO-ab-positive at baseline (6/70
versus 1/38)• Source of funding: grant from the Deutsche Forschungsgesellschaft (SFB)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quasi-randomized. “The women were randomly assigned to two groups ac-
cording to the two different days of the week when they presented first in the
Pregnancy Care Unit”
Allocation concealment
(selection bias)
Low risk Randomization at cluster level is unlikely to produce selection bias
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding or use of placebo was reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Person who conducted thyroid volume assessment was blinded to group as-
signment however the report did not specify whether assessments of other
outcomes were blinded
Liesenkotter 1996  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement. Report stated that the study in-
cluded 108 women and reports outcome data for 108 women. However the
number randomised to each group and whether any (and how many) were lost
to follow-up was not reported
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk The study appears to be free of other sources of bias
Liesenkotter 1996  (Continued)
 
 
Methods • Study design: double-blind, placebo-controlled trial with imbalanced randomisation and 3 arms
(placebo, 75 or 150 µg iodine/d)• Unit of allocation: individual• Time period of recruitment and data collection: March 2004-October 2005
Participants • Description: pregnant women in the third trimester (intervention began postpartum)• Location/setting: Dunedin, New Zealand• How participants were recruited and selected: women were recruited in their final month of preg-
nancy through advertisements in a local newspaper and maternity hospital• Inclusion criteria: healthy, no history of thyroid disease, singleton birth, not currently taking a dietary
supplement containing iodine, due to deliver their infant between May 2004 and April 2005, and intend
to breastfeed for ≥ 24 weeks• Exclusion criteria:• Sample size: 109• Age: mean age 31-32 years• Socioeconomic status: 39%-55% had total household income > NZ$50,000, 65%-83% were tertiary
educated• Nutritional status: not reported• Baseline iodine status of participants/area: overall median (25th, 75th percentiles) UIC in the final
month of pregnancy was 42 (25, 58) µg/L• Baseline coverage of iodized salt: use of iodized salt as reported in final month of pregnancy was
82% in the 75 µg group, 92% in the 150 µg group and 89% in the placebo group• Breastfeeding practices (if applicable): at 24 weeks postpartum, 69% of infants were currently
breastfed and had not received any infant formula, and 27% were currently fed both breast milk and
infant formula• Other important information about participants or setting: 88%-95% white, 36%-48% nulliparous,
21%-52% exposed to iodine-containing antiseptic in labour. Mean birthweight was > 3500 and
46%-53% of infants were male
Interventions Experimental intervention: oral iodine supplementation (75 or 150 µg/d)
• Total number randomised: 75 µg/d: n = 19, 150 µg/d: n = 21• Timing: began as soon as possible after delivery (mean 5 ± 4.2 days postpartum)• Form: oral tablets• Frequency and duration: daily for 24 weeks• Iodine compound: potassium iodate• Iodine dose: 75 µg/d or 150 µg/d elemental iodine• Other nutrients: none• Adherence: mean 86% ± 17% overall (no difference between groups). Adherence defined as propor-
tion of the intended tablets consumed, measured by counting remaining tablets in the monthly bottle
at the end of each month
Mulrine 2010 
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Control/comparison intervention: placebo
• Total number randomised: n = 56• Description: placebo tablet• Adherence: see above
Co-intervention(s): none reported
Outcomes • Postpartum: urine (casual sample) and breast milk (foremilk sample) iodine content at the end of 1,
2, 4, 8, 12, 16, 20, and 24 weeks postpartum. Serum TSH and free T4 from finger prick blood sample
at week 24 (between 09:00 and 17:00)• Infant/child: urine (casual sample) iodine content at the end of 1, 2, 4, 8, 12, 16, 20, and 24 weeks
postpartum• All urine and breast milk samples were collected between 09:00 and 12:00, except for 5 maternal urine
and breast milk samples (0.6%) and 17 infant urine samples (2.6%)
Notes • 3-arm trial (placebo, 75 µg and 150 µg iodine) with unequal distribution (2:1:1). Because of imbalanced
randomisation and to maintain blinding, placebo arm was split into 2 groups and women were ran-
domised to 1 of 4 groups• Block randomisation was used. Each block contained 5 allocations for each of the 2 placebo groups
and the 75 µg/d and 150 µg/d iodine groups• Tablets described as indistinguishable from each other. Quality control testing confirmed placebo
tablets contained < 0.001 µg iodine, 75 µg tablet contained mean (range) 79 (73-86) µg iodine, and 150
µg contained mean (range) 154 (146-164) µg iodine• This study contributes no outcome data to the review analyses
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Block randomisation was “planned and generated by a researcher not directly
involved in data collection”. Although the method of sequence generation was
not described
Allocation concealment
(selection bias)
Unclear risk Method of concealment not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk “Both the researchers and participants were blinded to treatment until all data
collection and biochemical analyses were completed.”
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Trial described as double-blind with participants and researchers blinded
however it was not described whether outcome assessors were blinded as well
Incomplete outcome data
(attrition bias) 
All outcomes
High risk > 20% incomplete outcome data due to attrition (23%) as well as missing da-
ta (ranging from 3%-10% depending on outcome, and due to samples unable
to be collected or analysed). However there were no statistically significant dif-
ferences between those who withdrew and remained for treatment group, ed-
ucation level, compliance, household income, parity or maternal medical con-
ditions
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk The study appears to be free of other sources of bias
Mulrine 2010  (Continued)
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Methods • Study design: placebo-controlled, randomised, double-blind trial with 3 arms. Used stratified ran-
domisation according to TPO-ab level• Unit of allocation: individual• Time period of recruitment and data collection: not reported
Participants • Description: TPO-ab-positive pregnant women• Location/setting: Aalborg Hospital in Denmark• How participants were recruited and selected: a consecutive cohort of 1284 healthy pregnant Dan-
ish women (18–35 years of age) referred to Aalborg Hospital for a routine obstetrical ultrasound in
early pregnancy (median 11th gestational week) were screened for serum TPO-ab. TPO-ab was found
in 117 or 9.1%• Inclusion criteria: pregnant women with (TPO-ab ≥ 100 mL) no history of thyroid disease or clinical
symptoms of thyroid dysfunction (not specified as inclusion criteria)• Exclusion criteria:• Sample size: 72• Age: median age ranged from 29-30 years across groups• Socioeconomic status: not reported• Nutritional status: median baseline weight ranged from 67 kg–68 kg across groups• Baseline iodine status of participants/area: described by authors as mild to moderate deficiency.
Baseline UIC was median 50 µg/L-52 µg/L across the groups• Baseline coverage of iodized salt: not reported• Breastfeeding practices: not reported• Other important information about participants or setting: proportion of smokers ranged from
13%-27% across groups (there was a statistical trend towards fewer smokers in the control group).
68% of participants had previously taken vitamin-mineral supplements (75% of these women took
supplements containing iodine) though all reportedly stopped once entering the study. Median parity
was 2
Interventions Experimental intervention: oral iodine supplement
• Total number randomised: n = 46 (22 to pregnancy and postpartum supplementation group, 24 to
pregnancy-only supplementation group)• Timing: 2 groups: pregnancy and postpartum, pregnancy-only. Women were randomised at median
11th week gestation• Form: oral tablet• Frequency and duration: daily throughout pregnancy and postpartum or daily throughout pregnan-
cy (exact start and end of supplementation not specified)• Iodine compound: not specified• Iodine dose: 150 µg elemental iodine (same for both groups)• Other nutrients: “Recommended daily allowances of various vitamins and minerals, including 50 µg
selenium” (other nutrients and values not specified) (same for both groups)• Adherence: assessed with 24-h urinary iodine excretion during pregnancy (week 35) and postpartum
(7 months). During pregnancy, urinary iodine was higher in the 2 supplementation groups than the
control group. Postpartum, urinary iodine was higher in the pregnancy + postpartum supplementa-
tion group than the pregnancy-only supplementation and the control groups
Control/comparison intervention: oral multiple-micronutrient supplement with no iodine
• Total number randomised: n = 26• Description: oral tablets with same formulation as experimental intervention but no iodine• Adherence: not reported
Co-intervention(s): none reported
Nohr 2000 
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Outcomes • Pregnancy: serum total and free T4, total and free T3, TSH, Tg, TPO-ab, Tg-antibodies, and 24-h urinary
iodine excretion at week 35 of gestation• Postpartum: serum total and free T4, total and free T3, TSH, Tg, TPO-ab, Tg-antibodies and postpar-
tum thyroid disorder (clinical or subclinical hypo or hyperthyroidism) and biochemical dysfunction
score at 3, 5, 7, and 9 months postpartum, 24-h urinary iodine excretion at 7 months postpartum. Thy-
roid disease 3 years postpartum• Infant/child: none reported
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as “randomised, stratified according to TPO-ab level, to three
groups” though method for sequence generation was not reported
Allocation concealment
(selection bias)
Unclear risk Method of concealment not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Study was described as “double blind”. Unclear exactly who was blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Study was described as “double blind”. Unclear exactly who was blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data for 12 participants (< 20%) missing. 6 dropped out after pregnancy (4 in
the pregnancy-only supplementation group, 2 in control group) and data from
6 were censored due to missing postpartum data (these women were more
likely to be smokers)
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to make judgement
Other bias Unclear risk The study appears to be free of other sources of bias
Nohr 2000  (Continued)
 
 
Methods • Study design: randomised controlled trial, 2 arms• Unit of allocation: individuals• Time period of recruitment and data collection: not specified
Participants • Description: pregnant women• Location/setting: outpatient clinic of the Department of Obstetrics and Gynaecology, Rander Cen-
tralsygehus, East Jutland, Denmark• How participants were recruited and selected: through outpatient clinic• Inclusion criteria: White women with normal pregnancy with no previous thyroid disorder and not
on iodine supplementation• Exclusion criteria: as above• Sample size: initially 74 but 20 withdrew after the first visit, and 54 were randomised• Age: iodine-supplemented group: median 25 years (95% CI 24-27); control 26.3 years (25-29)
Pedersen 1993 
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• Socioeconomic status: not reported• Nutritional status: weight of iodine supplemented group: median 61.9 kg (58.5-67.2); controls 64 kg
(59.5-70• Baseline iodine status of participants/area: median UIC 55 (iodine supplemented group) and 51 µg/
L (controls)• Baseline coverage of iodized salt: not available• Breastfeeding practices: not reported• Other important information about participants or setting: none
Interventions Experimental intervention: oral iodine supplementation
• Total number randomised: n = 28• Timing: daily from 17-18 weeks' gestation until 12 months postpartum• Form: drops• Frequency and duration: 10 drops daily• Iodine compound: potassium iodide• Iodine dose: 200 μg iodine• Other nutrients: none• Adherence: not reported
Control/comparison intervention: no treatment
• Total number randomised: n = 26• Description: N/A• Adherence: N/A
Co-intervention(s): none specified
Outcomes Pregnancy:
• Thyroid volume (by ultrasound, method as per Bruun 1981) at 17-18, 28 and 37 weeks' gestation• Serum T3, T4, free T4, T4/T3, Tg, TSH, TPO-ab and urinary iodine concentration at 17-18, 28 and 37
weeks' gestation
Postpartum:
• Thyroid volume at day 5 postpartum, 26 weeks postpartum, 52 weeks postpartum• Serum T3, T4, free T4, T4/T3, Tg, TSH, TPO-ab and urinary iodine concentration at 13 and 39 weeks
postpartum. Also, urinary iodine concentration at 52 weeks postpartum (after stopping iodine sup-
plementation)• Breastmilk iodine concentration at day 5 postpartum
Infant/child:
• Urinary iodine concentration at day 5 postpartum• Cord blood T3, T4, free T4, Tg, TSH
Notes • Smokers: iodine supplement group: n = 9; controls n = 7• High dropout at initial visit 20/74 (27%) – reason provided was that the women felt that it would in-
terfere with their jobs – as it occurred prior to randomisation, unlikely to have significant impact on
study results since baseline data between the 2 groups were not different (p 1079)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described in the text
Pedersen 1993  (Continued)
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Allocation concealment
(selection bias)
Unclear risk Method of concealment not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Control group received no intervention
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Thyroid volume assessment was blinded: "The investigators performing the
volume measurements did not know which subjects received iodine or the re-
sults of previous volume determinations." Report did not specify for other out-
comes though
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk After the first visit, 20 women leP the study (mainly because they felt that it
would interfere with their jobs) but this took place prior to randomisation. Re-
port did not provide adequate information to assess incomplete outcome data
Selective reporting (re-
porting bias)
Unclear risk Protocol not available
Other bias Unclear risk The study appears to be free of other sources of bias
Pedersen 1993  (Continued)
 
 
Methods • Study design: double-blind, cluster, quasi-randomized placebo-controlled trial with 2 arms. Alter-
nate families were injected with either iodized oil or saline solution• Unit of allocation: family• Time period of recruitment and data collection: trial took place in August-September 1966. Subse-
quent follow-ups were carried out in 1967, 1969, 1970 and 1974-1982
Participants • Description: entire families including pregnant and non-pregnant women• Location/setting: Jimi River valley in the highlands of Papua New Guinea (at the time accessible only
by light aircraft)• How participants were recruited and selected: through a census conducted for the purposes of the
study in 27 villages• Inclusion criteria: none reported• Exclusion criteria: none reported• Sample size: approximately 16,500 individuals in total (including pregnant and non-pregnant
women)• Age: not reported• Socioeconomic status: subsistence economy• Nutritional status: not reported• Baseline iodine status of participants/area: severe deficiency (the area had high incidence of en-
demic cretinism and high prevalence of goitre). 20% of participants had goitre at baseline.• Baseline coverage of iodized salt: not reported• Breastfeeding practices: not reported• Other important information about participants or setting: none
Interventions Experimental intervention: injected iodized oil
• Total number randomised: n = not reported• Timing: before and during pregnancy. Included pregnant women (pregnancy was self-reported) and
women who later became pregnant• Form: injected iodized oil
Pharoah 1971 (C) 
Iodine supplementation for women during the preconception, pregnancy and postpartum period (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
60
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• Frequency and duration: single dose• Iodine compound: not reported• Iodine dose: ˜1600 mg iodine (4 mL) oil if 12 years of age or older, ˜800 mg iodine (2 Ll) oil if under 12
years of age (approximately 400 mg elemental iodine per mL)• Other nutrients: none• Adherence: not reported
Control/comparison intervention: placebo
• Total number randomised: n = not reported• Description: injected saline solution• Adherence: not reported
Co-intervention(s): none reported
Outcomes • Pregnancy: pregnancy total T4 and TBG assessed in 1970 and 1971• Postpartum: serum-protein-bound-iodine in a subsample of mothers of children with cretinism in
1970• Infant/child: child motor milestones, hearing and speech and squint were assessed from 1967-1971.
Endemic cretinism was diagnosed initially based on motor retardation with deafness and/or squint
(though later follow-ups used different definition). Motor performance was assessed in 1978 and
cognitive and motor performance from 1974-1982. Cretinism (definite versus possible) was assessed
again later in a sub-sample. Since 1972, follow-ups took place in 5 of the original villages for logistical
reasons. Births and deaths were also recorded. Unable to extract infant mortality because it was not
reported separately
Notes • We did not adjust for clustering because it was not possible to know if there was more than 1 pregnant
woman per family and therefore any clustering effect• After it became clear that iodine was an effective prophylactic for endemic cretinism, iodinated oil
injections were given to all women of child-bearing age in each of the villages in 1972.• Different reports provide different numbers for cretinism. We used numbers from the Pharoah 1971
report as it provided both the number of children with diagnosed cretinism and the number of children
examined and included more villages than later assessments (though the assessments could have
taken place beyond 2 years of age, cretinism is a permanent condition so would not have changed
after that age)• In 6/7 cases of cretinism in the iodine group and 5/26 in the control group, the mothers received the
injection during pregnancy
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quasi-randomized allocation (alternate families)
Allocation concealment
(selection bias)
High risk Quasi-randomized allocation (alternate families)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Insufficient information to make judgement. Described as double-blind. Moth-
ers reportedly did not know which group they belonged to though no report
specified anything about study personnel
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The initial follow-up assessments and diagnosis of cretinism were made with-
out knowledge of whether the mother received iodine or saline. Cretinism is
the only trial outcome included in this review
Pharoah 1971 (C)  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
High risk Due to remoteness of the region, only 13 or 16 of the original 27 villages were
visited for the initial follow-up visits where cretinism was originally assessed
(different numbers provided in different reports). Later follow-up assessments
were only performed in 5 villages for logistical reasons
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to make judgement
Other bias High risk This trial recruited some women (and provided the intervention to these
women) before they became pregnant. The intervention may have affected
their probability of becoming pregnant, potentially leading to differences be-
tween groups and introducing bias
Pharoah 1971 (C)  (Continued)
 
 
Methods • Study design: quasi-randomized trial with 2 arms. 1 of every 4 participating women was not treated
(control group)• Unit of allocation: individuals• Time period of recruitment and data collection: not specified
Participants • Description: pregnant women of various gestational ages (baseline gestational ages of final sample
of 46 women ranged from 9-32 weeks)• Location/setting: Eastern greater Santiago, Chile (women came from various suburban and rural ar-
eas)• How participants were recruited and selected: recruited women who attended prenatal outpatient
clinics (did not specify how they were selected)• Inclusion criteria: not specified• Exclusion criteria: not specified• Sample size: 250• Age: not specified• Socioeconomic status: not specified• Nutritional status: not specified• Baseline iodine status of participants/area: half of participants had “significant degree” of iodine
deficiency (50/µg I/g creatinine or less), 25% had moderate deficiency and 15% had adequate intake• Baseline coverage of iodized salt: previous analysis of salt from this area of Chile showed wide vari-
ation in iodine concentration (50 samples ranged from 0-135 µg iodine/g salt with 50% being below
10 µg and 12% between 60 and 135 µg)• Breastfeeding practices: not specified• Other important information about participants or setting:
Interventions Experimental intervention: iodine drops
• Total number randomised: unclear (report says 160, though this is not the expected 75% of 250, or
188)• Timing: baseline gestational ages of final sample of 36 women ranged from 9-32 weeks• Form: drops• Frequency and duration: daily, duration in women who completed study ranged from 4-16 weeks• Iodine compound: potassium iodide (KI)• Iodine dose: approximately 300 µg iodine/d (10 drops 785 µg/mL KI solution)• Other nutrients: none specified• Adherence: 22% (36 of 160) of women in intervention group successfully completed protocol and
adherence was validated by urinary iodine excretion
Control/comparison intervention: no intervention
Silva 1981 
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• Total number randomised: unclear• Description: no intervention
Co-intervention(s): none specified
Outcomes • Pregnancy: urinary iodine, serum T4, T3, rT3, TSH• Postpartum: urinary iodine, serum T4, T3, rT3, TSH at delivery• Infant/child: serum T4, T3, rT3, TSH at delivery in cord blood
Notes None
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quasi-randomized controlled trial ("One of every four women was not treated,
forming a control group")
Allocation concealment
(selection bias)
High risk Quasi-randomized. Participants and personnel may have known their alloca-
tion before the intervention
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk The intervention (or lack of intervention) would have been evident to partici-
pants and personnel
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No information provided in the text about blinding of outcome assessment
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Only 36 (22.5%) out of 160 completed the intervention, and a similar propor-
tion (only 10) remained in the control group
Selective reporting (re-
porting bias)
Unclear risk We did not have access to the protocol. Insufficient information to make
judgement
Other bias Unclear risk We could not assess baseline differences between the intervention and control
groups
Silva 1981  (Continued)
 
 
Methods • Study design: randomised controlled trial, 2 arms• Unit of allocation: individual• Time period of recruitment and data collection: enrolment took place from 1973-1977
Participants • Description: pregnant women• Location/setting: Ubangi, northern Zaire• How participants were recruited and selected: participants attending their first prenatal visit at the
maternity ward of Karawa hospital. They originated form the city of Karawa and from the rural villages
surrounding Karawa• Inclusion criteria: pregnancy• Exclusion criteria: not specified• Sample size: 671 women randomised• Age: control: 22.8 ± 5.9 years; treated population: 23.4 ± 6.3 years
Thilly 1978 
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• Socioeconomic status: not specified• Nutritional status: not specified• Baseline iodine status of participants/area: region of Ubangi had a high goitre prevalence. The
prevalence of goitre was 70.2% in the intervention group and 70.6% in the control group• Baseline coverage of iodized salt: not specified• Breastfeeding practices: not specified• Other important information about participants or setting: None relevant.
Interventions Experimental intervention: iodized oil injection
• Total number randomised: n = 339• Timing: second or third trimester, on average 28th week• Form: injected intramuscularly• Frequency and duration: single dose• Iodine compound: not specified (lipiodol)• Iodine dose: 475 mg slowly resorbable iodine• Other nutrients: none• Adherence: not specified
Control/comparison intervention: placebo (described in some reports as multivitamin injection free
of iodine)
• Total number randomised: n = 332• Description: single dose injected intramuscularly• Adherence: not specified
Co-intervention(s): no other co-interventions specified
Outcomes • Pregnancy: serum T3, T4, TSH, TBG (assessed at baseline prior to intervention)• Postpartum: serum T3, T4, TSH, and TBG at delivery• Infant/child: psychomotor development (Brunet-Lezine scale - developmental quotient, frequency
of success for certain tasks, time of acquisition for 4 specific tasks) at 4-9 months, 10-15 months, and
16-23 months, and neonatal T3, T4, TSH
Notes • We found conflicting information in the various reports on this trial about the control supplement
composition. Some stated it was a placebo and some stated it included vitamins. Because it was not
possible to verify this information, for the purposes of this review we have considered the control for
this trial as placebo
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "The two groups were constituted at random using random number tables
and numbered envelopes"
Allocation concealment
(selection bias)
Unclear risk Numbered envelopes were used, with no reference to the envelopes being se-
quentially numbered, opaque, or sealed, therefore the risk is unclear
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Investigators and participants were blinded: "performed all interviews and
examinations under strict double-blind precautions, i.e., neither the mother
nor the investigator knew whether the mother had received the iodine supple-
ment"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The study was described as "double-blind" but the reports did not mention
blinding on outcome assessors, therefore insufficient information to permit
judgement
Thilly 1978  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
High risk High loss to follow-up. For example development quotient results were report-
ed for 39 children in the intervention group (339 women randomised) and 36 in
the control group (332 women randomised)
Selective reporting (re-
porting bias)
Unclear risk The study protocol was not available therefore we had insufficient information
to permit judgement
Other bias Unclear risk The study appears to be free of other sources of bias
Thilly 1978  (Continued)
 
 
Methods  
Participants • Description: pregnant women• Location/setting: Women’s & Children’s Hospital and the Flinders Medical Centre in Adelaide, Aus-
tralia• How participants were recruited and selected:• Inclusion criteria: singleton pregnancy, less than 20 weeks' gestation• Exclusion criteria: taking supplements containing iodine, history of thyroid disease or drug or alcohol
abuse, fetus with known major abnormality, or English not the main language spoken at home• Sample size: 59 (planned n = 1089)• Age: iodine group 29.1 ± 5.7, placebo group 29.8 ± 5.1 (mean ± SD) years old• Socioeconomic status: no difference at baseline• Nutritional status (e.g. BMI, % under or overweight): iodine group, pre-pregnancy BMI 23.6 ± 5.5,
placebo group 22.2 ± 4.3 (mean ± SD)kg/m2• Baseline iodine status of participants/area: not specified• Baseline coverage of iodized salt: not specified• Breastfeeding practices (if applicable): not specified• Other important information about participants or setting: infant sex was significantly different
between groups: 20 male infants (71.4%) for iodine group, 9 male infants (31.0%) in control group
Interventions Experimental intervention: daily iodine supplementation.
• Total number randomised: n = 29
• Description of supplementation
• Timing: daily.
• Form (injected/oral, tablet, drops etc): tablet.
• Frequency and duration (daily until birth, single dose, etc): daily.
• Iodine compound: not specified.
• Iodine dose (specify if compound or elemental iodine): 150 μg/day.
• Other nutrients: none.
• Adherence (give definition too): Five discontinued after opening code
(unblinding).
Control/comparison intervention: placebo.
• Total number randomised: n =30
• Description: single table daily dose.
• Adherence: 18 discontinued and one started iodine supplements after unblinding.
Co-intervention(s): none reported.
Outcomes Pregnancy: general health and well being of mothers using validated
questionnaires (SF-36 & Depression, Anxiety and Stress) at 36 weeks and 6 weeks
postpartum.
• Postpartum: none reported.
• Infant/child: child development assessed at 18 months: bailey Scale of Infant and
Toddler Development III At birth: information on birthweight, length, head
circumference, gestational age; pregnancy related morbidities including still birth
Zhou 2015 
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preterm birth.
Notes • The trial was stopped after 59 participants recruited (planned n = 1098). Funding body the National
Health and Medical Research Council (NHRMC) withdrew its support for the trial due to being incon-
sistent with recommendation for iodine supplementation in pregnancy• Women were informed of their group allocation (mean gestational age at unblinding was 33 ± 7 weeks)• 2 women dropped (1 from each group) from studies, 18 women stopped taking placebo in the placebo
group, and 1 woman in the placebo group commenced iodine supplements after unblinding. 5 women
discontinued intervention for iodine group after unblinding
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Women were randomly assigned to iodine or placebo in the ratio of 1:1
through a web-based randomisation service. The randomisation schedule was
generated independently with balanced, variable-sized blocks and was strati-
fied by centre, parity (0 versus ≥ 1), and gestational age at randomisation (≤ 16
weeks’ versus > 16 weeks’)"
Allocation concealment
(selection bias)
Low risk Quote: “Randomization will be done through central allocation by computer
from a custom built Management Information System”
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Participants were told of their group assignment when the trial was stopped -
"mean gestational age at unblinding was 33 ± 7 weeks. The mean duration of
intervention before unblinding was 16 weeks (range 2–23 weeks)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Some self-reported outcomes were unblinded and likely to have detection
bias. Also, personnel would have been unblinded for some outcome assess-
ments (due to participants being told about group assignment when trial was
stopped early). Though "pregnancy and birth outcome data were collected by
blinded review of medical records", our review includes other outcome as well
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Iodine group 27/29 (93.1%), placebo group 26/30 (86.7%)
Selective reporting (re-
porting bias)
Low risk All outcomes reported in the trial registry ACTRN12610000411044
Other bias Unclear risk Appears to be free of other sources of bias
Zhou 2015  (Continued)
BMI: body mass index
EEG: electroencephalogram
IQR: interquartile range
KI: potassium iodide
SEM: standard error of the mean
T3: triiodothyronine
T4: thyroxine
TBG: thyroxine-binding globulin
TSH: thyroid-stimulating hormone
TPO-ab: thyroid peroxidase antibodies
TV: total volume
UIC: urinary iodine concentration
UIE: urinary iodine excretion
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Amiri 2016 100 pregnant women attending 5 healthcare centres in the southern region of Tehran, Iran were
randomly assigned to 1 of 2 groups: group 1 (n = 50) received a 4-month educational programme;
group 2 (n=50) received regular counselling. There was no provision of iodine supplementation.
This study was excluded because the type of intervention (education) was outside the scope of this
review.
Anees 2015 490 pregnant women of lower socioeconomic status belonging to goitre-endemic and non-goitre
areas in Pakistan were studied.
Group 1 (control): (n = 156) subjects from non-endemic goitre areas of Rawalpindi. All women were
clinically euthyroid and had no previous known thyroid disorders.
Group 2: (n = 154) subjects of the goitre-endemic areas of Muzaffarabad and Skardu with and with-
out thyroid enlargement.
Group 3: (n = 150) subjects of goitre-endemic areas of Muzaffarabad and Skardu with thyroid en-
largement up to stage 2. These women were given a single dose of 2 capsules of iodized oil (iodized
ethyl esters of poppy-seed oil; Lipoidal Ultrafluid, 400 mg of iodine, Guerbet Laboratories, Paris,
France) orally in the first trimester from weeks 6–8 of pregnancy
Primary outcome measures included serum T4, T3, TSH and birthweight of newborns
The study was excluded because participants were not randomised (or quasi-randomized) and
therefore the design was outside the scope of this review.
Antonangeli 2002 Randomized comparison of 2 regimens of iodine with no control group
86 pregnant women, ages ranged from 20-38 years (mean 31 years) were enrolled from the
10th-16th week of gestation, between February 1995-March 1998
Group A: (n = 32) women, received 200 µg iodine daily for up to 6 months
Group B: (n = 35) women, received 50 µg iodine daily
Primary outcomes included urinary iodine concentration, thyroid volume and thyroid function
(changes in serum FT4 and FT3 levels), and clinical events. Thyroid volume, thyroid functional pa-
rameters and urinary iodine concentration were determined in all subjects at booking, at the 18th–
26th, and the 29th–33rd week of gestation, and at the 3rd and 6th month after delivery.
Both groups received iodine.
This study was excluded because it did not include a placebo/no intervention group therefore the
comparison was outside the scope of this review.
Azizi 2003 The study was a cross-sectional study performed on schoolchildren and pregnant women in 4 cities
in the Islamic Republic of Iran. The study evaluated UIE in 438 school children and 403 pregnant
women. In Isfahan City, thyroid volume was also measured by sonography for 30 pregnant women
in each trimester of pregnancy and for 90 non-pregnant women who also had urinary iodine mea-
surement.
This study was excluded because it was cross-sectional, therefore the design was outside the scope
of this review.
Berbel 2009 The aim of the study was to determine the effects of delayed iodine supplementation to mildly hy-
pothyroxinaemic pregnant women
Group 1: (n = 92), children of women with FT4 above the 20th percentile at 4–6 gestational weeks
and at full-term
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Study Reason for exclusion
Group 2: (n = 102), enrolled at their first pregnancy visit, children of mildly hypothyroxinaemic
women diagnosed during the first 12–14 gestational weeks and with FT4 above the 20th percentile
at full-term
Group 3: (n = 151), children born to mildly hypothyroxinaemic women at full-term, without iodine
supplementation during gestation
The study used the Brunet–Lezine scale to evaluate neurocognitive performance at 18 months of
age
All women were supplemented orally with iodine (200 µg KI per day) from the day of enrolment to
the end of lactation
The study was excluded because participants were not randomised (or quasi-randomized), there-
fore the study design was outside the scope of this review.
Cao 1994 This study was a review on the efficacy of iodination of irrigation water as a method of supplying io-
dine to a severely iodine-deficient population in Xin Jiang, China. This study was excluded because
it assessed iodination of water, therefore it was outside the scope of this review.
Chaouki 1994 The aim of the study was to determine the effectiveness of 3 treatment regimens of orally admin-
istered iodized oil. Participants were recruited in the mountainous region of Algeria. 3 groups of
treated mother-newborn pairs were compared with an untreated group.
Group A: (n = 213), mothers treated before pregnancy; 0.5 mL of iodized oil (lipiodol®, 240 mg of io-
dine)
Group B: (n = 190), mothers treated during the first month of pregnancy; 0.5 mL of iodized oil (lipi-
odol®, 240 mg of iodine)
Group C: (n = 151), mothers treated during the 3rd month of pregnancy; 0.5 mL of iodized oil (lipi-
odol®, 240 mg of iodine)
Group D: (n = 982), no treatment
Primary outcome measures included urinary and milk iodine concentration, TSH, FT4 and birth-
weight
This study was excluded because participants were not randomised (or quasi-randomized), there-
fore the design was outside the scope of this review.
Chiovato 1994 This is a review of the impact of iodine deficiency on neurological and cognitive development in
Europe. Specifically the article focused on the experiences of Spain and Italy in reducing the preva-
lence of iodine disorders.
The article was excluded because it was a descriptive paper, therefore the study design was out-
side the scope of this review.
Connelly 2012 The study reported the cases of 3 infants with congenital hypothyroidism detected with the use of
a newborn screening program. Evidence supported excess maternal iodine ingestion (12.5 mg/d)
as the etiology. Levels of whole blood iodine extracted from their newborn screening specimens
were 10 times above mean control levels.
The article was excluded because it was a case study, therefore the study design was outside the
scope of this review.
Dean 1950 The study started out with around 100 women in the intervention and around 100 in control
groups. However the numbers were greatly reduced before the final analysis of the results. In-
tervention mothers were given 12 drops of iodine solution twice a day in milk for 4 days starting
on the morning of the 6th day after delivery. The solution was made by dissolving 10 g of potas-
sium iodide in 100 mL of distilled water, then adding 5 g of iodine. Initially women in the control
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Study Reason for exclusion
group were given dummy milk drinks containing no iodine, but that practice was discontinued.
The health of the mother and child were investigated 3 months post-delivery. During this visit cases
were discarded if any illness or abnormality were disclosed. 5 women had a moderately enlarged
thyroid but no signs of thyrotoxicosis; 2 were given iodine and 3 received no treatment.
The study was excluded because participants were not randomised (or quasi-randomized), there-
fore the study design was outside the scope of this review.
Delange 1996 This paper presented a brief review of the available studies on iodized oil before or during pregnan-
cy.
The article was excluded because it was a review paper, therefore the study design was outside the
scope of this review.
Delange 2004 This paper reviewed the data from the literature on the iodine requirements during pregnancy, lac-
tation and the neonatal period, and provided recommendations regarding the median concentra-
tions of urinary iodine indicating optimal iodine nutrition during these critical periods of life.
The article was excluded because it was a review paper, therefore the study design was outside the
scope of this review.
Fierro-Benitez 1988 Children (8-15 years of age) of mothers who received injections of iodinated oil prior to the end of
the first trimester of pregnancy were compared with children of the same age from a comparable
neighbouring community whose mothers had received no iodinated oil. The authors used test of
intellectual function, psychomotor maturation, school dropout rates, grades achieved, grades re-
peated, and overall performance as judged by teacher notes in school records.
The article was excluded because participants were not randomised or quasi-randomized, there-
fore the study design was outside the scope of this review.
Gruñeiro-Papendieck 2004 The aim of the study was to estimate whether the WHO-recommended neonatal TSH screening cut-
oA, when applied to newborns older than 48 hours of age (native to Buenos Aires), coincides with
the traditional ones (goitre and urinary iodine in school-age children). The study also assessed if
the evaluation varies based on the methodology used for TSH measurement and/or the time of
specimen sampling. Primary outcome measures included TSH levels, thyroid volume (direct palpa-
tion) and urinary iodine levels.
The study was excluded because it assesses a screening methodology, therefore the study design
outside the scope of this review.
Hetzel 2002 This paper reported on the progress towards eliminating iodine deficiency, with particular ref-
erence to the role of the International Council for Control of Iodine Deficiency Disorders, a non-
governmental organization founded in 1986.
The article was excluded because it was a descriptive paper, therefore the study design was out-
side the scope of this review.
Isa 2000 Treatment group: 60 schoolchildren and 13 pregnant mothers were examined at the baseline. Dur-
ing the first visit iodized oil orally (Lipiodol; Laboratoire Guerbert, Paris, France) in the form of cap-
sules after the baseline data had been collected.
Control group: 105 schoolchildren and 18 pregnant mothers
Only areas with moderate-severe prevalence of iodine deficiency disease were selected. Legap Post
and Yum Post were selected as the intervention areas by purposive sampling. Areas selected for
control, namely Perwor Post and Poi Post, were also purposely selected as these areas were inhab-
ited by a similar tribe with similar IDD endemicity.
The study was excluded because participants were not randomised or quasi-randomized, therefore
the study design was outside the scope of this review.
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Study Reason for exclusion
Joshi 2011 The study assessed the effect of iodine supplementation during second half pregnancy and its ef-
fect on perinatal outcomes (maternal and neonatal health). The intervention group was of 60 preg-
nant women of first and second trimester those who were registered in Chautara Hospital and dis-
trict ANC centre; the control group was of 60 pregnant women of similar pregnancy status, admit-
ted in the maternity ward of same hospital. The intervention group was provided with a mineral
capsule containing 150 µg of iodine to take orally every day from the day of enrolment till delivery
along with iron plus folic acid tablets and maternal and neonatal healthcare package. The control
received no intervention.
The study was excluded because participants were not randomised or quasi-randomized, therefore
the study design was outside the scope of this review.
Kamiński 2003 The aim of the study was to determine the degree of iodine deficiency and thyroid function in preg-
nant women prior to and after the introduction of iodized salt. Primary outcomes included urinary
iodine excretion and serum levels of TSH, FT3 and FT4. They were determined in pregnant women
divided into 2 groups - with and without iodine supplementation.
The study was excluded because it was an observational study on iodized salt, therefore the study
design and intervention were outside the scope of this review.
Klett 1999 This was a cross-sectional study to assess the correlation between maternal iodine intake and
neonatal thyroid volume in 89 mother-child pairs. 32 mothers (36%) took iodide tablets on a regu-
lar basis during pregnancy (average daily iodine dose was 175 µg K-iodide).
57 mothers did not use iodine supplements.
Outcomes in mothers and neonates included thyroid volume and urinary iodine excretion
The study was excluded because it was cross-sectional, therefore the study design was outside the
scope of this review.
Kurtoglu 2004 The study assessed the iodine status and the thyroid function of pregnant women and their
neonates in the region of Kayseri (central Anatolia of Turkey).
Included 70 pregnant women (18-37 years of age) and their full term neonates
Outcomes included urinary iodine concentration, FT4, FT3, TSH and Tg of mothers and neonates,
breast milk iodine concentration
The study was excluded because it was cross-sectional, therefore the study design was outside the
scope of this review.
McDonnell 2003 The aim of the study was to assess iodine status and goitre prevalence in a sample of schoolchild-
ren (5–12 years) in Melbourne.
Primary outcome measures included urinary iodine concentration and presence of goitre (deter-
mined by thyroid gland palpation).
The study was excluded because it was cross-sectional, therefore the study design was outside the
scope of this review.
Mohammed 2015 The study examined the effects of iodized salt on the growth and mental development of infants
from the Amhara region of Ethiopia.
44 communities were randomly assigned to early access to iodized salt (intervention) or later
through market forces (control).
1220 pregnant women were recruited.
Primary outcome was child development (Bayley scales: cognition, expressive language, receptive
language and fine motor scales)
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Study Reason for exclusion
The study was excluded because it assessed iodized salt, therefore the comparison was outside the
scope of this review.
Moleti 2008 The study examined the effects of long-term iodized salt consumption on maternal thyroid func-
tion during gestation.
Thyroid function was prospectively evaluated in 100 consecutive TPO-ab-negative pregnant
women from a mildly iodine-deficient area in northeastern Sicily, Italy.
62 had regularly used iodized salt for at least 2 years prior to pregnancy (long-term iodine supple-
mented).
38 had commenced iodized salt consumption upon becoming pregnant (short-term iodine supple-
mented).
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
Morreale de Escobar 1993 This paper was a review of the literature on the role of maternal thyroxin transfer in the relation-
ship between iodine deficiency and thyroid hormone metabolism and the brain in fetal rats.
The study was excluded because it was an animal study and a review paper, therefore the study de-
sign was outside the scope of this review.
Murcia 2011 The authors assessed the association of maternal iodine intake from diet and supplements during
pregnancy and of maternal and neonatal thyroid function with infant neurodevelopment.
The Mental Development Index and Psychomotor Development Index (PDI) for 691 children was
obtained between 2005-2007 using the Bayley Scales of Infant Development at age 1 year in Valen-
cia, Spain.
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
Nohr 1993 The aim of the present study was to assess the extent to which iodine requirements were met in
pregnant women living in different regions throughout Denmark.
152 healthy pregnant women admitted to 5 different Danish departments of obstetrics participated
in the study. Iodine status was evaluated by measurement of urinary iodine 5 days postpartum. Uri-
nary iodine excretion and intake of iodine-containing vitamin/mineral tablets were assessed.
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
O'Donnell 2002 The study assessed the growth and development of children whose mothers received iodine during
pregnancy, and children who received iodine first in their 2nd year of life. Children were from the
southern part of China’s Xinjiang Province which has the lowest levels of iodine in water and soil
ever recorded.
Outcome measures included psychological development (Raven Progressive Matrices and the
Developmental Test of Visual Motor Integration), fine motor planning and speed (Purdue Pegboard
Test) and anthropometric measures.
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
Oltarzewski 2003 The paper described findings from neonatal TSH screening in hospitals in Poland, in relation to the
use of iodine-containing antiseptics.
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
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Qian 2005 This study was a systematic review and meta-analysis on the effects of iodine on the intellectual
development of children in China.
The study was excluded because it was a systematic review, therefore the study design was outside
the scope of this review.
Rebagliato 2013 This study assessed the association between iodine supplementation in pregnancy and infant psy-
chomotor development. It was a multicentre mother and child cohort study in Spain in the regions
of Valencia, Sabadell (Catalonia), Asturias, and Gipuzkoa (Basque Country). Neuropsychological
development was assessed using the Bayley Scales of Infant Development in 1519 infants (median
age, 16 months).
The study was excluded because it was observational, therefore the design was outside the scope
of this review.
Reinhardt 1998 The study evaluated the effect of iodine supplementation, using 2 different doses (50 and 200 µg),
on the prevalence of postpartum thyroiditis and the decrease in thyroid volume up to 8 months
postpartum, in an area of mild iodine deficiency. It involved 2 studies:
Study 1: 56 women were evaluated 5 days and 3 months after delivery.
Study 2: 70 women were randomised to receive 50 and 200 µg of potassium iodide for 8 months
postpartum, beginning 5 days after delivery. Outcomes included thyroid volume and thyroid hor-
mone parameters (T3, T4, FT4 and TSH), measured 5 days, 3 months, and 8 months postpartum.
Study 1 was excluded because it was observational, therefore the study design was outside the
scope of this review. Study 2 was excluded because it compared 2 iodine doses and lacked a place-
bo/no intervention control group, therefore the comparison was outside the scope of this review.
Romano 1991 This study assessed the effect of iodized salt on thyroid size during pregnancy.
Intervention: 17 women who received iodized salt (equivalent to 120 µg-180 µg of iodine/d)
Control: 18 women who received no iodized salt
Outcomes included thyroid volume and urinary iodine concentration in each trimester.
The study was excluded because it compared iodized salt to no intervention, therefore the compar-
ison was outside the scope of this review.
Saadat 2004 Study compared thyroid function of neonates/infants born to women who had received iodized oil
to those of a control group.
Intervention: 669 healthy pregnant women received 1 mL containing 480 mg injected iodized oil
(Lipidol, Laboratory Guerbet, France) intramuscularly.
Controls: randomly selected among non-injected (at the time of this study) pregnant women's in-
fants. Outcome included serum T4, T3 and TSH concentrations.
The study was excluded because it was not randomised (or quasi-randomized), therefore the study
design was outside the scope of this review.
Sack 2003 This study examined factors that may have an impact on iodine economy in postpartum women,
including pregnancy duration, infant body weight, and recovery of TSH levels postnatally (data
came from a randomised controlled trial on the Kangaroo Care Method).
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
Salarkia 2004 The study examined the timing of the effect of iodine supplementation on intelligence quotient of
children. It was a retrospective study of 40 schoolchildren aged 7-13 years, from the previously io-
dine deficient villages of Kiga and Randan, Iran. The children were divided into 3 subgroups: sub-
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group 1: the mother had received iodized oil 1-4 years prior to conception and infant consumed
iodized salt from the age 1-4 years onwards; subgroup 2: mothers received iodized oil during preg-
nancy and the child received iodized salt from the age 2-4 years and subgroup 3: the child received
iodized oil injection from age 1-3 years iodized salt from 3-6 years of age onwards.
A group of 40 age and sex matched schoolchildren from Tehran served as controls.
Outcome measures included the Bender Gestalt (BG) test, urinary iodine concentration and serum
concentrations of T4, T3, TSH.
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
Santiago 2013 This study assessed the effects of improving iodine intakes with iodized salt or different iodine sup-
plement doses. 131 pregnant women before week 10 of pregnancy, from a healthy pregnancy pro-
gramme at primary care centres in Jaen (Spain), were randomly assigned to 3 groups: group 1: (n
= 38), iodized salt group; group 2: (n = 55), supplementation with 200 µg potassium iodide/d; and
group 3: (n = 38), supplementation with 300 mg µg potassium iodide/d.
Outcome measures included urinary iodine concentration, thyroid volume, TSH, FT4, FT3, thy-
roglobulin and breast milk iodine concentration.
The study was excluded because it compared two iodine supplemental doses with iodized salt and
included no placebo/no intervention group, therefore the comparison was outside the scope of
this review.
Smyth 1997 The study aimed to examine the relationship between thyroid volume and urinary iodine excretion
during pregnancy in Ireland, an area of moderate iodine intake, and to study urinary iodine excre-
tion in neonates of mother who breast- and formula-fed. It included 2 groups:
Group A: 115 women, selected opportunistically, in that each trimester’s study group comprised
different individuals. An additional group of 108 women had urine sampled 3 days after delivery; 64
of these were breastfeeding and 44 were formula feeding. A further 84 women were studied during
the late puerperium (approximately 40 days postpartum.
Group B: 38, women's urine samples collected sequentially during the 3 trimesters of pregnancy
and at approximately 6 weeks postpartum. Of those 38 subjects, 20 had thyroid ultrasound scans
during each trimester of pregnancy and at 6 weeks postpartum.
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
Smyth 2005 The study assessed whether the high titers of thyroid antibodies previously reported in Sri Lankan
schoolgirls were also present in adult females, and also to assess alterations in antibody titer dur-
ing normal pregnancy and possible relationships to iodide intake.
25 pregnant Sri Lankan women aged 20-44 years had sequential blood samples taken during each
of the 3 trimesters of pregnancy and at 6 weeks postpartum.
57 nonpregnant females aged 21–38 years old served as controls.
Outcomes included thyroglobulin antibodies, thyroid peroxidase antibodies and urinary iodine
concentration
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
Troshina 2010 The objectives of this study were to evaluate results of controlled epidemiological studies of iodine
deficiency in pregnant women and to develop a standard prophylactic iodine dose schedule for
these women.
Group 1: (n = 52), treated with 200 µg potassium iodide/d
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Group 2: (n = 69), treated with 300 µg potassium iodide/d
Outcome measures included TSH, free thyroxin and antithyroid peroxidase antibody levels, urinary
iodine and thyroid volume.
This study was excluded because it compared 2 different iodine doses with no placebo/no inter-
vention group, therefore the comparison was outside the scope of this review.
Urban 2000 One of the study objectives was to assess the impact of iodine supplements in pregnancy on uri-
nary iodine excretion of women and their newborns.
54 women were divided into 2 groups
Group 1: (n = 26) women who took multivitamin supplements that contained 150/μg potassium io-
dide in pregnancy and their newborns
Group 1: (n = 28) parturient women who did not take any iodine supplements, and their newborns
(report does not specify whether they took a supplement containing other vitamins/minerals)
Urinary iodine excretions studied in both groups (in women a few days before childbirth or during
labour, and on newborns during 1st or 2nd 24 hours of life
This study was excluded because it was a prospective study with allocation to groups (intervention
and control) (with no indication of random or quasi-random allocation), therefore the study design
was outside the scope of this review.
Velasco 2009 Study aim was to evaluate the psychological development of infants (3-18 months of age) whose
mothers received iodine supplements during the first trimester of pregnancy, and compare with
those whose mothers received no iodine.
Intervention: (133 women) infants (3 to 18 mo of age) whose mothers received 300 μg iodine during
the first trimester.
Control: (61 women) infants whose mothers did not receive any iodine supplementation during
pregnancy.
Main outcomes included child neuropsychological status (evaluated with the Bayley Scales of In-
fant Development), TSH, free T3, free T4, and urinary iodine concentration.
The study was excluded because it was a non-randomized controlled trial, therefore the study de-
sign was outside the scope of this review.
Vermiglio 2004 The study aim was to identify the long-term effects of iodine deficiency-related maternal hypothy-
roxinaemia on child development (behavioral, psychoneurological, and intellectual).
16 children born to healthy mothers living in a moderately iodine-deficient area were compared to
11 children born to age-matched women from an area with marginally sufficient iodine intake. Thy-
roid function of the mothers was monitored during early gestation.
Outcome measures included behavioral and neuropsychological evaluation and attention deficit
and hyperactivity disorder screening, intelligence testing (Wechsler Intelligence Scale for Children,
3rd edition), and maternal and child thyroid function tests.
This study was excluded because it was a prospective observational study, therefore the study de-
sign was outside the scope of this review.
Versloot 1997 The aim of this study was to clarify the effects of iodine deficiency and pregnancy on iodide uptake
by the thyroid. Radioiodide was injected intravenously into non-pregnant and 19-day pregnant rats
(Wistar rats (CPB/WU,IFFA CREDO, Brussels) receiving a normal or marginally iodine-deficient diet.
The study was excluded because it was an animal study, therefore the participants were outside
the scope of this review.
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Vitnerova 2000 Study aim was to estimate the iodine supply for pregnant women in Teplice district, Czech Repub-
lic.
A cohort of 348 pregnant women who received daily iodine supplementation during pregnancy and
the control groups was 231 women of similar age. The main outcome was urinary iodine concentra-
tion.
This study was excluded because it was not randomised (or quasi-randomized), therefore the study
design was outside the scope of this review.
Vitti 1992 Study aim was to analyse neuropsychological performance of schoolchildren living in areas with
different iodine intake, and in an area before and after iodine prophylaxis.
Outcomes included various neuropsychological tests: 1) reaction time, 2) the block design subtest
of the WISC-R, 3) the coding subtest of the WISC-R.
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
Yan 2005 The study compared different approaches to assessing iodine nutrition within communities, espe-
cially for pregnant and lactating women. The researchers examined iodine content of household
salt and drinking water in 11 Chinese provinces.
Outcome measures included iodine content of household salt and drinking water, thyroid volume,
urinary iodine concentration, and iodine in breast milk and thyroid size in adult women.
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
Zhu 1995 This study assessed the effects of iodine deficiency in pregnancy on infant physical development.
Urine samples from 950 young women from iodine deficient areas and urinary iodine concentra-
tion determined. 150 of the 347 included pregnant women were selected and divided into 3 groups:
Group A - normal control (urinary iodine > 0.788 μmol/L); Group B - an iodine-deficient placebo
control and Group C - iodine-deficient supplemented with iodine. The intervention was iodine sup-
plementation (not specified in the English language abstract).
Outcomes included infant height, weight and head circumference.
The study was excluded because it was not randomised (or quasi-randomized), therefore the study
design was outside the scope of this review.
Zimmermann 2005 The study evaluated iodine nutrition in Switzerland after the 1999 increase in salt iodine concen-
tration.
Nationally representative sample of primary schoolchildren and pregnant women were selected
in 1999 and 2004 and the iodine content of household salt and urine were determined. Neonatal
elevated thyrotropin concentration from a screening program was evaluated before and after the
change.
The study was excluded because it was observational, therefore the study design was outside the
scope of this review.
FT3: free triiodothyronine
FT4: free thyroxine
IDD: iodine deficiency disorder
KI: potassium iodide
Tg: thyroglobulin
TPO-ab: thyroid peroxidase antibodies
TSH: thyroid-stimulating hormone
Iodine supplementation for women during the preconception, pregnancy and postpartum period (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
75
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
UIE: urinary iodine excretion
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods The study objective was to evaluate iodine status in pregnant women and their newborns and the
effectiveness of antenatal iodine prophylaxis. A total of 183 pregnant women and their newborns
were enrolled and assigned to 3 groups: 46 mothers (1st group) were in the iodine supplementa-
tion during pregnancy and lactation group (200 µg/day potassium iodide), 96 women did not re-
ceive supplementation (2nd group) and 58 were in the iodized salt group (3rd group). The abstract
also mentioned a study in 1052 women, pregnant in the third trimester of gestation (where urinary
iodine concentration (UIC), BMIC, serum TSH and FT4 were determined) and also iodine status in
newborns evaluated as part of neonatal screening for congenital hypothyroidism (n = 948).
Participants Pregnant and lactating women (for the iodine supplementation component of the study)
Interventions Iodine supplementation (200 µg/day potassium iodide) and iodized salt
Outcomes UIC, TSH and FT4 in pregnancy, elevated TSH in newborns, UIC in infants, BMIC in postpartum
women
Notes Conference proceedings abstract (from the European Thyroid Association 38th Annual Meeting,
Santiago de Compostela, September 2014). We cannot locate a published manuscript from this
study.
The method of allocation is unclear therefore this study is awaiting classification until further infor-
mation is available.
Belykh 2014 
 
 
Methods The article describes the physiology of the thyroid gland, consequences of low iodine intake, and
the importance and risk of iodine supplementation in pregnancy.
Participants Information not available
Interventions Information not available
Outcomes Information not available
Notes Article is written in Czech and requires translation. Only the abstract is available in English and it
does not contain sufficient information to determine whether the study is eligible therefore it is
awaiting classification until further information is available.
Hronek 2001 
BMIC: breast milk iodine concentration
FT4: free thyroxine
TSH: thyroid-stimulating hormone
UIC: urinary iodine concentration
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Phase III: Preventing lack of iodine during pregnancy. Effect of supplying women with potassium
iodide to the neuro-cognitive children development until 2 years.
Caron 2006 
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Methods Pregnant women randomised to 2 parallel groups before 12 weeks amenorrhoea (each group with
187 participants). 1 group receives iodine and the other receives a placebo. Follow up visits at the
5th and 8th month of pregnancy, the day of birth, and 6, 12, and 24 months postpartum
Participants 374 pregnant women. Inclusion criteria: pregnancy less 12 weeks amenorrhoea with clinically nor-
mal pregnancy, agree to take part in the study and able to sign an informed consent form
Interventions Intervention group: daily dose of 200 µg of potassium iodide
Control group: placebo
Outcomes Primary outcome: neuro-cognitive development of children. Secondary outcomes: prevalence of
hypothyroxinaemia and hypothyroidism during pregnancy, change in the functional thyroid para-
meters of mother during iodine treatment, psychometric development of children, quantify the io-
dine supply from the woman to the baby during breast feeding
Starting date December 2006
Contact information Principal Investigator: Philippe Caron/Endocrinology - University Hospital Toulouse, France, 31059
Notes None
Caron 2006  (Continued)
 
 
Trial name or title Iodine status in Swedish pregnant women - effect of iodine supplementation in the thyroid func-
tion of mother and infant
Methods This is a prospective, double-blinded placebo-controlled trial of 200 pregnant women and their
children. Mothers are randomised to 150 μg/day iodide supplementation or placebo for 26 weeks.
In parallel 90 healthy female controls are recruited from the same community stratified for age and
smoking habits. Participants are included after the first mother health care (MVC) visit by the mid-
wife at Skövde. UIC, U-creatinine, thyroid hormones, TSH, Tg and TPO-ab are collected and a sim-
ple questionnaire is filled in week 10 ± 2 of pregnancy and placebo/iodide is started. Selenium and
iron will also be measured. The same measurements are collected in week 25 ± 1 week and week 36
± 2 weeks. Directly after delivery (within 5 days), BMIC and UIC in the mother as well as UIC and TSH
in the newborn child are collected and a simple questionnaire is filled in. Weight, length and AP-
GAR in the child and pregnancy complications are registered. Blood is also frozen for future analy-
ses. Controls are collected from a randomised sample attained by the Swedish Tax Agency of pre-
menopausal women from the same community stratified for age and smoking habits. UIC, u-crea-
tinine, FT4, TSH, Tg, TPO-ab, selenium, iron and samples to be frozen are collected and a question-
naire is filled in. The primary purpose for having a control population is to ascertain that the nor-
mal population in the area of Skövde is iodine sufficient.
Participants Pregnant women (< 11 weeks' gestation), aged 18-40 years, intent on a full-term pregnancy, who
agree to taking no iodine-containing supplements during the study except for the study medication
Interventions Intervention group: iodine-containing multivitamin (150 µg iodine), 1 tablet daily starting at 10 ± 2
weeks' gestation
Control group: non-iodine containing multivitamin, 1 tablet daily
Outcomes Primary outcomes: milk iodine concentration in colostrum, urinary iodine concentration in the
newborn child, TSH in the newborn child
Secondary outcomes: urinary iodine concentration in the mother (weeks 10 ± 2, 25 ± 1, and 36 ± 2
of pregnancy), Tg in the mother (weeks 10 ± 2, 25 ± 1, and 36 ± 2 of pregnancy), FT4 in the mother
Nyström 2015a 
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(week 10 ± 2, 25 ± 1, and 36 ± 2 of pregnancy), TSH in the mother (weeks 10 ± 2, 25 ± 1, and 36 ± 2 of
pregnancy)
Starting date November 2012
Contact information Location: Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, Gothenburg,
Sweden
Principal Investigator: Helena Filipsson Nyström, Ass. Prof.
Contact: Åsa Nilsson, Nurse +46500 - 432500 asa.maria.nilsson@vgergion.se
Contact: Sofia Manousou, PhD student +46700595310 sofia.manousou@vgergion.se
Contact: Lena Hulthén, Prof +46708574991 lena.hulthén@gu.se
Notes Helena Filipsson Nyström is conducting a similar trial with breastfeeding women (Nyström 2015b)
Nyström 2015a  (Continued)
 
 
Trial name or title Iodine status in Swedish lactating women - effect of iodine supplementation in the thyroid function
of mother and infant
Methods This is as a prospective, double-blind, placebo-controlled study of 200 mothers and their infants. In
parallel, 90 age-matched healthy non-pregnant women are recruited. Mothers are randomised to
150 μg/day iodide supplementation or placebo. Pregnant women are asked to participate during
a visit in pregnancy week 35, at the mother health care (MVC) at Mölnlycke and Skövde. The study
will run for approximately 6 months for each individual and begins by sampling 1 (UIC, TSH, FT4,
TPO-ab) at week 37 of the pregnancy. 1 week after birth, when sample 2 is collected (as above in-
clusively BMIC), women get randomised to 150 μg iodine or placebo. New sampling 3 (UIC, TSH,
FT4, BMIC) and 4 (same as sampling 2) is collected after 3 and 6 months respectively. 6 months af-
ter birth the study is completed for every individual. In parallel, 90 healthy non-pregnant, non-lac-
tating women in the same age range are recruited and followed with UIC, TSH, FT4, TPO-ab for 6
months as a control group. In each case a simple questionnaire is filled and blood is also frozen for
future analyses.
Participants Pregnant women aged 18-40 years, > 36 weeks' gestation with singleton pregnancy, who intend to
breastfeed, have no thyroid disease, and agree to take no iodine-containing supplements during
the study except as provided through the study. Women are recruited during pregnancy and the in-
tervention begins 1 week postpartum.
Interventions Intervention group: iodine-containing multivitamin (150 µg iodine), 1 tablet daily
Control group: non-iodine containing multivitamin, 1 tablet daily
Outcomes Primary outcomes: milk iodine concentration (3 and 6 months after birth), urinary iodine concen-
tration in the infant (3 and 6 months after birth)
Secondary outcomes: TSH in the mother (3 and 6 months after birth), FT4 in the mother (3 and 6
months after birth), TPO-ab in the mother (6 months after birth), urinary iodine concentration in
the mother (3 and 6 months after birth)
Starting date October 2011
Contact information Location: Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, Gothenburg,
Sweden.
Principal Investigator: Ass. Prof. Helena Filipsson Nyström
Contact: Mille Milakovic, MD, PhD +4610 473 36 10 mille.milakovic@vgregion.se
Nyström 2015b 
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Contact: Sofia Manousou, PhD student +4670 0595310 sofia.manousou@vgregion.se
Contact: Robert Eggertsen, Prof +4670 8782250 robert.eggertsen@vgregion.
Notes Helena Filipsson Nyström is conducting a similar trial with pregnant women (Nyström 2015a)
Nyström 2015b  (Continued)
 
 
Trial name or title Screening and intervention for iodine deficiency, iron deficiency and subclinical thyroid insufficien-
cy in women planning pregnancy and in early pregnant women
Methods Randomized parallel-controlled trial. Women randomised to the following groups. Group A: iodine
supplement in pregnant women with mild iodine deficiency (sample size: 300), Group B: no inter-
vention in pregnant women with mild iodine deficiency (sample size: 300), Group C: no intervention
in pregnant women with adequate iodine status (sample size: 300), Group D: iodine supplement in
women with mild iodine deficiency before pregnancy (sample size: 300), Group E: no intervention
in women with mild iodine deficiency before pregnancy (sample size: 300), Group F: no interven-
tion in women with adequate iodine status before pregnancy (sample size: 300), Group G: no inter-
vention in TPO-ab+ pregnant women (sample size: 200), Group H: levothyroxine treatment in TPO-
ab+ pregnant women (sample size: 200), Group I: no intervention in TPO-ab+ women before preg-
nancy (sample size: 200), Group J: levothyroxine treatment in TPO-ab+ women before pregnancy
(sample size: 200), Group K: no intervention in pregnant women with hypothyroxinaemia (sample
size: 200), Group I: levothyroxine treatment in pregnant women with hypothyroxinaemia (sample
size: 200), Group J: no intervention in women with hypothyroxinaemia before pregnancy (sample
size: 200)
Participants Pregnant women before the 8th gestational week (or women planning pregnancy)
Interventions As described in methods
Outcomes Primary outcomes: thyrotropin, T4, TPO-ab, UIC, urine creatine, pregnant and obstetric complica-
tions, delivery condition, neonatal quality, neonatal birth defects, neurodevelopmental index
Secondary outcomes: iodine in hair or nail and ferritin
Starting date December 2013
Contact information Study leader: Weiping Teng/+86 24 83283294/twp@vip.163.com/
Institute of Endocrinology of 1st Affiliated Hospital of China Medical University, Shenyang City, Chi-
na
Applicant: Xiaohui Yu /+86 24 83282152 / cmuyuxh@163.com / same address as study leader
Notes None
Teng 2013 
 
 
Trial name or title Nutritional status of iodine in the pregnant population of Catalonia: a study dietary habits and uri-
nary iodine
Methods Cluster randomised, controlled, multicentre trial. Randomization unit: Primary Care Team. Statis-
tical analysis: descriptive analysis of all variables will be performed as well as multilevel logistic re-
gression. All analyses will be carried out on an intention-to-treat basis and will be fitted for poten-
tial confounding factors and variables of clinical importance
Torres 2010 
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Participants 898 pregnant women over the age of 17 years attending consultation to a midwife during the first
trimester of pregnancy in the participating primary care centres
Interventions Intervention group: group education during the first trimester of gestation on healthy hygiene-di-
etetic habits and the importance of adequate iodine nutritional status
Control group: Usual care
Outcomes Primary outcomes: iodine deficiency (urinary iodine excretion below 150 µg/L) at 24 and 36 weeks
of pregnancy
Secondary outcome: many including iodized salt consumption, iodine supplementation consump-
tion, and consumption of iodine-rich foods
Starting date November 2008
Contact information Principal Investigator: Maria Teresa Torres Costa, Midwife, Institut Català de la Salut (ICS)
Notes None
Torres 2010  (Continued)
BMIC: breast milk iodine concentration
FT4: free thyroxine
Tg: thyroglobulin
TPO-ab: thyroid peroxidase antibodies
TSH: thyroid stimulating hormone
UIC: urinary iodine concentration
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Any supplement containing iodine versus same supplement without iodine or no intervention/
placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Maternal hypothyroidism - preg-
nancy
1 365 Risk Ratio (M-H, Random, 95% CI) 1.9 [0.57, 6.38]
2 Maternal hypothyroidism - postpar-
tum
3 540 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.06, 3.42]
3 Preterm birth 2 376 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.30, 1.66]
4 Maternal adverse effect: elevated
thyroid peroxidase antibodies - preg-
nancy
1 359 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.44, 2.07]
5 Maternal adverse effect: elevated
thyroid peroxidase antibodies - post-
partum
3 397 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.78, 1.30]
6 Maternal adverse effect: hyperthy-
roidism - pregnancy
1 365 Risk Ratio (M-H, Random, 95% CI) 1.9 [0.57, 6.38]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
7 Maternal adverse effect: hyperthy-
roidism - postpartum
3 543 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.11, 0.91]
8 Maternal adverse effect: digestive
intolerance - pregnancy
1 76 Risk Ratio (M-H, Random, 95% CI) 15.33 [2.07, 113.70]
9 Perinatal mortality 2 457 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.42, 1.03]
10 Low birthweight 2 377 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.26, 1.23]
11 Neonatal hypothyroidism or ele-
vated TSH
2 260 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.11, 3.12]
12 Neonatal adverse effect: elevated
thyroid peroxidase antibodies
1 108 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.07, 5.70]
13 Spontaneous miscarriage 3 645 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.64, 2.69]
14 Maternal goitre - pregnancy 2 486 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.33, 3.06]
15 Maternal goitre - postpartum 2 370 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.64, 2.16]
16 Maternal insufficient iodine intake
- pregnancy
2 432 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.51, 0.80]
17 Maternal insufficient iodine intake
- postpartum
2 425 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.70, 0.93]
18 Maternal excessive iodine intake -
pregnancy
1 356 Risk Ratio (M-H, Random, 95% CI) 4.33 [1.24, 15.07]
19 Small-for-gestational age 2 377 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.77, 2.05]
20 Congenital anomalies 2 875 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.12, 0.60]
21 Neonatal goitre 3 684 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.02, 0.56]
22 Neonatal thyroid volume (in mL) 3 359 Mean Difference (IV, Random, 95% CI) -0.34 [-0.58, -0.11]
23 Neonatal insufficient iodine intake 1 159 Risk Ratio (M-H, Random, 95% CI) 2.14 [1.04, 4.37]
24 Child mental or motor develop-
ment (IQ points)
2 174 Mean Difference (IV, Random, 95% CI) 11.21 [7.96, 14.46]
25 Child mental or motor develop-
ment (cognitive score)
1 53 Mean Difference (IV, Random, 95% CI) -2.30 [-7.88, 3.28]
26 Child mental or motor develop-
ment (language score)
1 53 Mean Difference (IV, Random, 95% CI) -0.70 [-7.08, 5.68]
27 Child mental or motor develop-
ment (motor score)
1 53 Mean Difference (IV, Random, 95% CI) 1.5 [-4.02, 7.02]
Iodine supplementation for women during the preconception, pregnancy and postpartum period (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
81
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
28 Child mental or motor develop-
ment (social-emotional score)
1 53 Mean Difference (IV, Random, 95% CI) 0.40 [-8.25, 9.05]
29 Child mental or motor develop-
ment (adaptive behaviour score)
1 53 Mean Difference (IV, Random, 95% CI) 1.70 [-6.40, 9.80]
30 Child mental or motor develop-
ment (cognitive score < 85)
1 53 Risk Ratio (M-H, Random, 95% CI) 2.89 [0.12, 67.96]
31 Child mental or motor develop-
ment (cognitive score < 70)
1 53 Risk Ratio (M-H, Random, 95% CI) 2.89 [0.12, 67.96]
32 Child mental or motor develop-
ment (language score < 85)
1 53 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.21, 4.35]
33 Child mental or motor develop-
ment (language score < 70)
1 53 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34 Child mental or motor develop-
ment (motor score < 85)
1 53 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.08, 1.81]
35 Child mental or motor develop-
ment (motor score < 70)
1 53 Risk Ratio (M-H, Random, 95% CI) 2.89 [0.12, 67.96]
 
 
Analysis 1.1.   Comparison 1 Any supplement containing iodine versus same supplement
without iodine or no intervention/placebo, Outcome 1 Maternal hypothyroidism - pregnancy.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 7/175 4/190 100% 1.9[0.57,6.38]
   
Total (95% CI) 175 190 100% 1.9[0.57,6.38]
Total events: 7 (Any iodine), 4 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.2.   Comparison 1 Any supplement containing iodine versus same supplement
without iodine or no intervention/placebo, Outcome 2 Maternal hypothyroidism - postpartum.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bouhouch 2014 (C) 0/95 2/83 45.49% 0.18[0.01,3.59]
Gowachirapant 2014 1/129 1/125 54.51% 0.97[0.06,15.32]
Liesenkotter 1996 0/38 0/70   Not estimable
   
Favours an y iodine 1000.01 100.1 1 Favours no iodine
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Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total (95% CI) 262 278 100% 0.44[0.06,3.42]
Total events: 1 (Any iodine), 3 (No iodine)  
Heterogeneity: Tau2=0; Chi2=0.69, df=1(P=0.41); I2=0%  
Test for overall effect: Z=0.78(P=0.44)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.3.   Comparison 1 Any supplement containing iodine versus same
supplement without iodine or no intervention/placebo, Outcome 3 Preterm birth.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 8/148 18/170 63.23% 0.51[0.23,1.14]
Zhou 2015 5/29 4/29 36.77% 1.25[0.37,4.19]
   
Total (95% CI) 177 199 100% 0.71[0.3,1.66]
Total events: 13 (Any iodine), 22 (No iodine)  
Heterogeneity: Tau2=0.13; Chi2=1.47, df=1(P=0.23); I2=31.85%  
Test for overall effect: Z=0.79(P=0.43)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.4.   Comparison 1 Any supplement containing iodine versus same supplement without iodine or no
intervention/placebo, Outcome 4 Maternal adverse e<ect: elevated thyroid peroxidase antibodies - pregnancy.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 11/169 13/190 100% 0.95[0.44,2.07]
   
Total (95% CI) 169 190 100% 0.95[0.44,2.07]
Total events: 11 (Any iodine), 13 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.13(P=0.9)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.5.   Comparison 1 Any supplement containing iodine versus same supplement without iodine or no
intervention/placebo, Outcome 5 Maternal adverse e<ect: elevated thyroid peroxidase antibodies - postpartum.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 57/115 58/120 96.67% 1.03[0.79,1.33]
Liesenkotter 1996 1/38 5/70 1.48% 0.37[0.04,3.04]
Pedersen 1993 2/28 2/26 1.85% 0.93[0.14,6.12]
   
Total (95% CI) 181 216 100% 1.01[0.78,1.3]
Total events: 60 (Any iodine), 65 (No iodine)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
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Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=0.93, df=2(P=0.63); I2=0%  
Test for overall effect: Z=0.06(P=0.95)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.6.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 6 Maternal adverse e<ect: hyperthyroidism - pregnancy.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 7/175 4/190 100% 1.9[0.57,6.38]
   
Total (95% CI) 175 190 100% 1.9[0.57,6.38]
Total events: 7 (Any iodine), 4 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.7.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 7 Maternal adverse e<ect: hyperthyroidism - postpartum.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bouhouch 2014 (C) 0/95 2/83 11.79% 0.18[0.01,3.59]
Gowachirapant 2014 4/125 12/132 88.21% 0.35[0.12,1.06]
Liesenkotter 1996 0/38 0/70   Not estimable
   
Total (95% CI) 258 285 100% 0.32[0.11,0.91]
Total events: 4 (Any iodine), 14 (No iodine)  
Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%  
Test for overall effect: Z=2.13(P=0.03)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.8.   Comparison 1 Any supplement containing iodine versus same supplement without iodine
or no intervention/placebo, Outcome 8 Maternal adverse e<ect: digestive intolerance - pregnancy.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brucker-Davis 2013 10/30 1/46 100% 15.33[2.07,113.7]
   
Total (95% CI) 30 46 100% 15.33[2.07,113.7]
Total events: 10 (Any iodine), 1 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.67(P=0.01)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
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Analysis 1.9.   Comparison 1 Any supplement containing iodine versus same
supplement without iodine or no intervention/placebo, Outcome 9 Perinatal mortality.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Thilly 1978 27/197 42/202 100% 0.66[0.42,1.03]
Zhou 2015 0/29 0/29   Not estimable
   
Total (95% CI) 226 231 100% 0.66[0.42,1.03]
Total events: 27 (Any iodine), 42 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.85(P=0.06)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.10.   Comparison 1 Any supplement containing iodine versus same
supplement without iodine or no intervention/placebo, Outcome 10 Low birthweight.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 8/149 15/170 87.59% 0.61[0.27,1.39]
Zhou 2015 1/29 3/29 12.41% 0.33[0.04,3.02]
   
Total (95% CI) 178 199 100% 0.56[0.26,1.23]
Total events: 9 (Any iodine), 18 (No iodine)  
Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%  
Test for overall effect: Z=1.44(P=0.15)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.11.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 11 Neonatal hypothyroidism or elevated TSH.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 2/101 4/118 100% 0.58[0.11,3.12]
Zhou 2015 0/19 0/22   Not estimable
   
Total (95% CI) 120 140 100% 0.58[0.11,3.12]
Total events: 2 (Any iodine), 4 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.63(P=0.53)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
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Analysis 1.12.   Comparison 1 Any supplement containing iodine versus same supplement without iodine
or no intervention/placebo, Outcome 12 Neonatal adverse e<ect: elevated thyroid peroxidase antibodies.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Liesenkotter 1996 1/38 3/70 100% 0.61[0.07,5.7]
   
Total (95% CI) 38 70 100% 0.61[0.07,5.7]
Total events: 1 (Any iodine), 3 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.43(P=0.67)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.13.   Comparison 1 Any supplement containing iodine versus same supplement
without iodine or no intervention/placebo, Outcome 13 Spontaneous miscarriage.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brucker-Davis 2013 4/30 3/46 25.3% 2.04[0.49,8.5]
Gowachirapant 2014 10/249 10/262 69.56% 1.05[0.45,2.48]
Zhou 2015 1/29 0/29 5.14% 3[0.13,70.74]
   
Total (95% CI) 308 337 100% 1.31[0.64,2.69]
Total events: 15 (Any iodine), 13 (No iodine)  
Heterogeneity: Tau2=0; Chi2=0.89, df=2(P=0.64); I2=0%  
Test for overall effect: Z=0.75(P=0.46)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.14.   Comparison 1 Any supplement containing iodine versus same supplement
without iodine or no intervention/placebo, Outcome 14 Maternal goitre - pregnancy.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Glinoer 1993 6/60 10/60 55.63% 0.6[0.23,1.55]
Gowachirapant 2014 7/176 4/190 44.37% 1.89[0.56,6.34]
   
Total (95% CI) 236 250 100% 1[0.33,3.06]
Total events: 13 (Any iodine), 14 (No iodine)  
Heterogeneity: Tau2=0.35; Chi2=2.15, df=1(P=0.14); I2=53.4%  
Test for overall effect: Z=0(P=1)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
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Analysis 1.15.   Comparison 1 Any supplement containing iodine versus same supplement
without iodine or no intervention/placebo, Outcome 15 Maternal goitre - postpartum.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 8/129 4/133 21.28% 2.06[0.64,6.68]
Liesenkotter 1996 23/38 42/70 78.72% 1.01[0.73,1.39]
   
Total (95% CI) 167 203 100% 1.17[0.64,2.16]
Total events: 31 (Any iodine), 46 (No iodine)  
Heterogeneity: Tau2=0.1; Chi2=1.5, df=1(P=0.22); I2=33.35%  
Test for overall effect: Z=0.52(P=0.61)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.16.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 16 Maternal insu<icient iodine intake - pregnancy.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brucker-Davis 2013 13/30 35/46 26.98% 0.57[0.37,0.88]
Gowachirapant 2014 54/171 88/185 73.02% 0.66[0.51,0.87]
   
Total (95% CI) 201 231 100% 0.64[0.51,0.8]
Total events: 67 (Any iodine), 123 (No iodine)  
Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%  
Test for overall effect: Z=3.87(P=0)  
Favours an y iodine 100.1 50.2 20.5 1 Favours no iodine
 
 
Analysis 1.17.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 17 Maternal insu<icient iodine intake - postpartum.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bouhouch 2014 (C) 65/94 69/81 73.37% 0.81[0.69,0.96]
Gowachirapant 2014 51/124 65/126 26.63% 0.8[0.61,1.04]
   
Total (95% CI) 218 207 100% 0.81[0.7,0.93]
Total events: 116 (Any iodine), 134 (No iodine)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.9); I2=0%  
Test for overall effect: Z=3(P=0)  
Favours an y iodine 100.1 50.2 20.5 1 Favours no iodine
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Analysis 1.18.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 18 Maternal excessive iodine intake - pregnancy.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 12/171 3/185 100% 4.33[1.24,15.07]
   
Total (95% CI) 171 185 100% 4.33[1.24,15.07]
Total events: 12 (Any iodine), 3 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.3(P=0.02)  
Favours an y iodine 2000.005 100.1 1 Favours no iodine
 
 
Analysis 1.19.   Comparison 1 Any supplement containing iodine versus same supplement
without iodine or no intervention/placebo, Outcome 19 Small-for-gestational age.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 26/149 24/170 91.88% 1.24[0.74,2.06]
Zhou 2015 3/29 2/29 8.12% 1.5[0.27,8.32]
   
Total (95% CI) 178 199 100% 1.26[0.77,2.05]
Total events: 29 (Any iodine), 26 (No iodine)  
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%  
Test for overall effect: Z=0.91(P=0.36)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.20.   Comparison 1 Any supplement containing iodine versus same supplement
without iodine or no intervention/placebo, Outcome 20 Congenital anomalies.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pharoah 1971 (C) 7/412 26/406 100% 0.27[0.12,0.6]
Zhou 2015 0/28 0/29   Not estimable
   
Total (95% CI) 440 435 100% 0.27[0.12,0.6]
Total events: 7 (Any iodine), 26 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.16(P=0)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.21.   Comparison 1 Any supplement containing iodine versus same
supplement without iodine or no intervention/placebo, Outcome 21 Neonatal goitre.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Glinoer 1993 0/60 6/60 32.71% 0.08[0,1.34]
Favours an y iodine 1000.01 100.1 1 Favours no iodine
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Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kevany 1969 0/254 0/202   Not estimable
Liesenkotter 1996 1/38 14/70 67.29% 0.13[0.02,0.96]
   
Total (95% CI) 352 332 100% 0.11[0.02,0.56]
Total events: 1 (Any iodine), 20 (No iodine)  
Heterogeneity: Tau2=0; Chi2=0.09, df=1(P=0.76); I2=0%  
Test for overall effect: Z=2.65(P=0.01)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.22.   Comparison 1 Any supplement containing iodine versus same supplement
without iodine or no intervention/placebo, Outcome 22 Neonatal thyroid volume (in mL).
Study or subgroup Favours an y iodine No iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Glinoer 1993 60 0.8 (0.2) 60 1.1 (0.2) 37.95% -0.29[-0.36,-0.22]
Gowachirapant 2014 64 0.6 (0.3) 67 0.7 (0.2) 37.18% -0.09[-0.18,-0]
Liesenkotter 1996 38 0.7 (0.4) 70 1.5 (1.1) 24.86% -0.8[-1.09,-0.51]
   
Total *** 162   197   100% -0.34[-0.58,-0.11]
Heterogeneity: Tau2=0.04; Chi2=27.86, df=2(P<0.0001); I2=92.82%  
Test for overall effect: Z=2.83(P=0)  
Favours an y iodine 21-2 -1 0 Favours no iodine
 
 
Analysis 1.23.   Comparison 1 Any supplement containing iodine versus same supplement
without iodine or no intervention/placebo, Outcome 23 Neonatal insu<icient iodine intake.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 21/83 9/76 100% 2.14[1.04,4.37]
   
Total (95% CI) 83 76 100% 2.14[1.04,4.37]
Total events: 21 (Any iodine), 9 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.08(P=0.04)  
Favours an y iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.24.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 24 Child mental or motor development (IQ points).
Study or subgroup Any iodine No iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Kevany 1969 14 84.4 (15.3) 22 71.3 (15.5) 9.93% 13.1[2.8,23.4]
Thilly 1978 66 115 (7.9) 72 104 (12.3) 90.07% 11[7.58,14.42]
   
Favours n o iodine 10050-100 -50 0 Favours a ny iodine
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Study or subgroup Any iodine No iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Total *** 80   94   100% 11.21[7.96,14.46]
Heterogeneity: Tau2=0; Chi2=0.14, df=1(P=0.7); I2=0%  
Test for overall effect: Z=6.77(P<0.0001)  
Favours n o iodine 10050-100 -50 0 Favours a ny iodine
 
 
Analysis 1.25.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 25 Child mental or motor development (cognitive score).
Study or subgroup Favours no iodine No iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 99.4 (12.2) 26 101.7 (8.2) 100% -2.3[-7.88,3.28]
   
Total *** 27   26   100% -2.3[-7.88,3.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.81(P=0.42)  
Favours no iodine 10050-100 -50 0 Favours any iodine
 
 
Analysis 1.26.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 26 Child mental or motor development (language score).
Study or subgroup Any iodine No iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 97.2 (12.2) 26 97.9 (11.5) 100% -0.7[-7.08,5.68]
   
Total *** 27   26   100% -0.7[-7.08,5.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.22(P=0.83)  
Favours no iodine 10050-100 -50 0 Favours any iodine
 
 
Analysis 1.27.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 27 Child mental or motor development (motor score).
Study or subgroup Any iodine No iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 93.9 (10.8) 26 92.4 (9.7) 100% 1.5[-4.02,7.02]
   
Total *** 27   26   100% 1.5[-4.02,7.02]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.53(P=0.59)  
Favours no iodine 10050-100 -50 0 Favours any iodine
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Analysis 1.28.   Comparison 1 Any supplement containing iodine versus same supplement without iodine
or no intervention/placebo, Outcome 28 Child mental or motor development (social-emotional score).
Study or subgroup Any iodine No iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 105.8 (15.9) 26 105.4 (16.2) 100% 0.4[-8.25,9.05]
   
Total *** 27   26   100% 0.4[-8.25,9.05]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.09(P=0.93)  
Favours no iodine 10050-100 -50 0 Favours any iodine
 
 
Analysis 1.29.   Comparison 1 Any supplement containing iodine versus same supplement without iodine
or no intervention/placebo, Outcome 29 Child mental or motor development (adaptive behaviour score).
Study or subgroup Any iodine No iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 105.2 (15.2) 26 103.5 (14.9) 100% 1.7[-6.4,9.8]
   
Total *** 27   26   100% 1.7[-6.4,9.8]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
Favours no iodine 10050-100 -50 0 Favours any iodine
 
 
Analysis 1.30.   Comparison 1 Any supplement containing iodine versus same supplement without iodine
or no intervention/placebo, Outcome 30 Child mental or motor development (cognitive score < 85).
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 1/27 0/26 100% 2.89[0.12,67.96]
   
Total (95% CI) 27 26 100% 2.89[0.12,67.96]
Total events: 1 ( Any iodine ), 0 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours any iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.31.   Comparison 1 Any supplement containing iodine versus same supplement without iodine
or no intervention/placebo, Outcome 31 Child mental or motor development (cognitive score < 70).
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 1/27 0/26 100% 2.89[0.12,67.96]
   
Total (95% CI) 27 26 100% 2.89[0.12,67.96]
Total events: 1 ( Any iodine ), 0 (No iodine)  
Heterogeneity: Not applicable  
Favours any iodine 1000.01 100.1 1 Favours no iodine
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Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.66(P=0.51)  
Favours any iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.32.   Comparison 1 Any supplement containing iodine versus same supplement without iodine
or no intervention/placebo, Outcome 32 Child mental or motor development (language score < 85).
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 3/27 3/26 100% 0.96[0.21,4.35]
   
Total (95% CI) 27 26 100% 0.96[0.21,4.35]
Total events: 3 ( Any iodine ), 3 (No iodine)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.05(P=0.96)  
Favours any iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.33.   Comparison 1 Any supplement containing iodine versus same supplement without iodine
or no intervention/placebo, Outcome 33 Child mental or motor development (language score < 70).
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 0/27 0/26   Not estimable
   
Total (95% CI) 27 26 Not estimable
Total events: 0 ( Any iodine ), 0 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours any iodine 1000.01 100.1 1 Favours no iodine
 
 
Analysis 1.34.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 34 Child mental or motor development (motor score < 85).
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 2/27 5/26 100% 0.39[0.08,1.81]
   
Total (95% CI) 27 26 100% 0.39[0.08,1.81]
Total events: 2 ( Any iodine ), 5 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.21(P=0.23)  
Favours any iodine 1000.01 100.1 1 Favours no iodine
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Analysis 1.35.   Comparison 1 Any supplement containing iodine versus same supplement without
iodine or no intervention/placebo, Outcome 35 Child mental or motor development (motor score < 70).
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 1/27 0/26 100% 2.89[0.12,67.96]
   
Total (95% CI) 27 26 100% 2.89[0.12,67.96]
Total events: 1 ( Any iodine ), 0 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours any iodine 1000.01 100.1 1 Favours no iodine
 
 
Comparison 2.   Any oral iodine supplement versus same supplement without iodine or no intervention/placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Maternal hypothyroidism - preg-
nancy
1 365 Risk Ratio (M-H, Random, 95% CI) 1.9 [0.57, 6.38]
2 Maternal hypothyroidism - postpar-
tum
3 540 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.06, 3.42]
3 Preterm birth 2 376 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.30, 1.66]
4 Maternal adverse effect: elevated
thyroid peroxidase antibodies - preg-
nancy
1 359 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.44, 2.07]
5 Maternal adverse effect: elevated
thyroid peroxidase antibodies - post-
partum
3 397 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.78, 1.30]
6 Maternal adverse effect: hyperthy-
roidism - pregnancy
1 365 Risk Ratio (M-H, Random, 95% CI) 1.9 [0.57, 6.38]
7 Maternal adverse effect: hyperthy-
roidism - postpartum
3 543 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.11, 0.91]
8 Maternal adverse effect: digestive
intolerance - pregnancy
1 76 Risk Ratio (M-H, Random, 95% CI) 15.33 [2.07, 113.70]
9 Perinatal mortality 1 58 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Low birthweight 2 377 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.26, 1.23]
11 Neonatal hypothyroidism or ele-
vated TSH
2 260 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.11, 3.12]
12 Neonatal adverse effect: elevated
thyroid peroxidase antibodies
1 108 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.07, 5.70]
13 Spontaneous miscarriage 3 645 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.64, 2.69]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
14 Maternal goitre - pregnancy 2 486 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.33, 3.06]
15 Maternal goitre - postpartum 2 370 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.64, 2.16]
16 Maternal insufficient iodine intake
- pregnancy
2 432 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.51, 0.80]
17 Maternal insufficient iodine intake
- postpartum
2 425 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.70, 0.93]
18 Maternal excessive iodine intake -
pregnancy
1 356 Risk Ratio (M-H, Random, 95% CI) 4.33 [1.24, 15.07]
19 Small-for-gestational age 2 377 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.77, 2.05]
20 Congenital anomalies 1 57 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21 Neonatal goitre 2 228 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.02, 0.56]
22 Neonatal thyroid volume (in mL) 3 359 Mean Difference (IV, Random, 95% CI) -0.34 [-0.58, -0.11]
23 Neonatal insufficient iodine intake 1 159 Risk Ratio (M-H, Random, 95% CI) 2.14 [1.04, 4.37]
24 Child mental or motor develop-
ment (cognitive score)
1 53 Mean Difference (IV, Random, 95% CI) -2.30 [-7.88, 3.28]
25 Child mental or motor develop-
ment (language score)
1 53 Mean Difference (IV, Random, 95% CI) -0.70 [-7.08, 5.68]
26 Child mental or motor develop-
ment (motor score)
1 53 Mean Difference (IV, Random, 95% CI) 1.5 [-4.02, 7.02]
27 Child mental or motor develop-
ment (social-emotional score)
1 53 Mean Difference (IV, Random, 95% CI) 0.40 [-8.25, 9.05]
28 Child mental or motor develop-
ment (adaptive behaviour score)
1 53 Mean Difference (IV, Random, 95% CI) 1.70 [-6.40, 9.80]
29 Child mental or motor develop-
ment (cognitive score < 85)
1 53 Risk Ratio (M-H, Random, 95% CI) 2.89 [0.12, 67.96]
30 Child mental or motor develop-
ment (cognitive score < 70)
1 53 Risk Ratio (M-H, Random, 95% CI) 2.89 [0.12, 67.96]
31 Child mental or motor develop-
ment (language score < 85)
1 53 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.21, 4.35]
32 Child mental or motor develop-
ment (language score < 70)
1 53 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33 Child mental or motor develop-
ment (motor score < 85)
1 53 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.08, 1.81]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
34 Child mental or motor develop-
ment (motor score < 70)
1 53 Risk Ratio (M-H, Random, 95% CI) 2.89 [0.12, 67.96]
 
 
Analysis 2.1.   Comparison 2 Any oral iodine supplement versus same supplement without
iodine or no intervention/placebo, Outcome 1 Maternal hypothyroidism - pregnancy.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 7/175 4/190 100% 1.9[0.57,6.38]
   
Total (95% CI) 175 190 100% 1.9[0.57,6.38]
Total events: 7 (Any oral iodine), 4 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.2.   Comparison 2 Any oral iodine supplement versus same supplement without
iodine or no intervention/placebo, Outcome 2 Maternal hypothyroidism - postpartum.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bouhouch 2014 (C) 0/95 2/83 45.49% 0.18[0.01,3.59]
Gowachirapant 2014 1/129 1/125 54.51% 0.97[0.06,15.32]
Liesenkotter 1996 0/38 0/70   Not estimable
   
Total (95% CI) 262 278 100% 0.44[0.06,3.42]
Total events: 1 (Any oral iodine), 3 (No oral iodine)  
Heterogeneity: Tau2=0; Chi2=0.69, df=1(P=0.41); I2=0%  
Test for overall effect: Z=0.78(P=0.44)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.3.   Comparison 2 Any oral iodine supplement versus same supplement
without iodine or no intervention/placebo, Outcome 3 Preterm birth.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 8/148 18/170 63.23% 0.51[0.23,1.14]
Zhou 2015 5/29 4/29 36.77% 1.25[0.37,4.19]
   
Total (95% CI) 177 199 100% 0.71[0.3,1.66]
Total events: 13 (Any oral iodine), 22 (No oral iodine)  
Heterogeneity: Tau2=0.13; Chi2=1.47, df=1(P=0.23); I2=31.85%  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
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Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.79(P=0.43)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.4.   Comparison 2 Any oral iodine supplement versus same supplement without iodine or no
intervention/placebo, Outcome 4 Maternal adverse e<ect: elevated thyroid peroxidase antibodies - pregnancy.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 11/169 13/190 100% 0.95[0.44,2.07]
   
Total (95% CI) 169 190 100% 0.95[0.44,2.07]
Total events: 11 (Any oral iodine), 13 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.13(P=0.9)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.5.   Comparison 2 Any oral iodine supplement versus same supplement without iodine or no
intervention/placebo, Outcome 5 Maternal adverse e<ect: elevated thyroid peroxidase antibodies - postpartum.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 57/115 58/120 96.67% 1.03[0.79,1.33]
Liesenkotter 1996 1/38 5/70 1.48% 0.37[0.04,3.04]
Pedersen 1993 2/28 2/26 1.85% 0.93[0.14,6.12]
   
Total (95% CI) 181 216 100% 1.01[0.78,1.3]
Total events: 60 (Any oral iodine), 65 (No oral iodine)  
Heterogeneity: Tau2=0; Chi2=0.93, df=2(P=0.63); I2=0%  
Test for overall effect: Z=0.06(P=0.95)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.6.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 6 Maternal adverse e<ect: hyperthyroidism - pregnancy.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 7/175 4/190 100% 1.9[0.57,6.38]
   
Total (95% CI) 175 190 100% 1.9[0.57,6.38]
Total events: 7 (Any oral iodine), 4 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
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Analysis 2.7.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 7 Maternal adverse e<ect: hyperthyroidism - postpartum.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bouhouch 2014 (C) 0/95 2/83 11.79% 0.18[0.01,3.59]
Gowachirapant 2014 4/125 12/132 88.21% 0.35[0.12,1.06]
Liesenkotter 1996 0/38 0/70   Not estimable
   
Total (95% CI) 258 285 100% 0.32[0.11,0.91]
Total events: 4 (Any oral iodine), 14 (No oral iodine)  
Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%  
Test for overall effect: Z=2.13(P=0.03)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.8.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 8 Maternal adverse e<ect: digestive intolerance - pregnancy.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brucker-Davis 2013 10/30 1/46 100% 15.33[2.07,113.7]
   
Total (95% CI) 30 46 100% 15.33[2.07,113.7]
Total events: 10 (Any oral iodine), 1 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.67(P=0.01)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.9.   Comparison 2 Any oral iodine supplement versus same supplement
without iodine or no intervention/placebo, Outcome 9 Perinatal mortality.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 0/29 0/29   Not estimable
   
Total (95% CI) 29 29 Not estimable
Total events: 0 (Any oral iodine), 0 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours an y oral iodine 1000.01 100.1 1 Favours no oral iodine
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Analysis 2.10.   Comparison 2 Any oral iodine supplement versus same supplement
without iodine or no intervention/placebo, Outcome 10 Low birthweight.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 8/149 15/170 87.59% 0.61[0.27,1.39]
Zhou 2015 1/29 3/29 12.41% 0.33[0.04,3.02]
   
Total (95% CI) 178 199 100% 0.56[0.26,1.23]
Total events: 9 (Any oral iodine), 18 (No oral iodine)  
Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%  
Test for overall effect: Z=1.44(P=0.15)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.11.   Comparison 2 Any oral iodine supplement versus same supplement without
iodine or no intervention/placebo, Outcome 11 Neonatal hypothyroidism or elevated TSH.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 2/101 4/118 100% 0.58[0.11,3.12]
Zhou 2015 0/19 0/22   Not estimable
   
Total (95% CI) 120 140 100% 0.58[0.11,3.12]
Total events: 2 (Any oral iodine), 4 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.63(P=0.53)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.12.   Comparison 2 Any oral iodine supplement versus same supplement without iodine or
no intervention/placebo, Outcome 12 Neonatal adverse e<ect: elevated thyroid peroxidase antibodies.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Liesenkotter 1996 1/38 3/70 100% 0.61[0.07,5.7]
   
Total (95% CI) 38 70 100% 0.61[0.07,5.7]
Total events: 1 (Any oral iodine), 3 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.43(P=0.67)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.13.   Comparison 2 Any oral iodine supplement versus same supplement
without iodine or no intervention/placebo, Outcome 13 Spontaneous miscarriage.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brucker-Davis 2013 4/30 3/46 25.3% 2.04[0.49,8.5]
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
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Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 10/249 10/262 69.56% 1.05[0.45,2.48]
Zhou 2015 1/29 0/29 5.14% 3[0.13,70.74]
   
Total (95% CI) 308 337 100% 1.31[0.64,2.69]
Total events: 15 (Any oral iodine), 13 (No oral iodine)  
Heterogeneity: Tau2=0; Chi2=0.89, df=2(P=0.64); I2=0%  
Test for overall effect: Z=0.75(P=0.46)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.14.   Comparison 2 Any oral iodine supplement versus same supplement
without iodine or no intervention/placebo, Outcome 14 Maternal goitre - pregnancy.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Glinoer 1993 6/60 10/60 55.63% 0.6[0.23,1.55]
Gowachirapant 2014 7/176 4/190 44.37% 1.89[0.56,6.34]
   
Total (95% CI) 236 250 100% 1[0.33,3.06]
Total events: 13 (Any oral iodine), 14 (No oral iodine)  
Heterogeneity: Tau2=0.35; Chi2=2.15, df=1(P=0.14); I2=53.4%  
Test for overall effect: Z=0(P=1)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.15.   Comparison 2 Any oral iodine supplement versus same supplement
without iodine or no intervention/placebo, Outcome 15 Maternal goitre - postpartum.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 8/129 4/133 21.28% 2.06[0.64,6.68]
Liesenkotter 1996 23/38 42/70 78.72% 1.01[0.73,1.39]
   
Total (95% CI) 167 203 100% 1.17[0.64,2.16]
Total events: 31 (Any oral iodine), 46 (No oral iodine)  
Heterogeneity: Tau2=0.1; Chi2=1.5, df=1(P=0.22); I2=33.35%  
Test for overall effect: Z=0.52(P=0.61)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.16.   Comparison 2 Any oral iodine supplement versus same supplement without
iodine or no intervention/placebo, Outcome 16 Maternal insu<icient iodine intake - pregnancy.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brucker-Davis 2013 13/30 35/46 26.98% 0.57[0.37,0.88]
Gowachirapant 2014 54/171 88/185 73.02% 0.66[0.51,0.87]
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
Iodine supplementation for women during the preconception, pregnancy and postpartum period (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
99
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
Total (95% CI) 201 231 100% 0.64[0.51,0.8]
Total events: 67 (Any oral iodine), 123 (No oral iodine)  
Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%  
Test for overall effect: Z=3.87(P=0)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.17.   Comparison 2 Any oral iodine supplement versus same supplement without
iodine or no intervention/placebo, Outcome 17 Maternal insu<icient iodine intake - postpartum.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bouhouch 2014 (C) 65/94 69/81 73.37% 0.81[0.69,0.96]
Gowachirapant 2014 51/124 65/126 26.63% 0.8[0.61,1.04]
   
Total (95% CI) 218 207 100% 0.81[0.7,0.93]
Total events: 116 (Any oral iodine), 134 (No oral iodine)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.9); I2=0%  
Test for overall effect: Z=3(P=0)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.18.   Comparison 2 Any oral iodine supplement versus same supplement without
iodine or no intervention/placebo, Outcome 18 Maternal excessive iodine intake - pregnancy.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 12/171 3/185 100% 4.33[1.24,15.07]
   
Total (95% CI) 171 185 100% 4.33[1.24,15.07]
Total events: 12 (Any oral iodine), 3 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.3(P=0.02)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.19.   Comparison 2 Any oral iodine supplement versus same supplement
without iodine or no intervention/placebo, Outcome 19 Small-for-gestational age.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 26/149 24/170 91.88% 1.24[0.74,2.06]
Zhou 2015 3/29 2/29 8.12% 1.5[0.27,8.32]
   
Total (95% CI) 178 199 100% 1.26[0.77,2.05]
Total events: 29 (Any oral iodine), 26 (No oral iodine)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
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Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%  
Test for overall effect: Z=0.91(P=0.36)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.20.   Comparison 2 Any oral iodine supplement versus same supplement
without iodine or no intervention/placebo, Outcome 20 Congenital anomalies.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 0/28 0/29   Not estimable
   
Total (95% CI) 28 29 Not estimable
Total events: 0 ( Any oral iodine ), 0 ( No oral iodine )  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours any oral iodineFavours [experimental] 1000.01 100.1 1 Favours no oral iodineFavours [control]
 
 
Analysis 2.21.   Comparison 2 Any oral iodine supplement versus same supplement
without iodine or no intervention/placebo, Outcome 21 Neonatal goitre.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Glinoer 1993 0/60 6/60 32.71% 0.08[0,1.34]
Liesenkotter 1996 1/38 14/70 67.29% 0.13[0.02,0.96]
   
Total (95% CI) 98 130 100% 0.11[0.02,0.56]
Total events: 1 (Any oral iodine), 20 (No oral iodine)  
Heterogeneity: Tau2=0; Chi2=0.09, df=1(P=0.76); I2=0%  
Test for overall effect: Z=2.65(P=0.01)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.22.   Comparison 2 Any oral iodine supplement versus same supplement
without iodine or no intervention/placebo, Outcome 22 Neonatal thyroid volume (in mL).
Study or subgroup Any oral iodine No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Glinoer 1993 60 0.8 (0.2) 60 1.1 (0.2) 37.95% -0.29[-0.36,-0.22]
Gowachirapant 2014 64 0.6 (0.3) 67 0.7 (0.2) 37.18% -0.09[-0.18,-0]
Liesenkotter 1996 38 0.7 (0.4) 70 1.5 (1.1) 24.86% -0.8[-1.09,-0.51]
   
Total *** 162   197   100% -0.34[-0.58,-0.11]
Heterogeneity: Tau2=0.04; Chi2=27.86, df=2(P<0.0001); I2=92.82%  
Test for overall effect: Z=2.83(P=0)  
Favours any oral iodine 10050-100 -50 0 Favours no oral iodine
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Analysis 2.23.   Comparison 2 Any oral iodine supplement versus same supplement without
iodine or no intervention/placebo, Outcome 23 Neonatal insu<icient iodine intake.
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 21/83 9/76 100% 2.14[1.04,4.37]
   
Total (95% CI) 83 76 100% 2.14[1.04,4.37]
Total events: 21 (Any oral iodine), 9 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.08(P=0.04)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.24.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 24 Child mental or motor development (cognitive score).
Study or subgroup Any oral iodine No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 99.4 (12.2) 26 101.7 (8.2) 100% -2.3[-7.88,3.28]
   
Total *** 27   26   100% -2.3[-7.88,3.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.81(P=0.42)  
Favours n o oral iodine 10050-100 -50 0 Favours a ny oral iodine
 
 
Analysis 2.25.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 25 Child mental or motor development (language score).
Study or subgroup Any oral iodine No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 97.2 (12.2) 26 97.9 (11.5) 100% -0.7[-7.08,5.68]
   
Total *** 27   26   100% -0.7[-7.08,5.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.22(P=0.83)  
Favours n o oral iodine 10050-100 -50 0 Favours a ny oral iodine
 
 
Analysis 2.26.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 26 Child mental or motor development (motor score).
Study or subgroup Any oral iodine No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 93.9 (10.8) 26 92.4 (9.7) 100% 1.5[-4.02,7.02]
   
Total *** 27   26   100% 1.5[-4.02,7.02]
Favours n o oral iodine 10050-100 -50 0 Favours a ny oral iodine
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Study or subgroup Any oral iodine No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.53(P=0.59)  
Favours n o oral iodine 10050-100 -50 0 Favours a ny oral iodine
 
 
Analysis 2.27.   Comparison 2 Any oral iodine supplement versus same supplement without iodine or
no intervention/placebo, Outcome 27 Child mental or motor development (social-emotional score).
Study or subgroup Any oral iodine No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 105.8 (15.9) 26 105.4 (16.2) 100% 0.4[-8.25,9.05]
   
Total *** 27   26   100% 0.4[-8.25,9.05]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.09(P=0.93)  
Favours n o oral iodine 10050-100 -50 0 Favours a ny oral iodine
 
 
Analysis 2.28.   Comparison 2 Any oral iodine supplement versus same supplement without iodine or
no intervention/placebo, Outcome 28 Child mental or motor development (adaptive behaviour score).
Study or subgroup Any oral iodine No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 105.2 (15.2) 26 103.5 (14.9) 100% 1.7[-6.4,9.8]
   
Total *** 27   26   100% 1.7[-6.4,9.8]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
Favours n o oral iodine 10050-100 -50 0 Favours a ny oral iodine
 
 
Analysis 2.29.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 29 Child mental or motor development (cognitive score < 85).
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 1/27 0/26 100% 2.89[0.12,67.96]
   
Total (95% CI) 27 26 100% 2.89[0.12,67.96]
Total events: 1 ( Any oral iodine ), 0 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
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Analysis 2.30.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 30 Child mental or motor development (cognitive score < 70).
Study or subgroup Any ora l iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 1/27 0/26 100% 2.89[0.12,67.96]
   
Total (95% CI) 27 26 100% 2.89[0.12,67.96]
Total events: 1 ( Any ora l iodine ), 0 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.31.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 31 Child mental or motor development (language score < 85).
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 3/27 3/26 100% 0.96[0.21,4.35]
   
Total (95% CI) 27 26 100% 0.96[0.21,4.35]
Total events: 3 ( Any oral iodine ), 3 (No oral iodine)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.05(P=0.96)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.32.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 32 Child mental or motor development (language score < 70).
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 0/27 0/26   Not estimable
   
Total (95% CI) 27 26 Not estimable
Total events: 0 ( Any oral iodine ), 0 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.33.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 33 Child mental or motor development (motor score < 85).
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 2/27 5/26 100% 0.39[0.08,1.81]
   
Total (95% CI) 27 26 100% 0.39[0.08,1.81]
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
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Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 2 ( Any oral iodine ), 5 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.21(P=0.23)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Analysis 2.34.   Comparison 2 Any oral iodine supplement versus same supplement without iodine
or no intervention/placebo, Outcome 34 Child mental or motor development (motor score < 70).
Study or subgroup Any oral iodine No oral iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 1/27 0/26 100% 2.89[0.12,67.96]
   
Total (95% CI) 27 26 100% 2.89[0.12,67.96]
Total events: 1 ( Any oral iodine ), 0 (No oral iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours any oral iodine 1000.01 100.1 1 Favours no oral iodine
 
 
Comparison 3.   Oral iodine-only supplement versus no intervention or placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Maternal hypothyroidism - postpar-
tum
3 340 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.10, 8.60]
2 Preterm birth 1 58 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.37, 4.19]
3 Maternal adverse effect: elevated
thyroid peroxidase antibodies - post-
partum
2 162 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.15, 2.51]
4 Maternal adverse effect: hyperthy-
roidism - postpartum
2 286 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.01, 7.06]
5 Perinatal mortality 1 58 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Low birthweight 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 3.02]
7 Neonatal hypothyroidism or elevat-
ed TSH
1 41 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Neonatal adverse effect: elevated
thyroid peroxidase antibodies
1 108 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.07, 5.70]
9 Spontaneous miscarriage 1 58 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 70.74]
10 Maternal goitre - pregnancy 1 120 Risk Ratio (M-H, Random, 95% CI) 0.6 [0.23, 1.55]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
11 Maternal goitre - postpartum 1 108 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.73, 1.39]
12 Maternal insufficient iodine intake
- postpartum
1 175 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.69, 0.96]
13 Small-for-gestational age 1 58 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.27, 8.32]
14 Congenital anomalies 1 57 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15 Neonatal goitre 2 228 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.02, 0.56]
16 Neonatal thyroid volume (in mL) 2 228 Mean Difference (IV, Random, 95% CI) -0.53 [-1.02, -0.03]
17 Child mental or motor develop-
ment (cognitive score)
1 53 Mean Difference (IV, Random, 95% CI) -2.30 [-7.88, 3.28]
18 Child mental or motor develop-
ment (language score)
1 53 Mean Difference (IV, Random, 95% CI) -0.70 [-7.08, 5.68]
19 Child mental or motor develop-
ment (motor score)
1 53 Mean Difference (IV, Random, 95% CI) 1.5 [-4.02, 7.02]
20 Child mental or motor develop-
ment (social-emotional score)
1 53 Mean Difference (IV, Random, 95% CI) 0.40 [-8.25, 9.05]
21 Child mental or motor develop-
ment (adaptive behaviour score)
1 53 Mean Difference (IV, Random, 95% CI) 1.70 [-6.40, 9.80]
22 Child mental or motor develop-
ment (cognitive score < 85)
1 53 Risk Ratio (M-H, Random, 95% CI) 2.89 [0.12, 67.96]
23 Child mental or motor develop-
ment (cognitive score < 70)
1 53 Risk Ratio (M-H, Random, 95% CI) 2.89 [0.12, 67.96]
24 Child mental or motor develop-
ment (language score < 85)
1 53 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.21, 4.35]
25 Child mental or motor develop-
ment (language score < 70)
1 53 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26 Child mental or motor develop-
ment (motor score < 85)
1 53 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.08, 1.81]
27 Child mental or motor develop-
ment (motor score < 70)
1 53 Risk Ratio (M-H, Random, 95% CI) 2.89 [0.12, 67.96]
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Analysis 3.1.   Comparison 3 Oral iodine-only supplement versus no
intervention or placebo, Outcome 1 Maternal hypothyroidism - postpartum.
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bouhouch 2014 (C) 0/95 1/83 49.53% 0.29[0.01,7.06]
Liesenkotter 1996 0/38 0/70   Not estimable
Pedersen 1993 1/28 0/26 50.47% 2.79[0.12,65.66]
   
Total (95% CI) 161 179 100% 0.91[0.1,8.6]
Total events: 1 (Oral iodine-only), 1 (Placebo/no intervention)  
Heterogeneity: Tau2=0; Chi2=0.97, df=1(P=0.32); I2=0%  
Test for overall effect: Z=0.08(P=0.94)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
 
 
Analysis 3.2.   Comparison 3 Oral iodine-only supplement
versus no intervention or placebo, Outcome 2 Preterm birth.
Study or subgroup Oral- io-
dine only
N o interven-
tion/placebo
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 5/29 4/29 100% 1.25[0.37,4.19]
   
Total (95% CI) 29 29 100% 1.25[0.37,4.19]
Total events: 5 ( Oral- iodine only ), 4 ( N o intervention/placebo )  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
 
 
Analysis 3.3.   Comparison 3 Oral iodine-only supplement versus no intervention or placebo,
Outcome 3 Maternal adverse e<ect: elevated thyroid peroxidase antibodies - postpartum.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Liesenkotter 1996 1/38 5/70 44.4% 0.37[0.04,3.04]
Pedersen 1993 2/28 2/26 55.6% 0.93[0.14,6.12]
   
Total (95% CI) 66 96 100% 0.62[0.15,2.51]
Total events: 3 (Any iodine), 7 (No iodine)  
Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%  
Test for overall effect: Z=0.68(P=0.5)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
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Analysis 3.4.   Comparison 3 Oral iodine-only supplement versus no intervention
or placebo, Outcome 4 Maternal adverse e<ect: hyperthyroidism - postpartum.
Study or subgroup Any iodine No iodine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bouhouch 2014 (C) 0/95 1/83 100% 0.29[0.01,7.06]
Liesenkotter 1996 0/38 0/70   Not estimable
   
Total (95% CI) 133 153 100% 0.29[0.01,7.06]
Total events: 0 (Any iodine), 1 (No iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.76(P=0.45)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
 
 
Analysis 3.5.   Comparison 3 Oral iodine-only supplement versus
no intervention or placebo, Outcome 5 Perinatal mortality.
Study or subgroup Oral iodine only No interven-
tion/placebo
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 0/29 0/29   Not estimable
   
Total (95% CI) 29 29 Not estimable
Total events: 0 ( Oral iodine only ), 0 ( No intervention/placebo )  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours o ral iodine only 1000.01 100.1 1 Favours no i ntervention/ placebo
 
 
Analysis 3.6.   Comparison 3 Oral iodine-only supplement
versus no intervention or placebo, Outcome 6 Low birthweight.
Study or subgroup Oral iodine only Placebo/no Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Zhou 2015 1/29 3/29 100% 0.33[0.04,3.02]
   
Total (95% CI) 29 29 100% 0.33[0.04,3.02]
Total events: 1 (Oral iodine only), 3 (Placebo/no)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.98(P=0.33)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
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Analysis 3.7.   Comparison 3 Oral iodine-only supplement versus no
intervention or placebo, Outcome 7 Neonatal hypothyroidism or elevated TSH.
Study or subgroup Oral iodine only P lacebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 0/19 0/22   Not estimable
   
Total (95% CI) 19 22 Not estimable
Total events: 0 ( Oral iodine only ), 0 ( P lacebo/no intervention )  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours oral iodine -only 1000.01 100.1 1 Favours placebo/no intervention
 
 
Analysis 3.8.   Comparison 3 Oral iodine-only supplement versus no intervention or
placebo, Outcome 8 Neonatal adverse e<ect: elevated thyroid peroxidase antibodies.
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Liesenkotter 1996 1/38 3/70 100% 0.61[0.07,5.7]
   
Total (95% CI) 38 70 100% 0.61[0.07,5.7]
Total events: 1 (Oral iodine-only), 3 (Placebo/no intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.43(P=0.67)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
 
 
Analysis 3.9.   Comparison 3 Oral iodine-only supplement versus
no intervention or placebo, Outcome 9 Spontaneous miscarriage.
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 1/29 0/29 100% 3[0.13,70.74]
   
Total (95% CI) 29 29 100% 3[0.13,70.74]
Total events: 1 ( Oral iodine-only ), 0 ( Placebo/no intervention )  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
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Analysis 3.10.   Comparison 3 Oral iodine-only supplement versus no
intervention or placebo, Outcome 10 Maternal goitre - pregnancy.
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Glinoer 1993 6/60 10/60 100% 0.6[0.23,1.55]
   
Total (95% CI) 60 60 100% 0.6[0.23,1.55]
Total events: 6 (Oral iodine-only), 10 (Placebo/no intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.06(P=0.29)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
 
 
Analysis 3.11.   Comparison 3 Oral iodine-only supplement versus no
intervention or placebo, Outcome 11 Maternal goitre - postpartum.
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Liesenkotter 1996 23/38 42/70 100% 1.01[0.73,1.39]
   
Total (95% CI) 38 70 100% 1.01[0.73,1.39]
Total events: 23 (Oral iodine-only), 42 (Placebo/no intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.05(P=0.96)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
 
 
Analysis 3.12.   Comparison 3 Oral iodine-only supplement versus no intervention
or placebo, Outcome 12 Maternal insu<icient iodine intake - postpartum.
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bouhouch 2014 (C) 65/94 69/81 100% 0.81[0.69,0.96]
   
Total (95% CI) 94 81 100% 0.81[0.69,0.96]
Total events: 65 (Oral iodine-only), 69 (Placebo/no intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.51(P=0.01)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
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Analysis 3.13.   Comparison 3 Oral iodine-only supplement versus
no intervention or placebo, Outcome 13 Small-for-gestational age.
Study or subgroup Oral iodine only Placebo/no Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Zhou 2015 3/29 2/29 100% 1.5[0.27,8.32]
   
Total (95% CI) 29 29 100% 1.5[0.27,8.32]
Total events: 3 (Oral iodine only), 2 (Placebo/no)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.46(P=0.64)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
 
 
Analysis 3.14.   Comparison 3 Oral iodine-only supplement versus
no intervention or placebo, Outcome 14 Congenital anomalies.
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 0/28 0/29   Not estimable
   
Total (95% CI) 28 29 Not estimable
Total events: 0 ( Oral iodine-only ), 0 ( Placebo/no intervention )  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours oral iodine-onlyFavours [experimental] 1000.01 100.1 1 Favours no intervention/placeboFavours
[control]
 
 
Analysis 3.15.   Comparison 3 Oral iodine-only supplement
versus no intervention or placebo, Outcome 15 Neonatal goitre.
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Glinoer 1993 0/60 6/60 32.71% 0.08[0,1.34]
Liesenkotter 1996 1/38 14/70 67.29% 0.13[0.02,0.96]
   
Total (95% CI) 98 130 100% 0.11[0.02,0.56]
Total events: 1 (Oral iodine-only), 20 (Placebo/no intervention)  
Heterogeneity: Tau2=0; Chi2=0.09, df=1(P=0.76); I2=0%  
Test for overall effect: Z=2.65(P=0.01)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
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Analysis 3.16.   Comparison 3 Oral iodine-only supplement versus no
intervention or placebo, Outcome 16 Neonatal thyroid volume (in mL).
Study or subgroup Oral iodine-only Placebo/no
intervention
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Glinoer 1993 60 0.8 (0.2) 60 1.1 (0.2) 53.9% -0.29[-0.36,-0.22]
Liesenkotter 1996 38 0.7 (0.4) 70 1.5 (1.1) 46.1% -0.8[-1.09,-0.51]
   
Total *** 98   130   100% -0.53[-1.02,-0.03]
Heterogeneity: Tau2=0.12; Chi2=11.46, df=1(P=0); I2=91.27%  
Test for overall effect: Z=2.07(P=0.04)  
Favours oral iodine-only 10050-100 -50 0 Favours no intervention/placebo
 
 
Analysis 3.17.   Comparison 3 Oral iodine-only supplement versus no intervention
or placebo, Outcome 17 Child mental or motor development (cognitive score).
Study or subgroup Favours no inter-
vention/placebo
No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 99.4 (12.2) 26 101.7 (8.2) 100% -2.3[-7.88,3.28]
   
Total *** 27   26   100% -2.3[-7.88,3.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.81(P=0.42)  
Favours no intervention/placebo 10050-100 -50 0 Favours oral iodine-only
 
 
Analysis 3.18.   Comparison 3 Oral iodine-only supplement versus no intervention
or placebo, Outcome 18 Child mental or motor development (language score).
Study or subgroup Oral iodine only No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 97.2 (12.2) 26 97.9 (11.5) 100% -0.7[-7.08,5.68]
   
Total *** 27   26   100% -0.7[-7.08,5.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.22(P=0.83)  
Favours no intervention/placebo 10050-100 -50 0 Favours oral iodine-only
 
 
Analysis 3.19.   Comparison 3 Oral iodine-only supplement versus no intervention
or placebo, Outcome 19 Child mental or motor development (motor score).
Study or subgroup Oral iodine only No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 93.9 (10.8) 26 92.4 (9.7) 100% 1.5[-4.02,7.02]
   
Total *** 27   26   100% 1.5[-4.02,7.02]
Favours no intervention/placebo 10050-100 -50 0 Favours oral iodine-only
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Study or subgroup Oral iodine only No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.53(P=0.59)  
Favours no intervention/placebo 10050-100 -50 0 Favours oral iodine-only
 
 
Analysis 3.20.   Comparison 3 Oral iodine-only supplement versus no intervention or
placebo, Outcome 20 Child mental or motor development (social-emotional score).
Study or subgroup Oral iodine only No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 105.8 (15.9) 26 105.4 (16.2) 100% 0.4[-8.25,9.05]
   
Total *** 27   26   100% 0.4[-8.25,9.05]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.09(P=0.93)  
Favours no intervention/placebo 10050-100 -50 0 Favours oral iodine-only
 
 
Analysis 3.21.   Comparison 3 Oral iodine-only supplement versus no intervention or
placebo, Outcome 21 Child mental or motor development (adaptive behaviour score).
Study or subgroup Oral iodine only No oral iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Zhou 2015 27 105.2 (15.2) 26 103.5 (14.9) 100% 1.7[-6.4,9.8]
   
Total *** 27   26   100% 1.7[-6.4,9.8]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
Favours no intervention/placebo 10050-100 -50 0 Favours oral iodine-only
 
 
Analysis 3.22.   Comparison 3 Oral iodine-only supplement versus no intervention
or placebo, Outcome 22 Child mental or motor development (cognitive score < 85).
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 1/27 0/26 100% 2.89[0.12,67.96]
   
Total (95% CI) 27 26 100% 2.89[0.12,67.96]
Total events: 1 ( Oral iodine-only ), 0 ( Placebo/no intervention )  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
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Analysis 3.23.   Comparison 3 Oral iodine-only supplement versus no intervention
or placebo, Outcome 23 Child mental or motor development (cognitive score < 70).
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 1/27 0/26 100% 2.89[0.12,67.96]
   
Total (95% CI) 27 26 100% 2.89[0.12,67.96]
Total events: 1 ( Oral iodine-only ), 0 ( Placebo/no intervention )  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
 
 
Analysis 3.24.   Comparison 3 Oral iodine-only supplement versus no intervention
or placebo, Outcome 24 Child mental or motor development (language score < 85).
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 3/27 3/26 100% 0.96[0.21,4.35]
   
Total (95% CI) 27 26 100% 0.96[0.21,4.35]
Total events: 3 ( Oral iodine-only ), 3 ( Placebo/no intervention )  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.05(P=0.96)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
 
 
Analysis 3.25.   Comparison 3 Oral iodine-only supplement versus no intervention
or placebo, Outcome 25 Child mental or motor development (language score < 70).
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 0/27 0/26   Not estimable
   
Total (95% CI) 27 26 Not estimable
Total events: 0 ( Oral iodine-only ), 0 ( Placebo/no intervention )  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
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Analysis 3.26.   Comparison 3 Oral iodine-only supplement versus no intervention
or placebo, Outcome 26 Child mental or motor development (motor score < 85).
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 2/27 5/26 100% 0.39[0.08,1.81]
   
Total (95% CI) 27 26 100% 0.39[0.08,1.81]
Total events: 2 ( Oral iodine-only ), 5 ( Placebo/no intervention )  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.21(P=0.23)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
 
 
Analysis 3.27.   Comparison 3 Oral iodine-only supplement versus no intervention
or placebo, Outcome 27 Child mental or motor development (motor score < 70).
Study or subgroup Oral io-
dine-only
Placebo/no
intervention
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zhou 2015 1/27 0/26 100% 2.89[0.12,67.96]
   
Total (95% CI) 27 26 100% 2.89[0.12,67.96]
Total events: 1 ( Oral iodine-only ), 0 ( Placebo/no intervention )  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours oral iodine-only 1000.01 100.1 1 Favours no intervention/placebo
 
 
Comparison 4.   Oral iodine supplement with other vitamins and/or minerals versus only other vitamins and/or
minerals but no iodine
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Maternal hypothyroidism - preg-
nancy
1 365 Risk Ratio (M-H, Random, 95% CI) 1.9 [0.57, 6.38]
2 Maternal hypothyroidism - post-
partum
1 254 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.06, 15.32]
3 Preterm birth 1 318 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.23, 1.14]
4 Maternal adverse effect: elevat-
ed thyroid peroxidase antibodies -
pregnancy
1 359 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.44, 2.07]
5 Maternal adverse effect: elevat-
ed thyroid peroxidase antibodies -
postpartum
1 235 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.79, 1.33]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
6 Maternal adverse effect: hyperthy-
roidism - pregnancy
1 365 Risk Ratio (M-H, Random, 95% CI) 1.9 [0.57, 6.38]
7 Maternal adverse effect: hyperthy-
roidism - postpartum
1 257 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.12, 1.06]
8 Maternal adverse effect: digestive
intolerance - pregnancy
1 76 Risk Ratio (M-H, Random, 95% CI) 15.33 [2.07, 113.70]
9 Low birthweight 1 319 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.27, 1.39]
10 Neonatal hypothyroidism or ele-
vated TSH
1 219 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.11, 3.12]
11 Spontaneous miscarriage 2 587 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.60, 2.62]
12 Maternal goitre - pregnancy 1 366 Risk Ratio (M-H, Random, 95% CI) 1.89 [0.56, 6.34]
13 Maternal goitre - postpartum 1 262 Risk Ratio (M-H, Random, 95% CI) 2.06 [0.64, 6.68]
14 Maternal insufficient iodine in-
take - pregnancy
2 432 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.51, 0.80]
15 Maternal insufficient iodine in-
take - postpartum
1 250 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.61, 1.04]
16 Maternal excessive iodine intake
- pregnancy
1 356 Risk Ratio (M-H, Random, 95% CI) 4.33 [1.24, 15.07]
17 Small-for-gestational age 1 319 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.74, 2.06]
18 Neonatal thyroid volume (in mL) 1 131 Mean Difference (IV, Random, 95% CI) -0.09 [-0.18, -0.00]
19 Neonatal insufficient iodine in-
take
1 159 Risk Ratio (M-H, Random, 95% CI) 2.14 [1.04, 4.37]
 
 
Analysis 4.1.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus only
other vitamins and/or minerals but no iodine, Outcome 1 Maternal hypothyroidism - pregnancy.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 7/175 4/190 100% 1.9[0.57,6.38]
   
Total (95% CI) 175 190 100% 1.9[0.57,6.38]
Total events: 7 (Oral iodine with other), 4 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
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Analysis 4.2.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus only
other vitamins and/or minerals but no iodine, Outcome 2 Maternal hypothyroidism - postpartum.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 1/129 1/125 100% 0.97[0.06,15.32]
   
Total (95% CI) 129 125 100% 0.97[0.06,15.32]
Total events: 1 (Oral iodine with other), 1 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.02(P=0.98)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Analysis 4.3.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals
versus only other vitamins and/or minerals but no iodine, Outcome 3 Preterm birth.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 8/148 18/170 100% 0.51[0.23,1.14]
   
Total (95% CI) 148 170 100% 0.51[0.23,1.14]
Total events: 8 (Oral iodine with other), 18 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.64(P=0.1)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Analysis 4.4.   Comparison 4 Oral iodine supplement with other vitamins and/
or minerals versus only other vitamins and/or minerals but no iodine, Outcome
4 Maternal adverse e<ect: elevated thyroid peroxidase antibodies - pregnancy.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 11/169 13/190 100% 0.95[0.44,2.07]
   
Total (95% CI) 169 190 100% 0.95[0.44,2.07]
Total events: 11 (Oral iodine with other), 13 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.13(P=0.9)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
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Analysis 4.5.   Comparison 4 Oral iodine supplement with other vitamins and/
or minerals versus only other vitamins and/or minerals but no iodine, Outcome
5 Maternal adverse e<ect: elevated thyroid peroxidase antibodies - postpartum.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 57/115 58/120 100% 1.03[0.79,1.33]
   
Total (95% CI) 115 120 100% 1.03[0.79,1.33]
Total events: 57 (Oral iodine with other), 58 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Analysis 4.6.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus only other
vitamins and/or minerals but no iodine, Outcome 6 Maternal adverse e<ect: hyperthyroidism - pregnancy.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 7/175 4/190 100% 1.9[0.57,6.38]
   
Total (95% CI) 175 190 100% 1.9[0.57,6.38]
Total events: 7 (Oral iodine with other), 4 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Analysis 4.7.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus only other
vitamins and/or minerals but no iodine, Outcome 7 Maternal adverse e<ect: hyperthyroidism - postpartum.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 4/125 12/132 100% 0.35[0.12,1.06]
   
Total (95% CI) 125 132 100% 0.35[0.12,1.06]
Total events: 4 (Oral iodine with other), 12 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.85(P=0.06)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
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Analysis 4.8.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus only other
vitamins and/or minerals but no iodine, Outcome 8 Maternal adverse e<ect: digestive intolerance - pregnancy.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brucker-Davis 2013 10/30 1/46 100% 15.33[2.07,113.7]
   
Total (95% CI) 30 46 100% 15.33[2.07,113.7]
Total events: 10 (Oral iodine with other), 1 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.67(P=0.01)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Analysis 4.9.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals
versus only other vitamins and/or minerals but no iodine, Outcome 9 Low birthweight.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 8/149 15/170 100% 0.61[0.27,1.39]
   
Total (95% CI) 149 170 100% 0.61[0.27,1.39]
Total events: 8 (Oral iodine with other), 15 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.17(P=0.24)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Analysis 4.10.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus only
other vitamins and/or minerals but no iodine, Outcome 10 Neonatal hypothyroidism or elevated TSH.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 2/101 4/118 100% 0.58[0.11,3.12]
   
Total (95% CI) 101 118 100% 0.58[0.11,3.12]
Total events: 2 (Oral iodine with other), 4 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.63(P=0.53)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
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Analysis 4.11.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals
versus only other vitamins and/or minerals but no iodine, Outcome 11 Spontaneous miscarriage.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brucker-Davis 2013 4/30 3/46 26.67% 2.04[0.49,8.5]
Gowachirapant 2014 10/249 10/262 73.33% 1.05[0.45,2.48]
   
Total (95% CI) 279 308 100% 1.26[0.6,2.62]
Total events: 14 (Oral iodine with other), 13 (Only other)  
Heterogeneity: Tau2=0; Chi2=0.61, df=1(P=0.43); I2=0%  
Test for overall effect: Z=0.61(P=0.54)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Analysis 4.12.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus
only other vitamins and/or minerals but no iodine, Outcome 12 Maternal goitre - pregnancy.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 7/176 4/190 100% 1.89[0.56,6.34]
   
Total (95% CI) 176 190 100% 1.89[0.56,6.34]
Total events: 7 (Oral iodine with other), 4 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.03(P=0.3)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Analysis 4.13.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus
only other vitamins and/or minerals but no iodine, Outcome 13 Maternal goitre - postpartum.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 8/129 4/133 100% 2.06[0.64,6.68]
   
Total (95% CI) 129 133 100% 2.06[0.64,6.68]
Total events: 8 (Oral iodine with other), 4 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.21(P=0.23)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
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Analysis 4.14.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus only
other vitamins and/or minerals but no iodine, Outcome 14 Maternal insu<icient iodine intake - pregnancy.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brucker-Davis 2013 13/30 35/46 26.98% 0.57[0.37,0.88]
Gowachirapant 2014 54/171 88/185 73.02% 0.66[0.51,0.87]
   
Total (95% CI) 201 231 100% 0.64[0.51,0.8]
Total events: 67 (Oral iodine with other), 123 (Only other)  
Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%  
Test for overall effect: Z=3.87(P=0)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Analysis 4.15.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus only
other vitamins and/or minerals but no iodine, Outcome 15 Maternal insu<icient iodine intake - postpartum.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 51/124 65/126 100% 0.8[0.61,1.04]
   
Total (95% CI) 124 126 100% 0.8[0.61,1.04]
Total events: 51 (Oral iodine with other), 65 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.64(P=0.1)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Analysis 4.16.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus only
other vitamins and/or minerals but no iodine, Outcome 16 Maternal excessive iodine intake - pregnancy.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 12/171 3/185 100% 4.33[1.24,15.07]
   
Total (95% CI) 171 185 100% 4.33[1.24,15.07]
Total events: 12 (Oral iodine with other), 3 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.3(P=0.02)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
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Analysis 4.17.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals
versus only other vitamins and/or minerals but no iodine, Outcome 17 Small-for-gestational age.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 26/149 24/170 100% 1.24[0.74,2.06]
   
Total (95% CI) 149 170 100% 1.24[0.74,2.06]
Total events: 26 (Oral iodine with other), 24 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.82(P=0.41)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Analysis 4.18.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus
only other vitamins and/or minerals but no iodine, Outcome 18 Neonatal thyroid volume (in mL).
Study or subgroup Oral iodine
with other
Only other Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Gowachirapant 2014 64 0.6 (0.3) 67 0.7 (0.2) 100% -0.09[-0.18,-0]
   
Total *** 64   67   100% -0.09[-0.18,-0]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.01(P=0.04)  
Favours oral iodine + other vitamins/minerals 10050-100 -50 0 Favours other vitamins/minerals on-
ly
 
 
Analysis 4.19.   Comparison 4 Oral iodine supplement with other vitamins and/or minerals versus
only other vitamins and/or minerals but no iodine, Outcome 19 Neonatal insu<icient iodine intake.
Study or subgroup Oral iodine
with other
Only other Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gowachirapant 2014 21/83 9/76 100% 2.14[1.04,4.37]
   
Total (95% CI) 83 76 100% 2.14[1.04,4.37]
Total events: 21 (Oral iodine with other), 9 (Only other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.08(P=0.04)  
Favours oral iodine + other vitamins/minerals 1000.01 100.1 1 Favours other vitamins/minerals only
 
 
Comparison 5.   Any injected iodine supplement versus same supplement without iodine or no treatment/placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Perinatal mortality 1 399 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.42, 1.03]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2 Congenital anomalies 1 818 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.12, 0.60]
3 Neonatal goitre 1 456 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Child mental or motor development
(IQ points)
2 174 Mean Difference (IV, Random, 95%
CI)
11.21 [7.96, 14.46]
 
 
Analysis 5.1.   Comparison 5 Any injected iodine supplement versus same
supplement without iodine or no treatment/placebo, Outcome 1 Perinatal mortality.
Study or subgroup Any inject-
ed iodine
No inject-
ed iodine
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Thilly 1978 27/197 42/202 100% 0.66[0.42,1.03]
   
Total (95% CI) 197 202 100% 0.66[0.42,1.03]
Total events: 27 (Any injected iodine), 42 (No injected iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.85(P=0.06)  
Favours any injected iodine 1000.01 100.1 1 Favours no injected iodine
 
 
Analysis 5.2.   Comparison 5 Any injected iodine supplement versus same supplement
without iodine or no treatment/placebo, Outcome 2 Congenital anomalies.
Study or subgroup Any inject-
ed iodine
No inject-
ed iodine
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pharoah 1971 (C) 7/412 26/406 100% 0.27[0.12,0.6]
   
Total (95% CI) 412 406 100% 0.27[0.12,0.6]
Total events: 7 (Any injected iodine), 26 (No injected iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.16(P=0)  
Favours any injected iodine 1000.01 100.1 1 Favours no injected iodine
 
 
Analysis 5.3.   Comparison 5 Any injected iodine supplement versus same
supplement without iodine or no treatment/placebo, Outcome 3 Neonatal goitre.
Study or subgroup Any inject-
ed iodine
No inject-
ed iodine
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kevany 1969 0/254 0/202   Not estimable
   
Total (95% CI) 254 202 Not estimable
Favours any injected iodine 1000.01 100.1 1 Favours no injected iodine
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Study or subgroup Any inject-
ed iodine
No inject-
ed iodine
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 0 (Any injected iodine), 0 (No injected iodine)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours any injected iodine 1000.01 100.1 1 Favours no injected iodine
 
 
Analysis 5.4.   Comparison 5 Any injected iodine supplement versus same supplement without
iodine or no treatment/placebo, Outcome 4 Child mental or motor development (IQ points).
Study or subgroup Any injected iodine No injected iodine Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Kevany 1969 14 84.4 (15.3) 22 71.3 (15.5) 9.93% 13.1[2.8,23.4]
Thilly 1978 66 115 (7.9) 72 104 (12.3) 90.07% 11[7.58,14.42]
   
Total *** 80   94   100% 11.21[7.96,14.46]
Heterogeneity: Tau2=0; Chi2=0.14, df=1(P=0.7); I2=0%  
Test for overall effect: Z=6.77(P<0.0001)  
Favours any injected iodine 10050-100 -50 0 Favours no injected iodine
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Urinary iodine concentration Breast milk iodine con-
centration
Study Setting Interven-
tion tim-
ing
Intervention description Timing of as-
sessment
Iodine Control Iodine Control
Baseline Median: 37
μg/L, IQR:
22-77 (n =
119)
Median: 30 μg/L, IQR: 18-61 (n =
115)
   Bouhouch
2014 (C)
Southern
Morocco
Postpar-
tum
Iodine: single dose oral 400
mg, control: single dose
placebo
Postpartum: 9
months
Median: 58
μg/L, IQR:
34-135 (n
= 94)
Median: 39 μg/L, IQR 24-62 (n = 81) Median:
39.4 μg/
L, IQR:
23.5-66.7
(n = 94)
Median:
26.2 μg/
L, IQR:
17.7-42.7
(n = 81)
Baseline: be-
fore 12 weeks of
amenorrhoea
Median:
111 μg/
L, IQR:
28-399 (n
= 32)
Median: 103 μg/L, IQR: 14-355 (n =
54)
   
Pregnancy: 3rd
trimester
Median:
160.5 μg/
L, IQR:
18-358 (n
= 30)
Median: 76 μg/L, IQR: 16-303 (n =
46)
   
Bruck-
er-Davis
2013
Nice,
France
Pregnancy Iodine: daily dose 150 μg of
iodine, control: vitamin mix
but no iodine
Postpartum: 3
months
Median: 58
μg/L, IQR:
34-135 (n
= 18)
Median: 58 μg/L, IQR: 34-135 (n =
18)
   
Glinoer
1993
Brussels,
Belgium
Pregnancy Iodine: single dose 1 mL
iodized oil, control: multivita-
min injection no iodine
Neonatal: 3-6
days
Mean: 77
μg/L, SEM:
+/- 8 (n =
60)
Mean: 43 μg/L, SEM: +/- 4 (n = 60) Mean: 61
μg/L, SEM:
+/-10, (n =
60)
Mean: 29
μg/L, SEM:
+/-2, (n =
60)
Liesenkot-
ter 1996
Berlin,
Germany
Pregnancy Daily dose oral 300 µg KI, con-
trol: no intervention
Postpartum:
mean 11 days
Median:
104.5 μg/
dl, IQR: NR
(n = NR)
Median: In fig only (n = NR)    
Table 1.   Urinary iodine concentration and breast milk iodine concentration following prepregnancy, pregnancy or postpartum iodine
supplementation  (Continued)
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Neonatal: 5
days
Median:
8.3 μg/dl,
IQR: In fig
only (n =
NR)
Median: 6.5 μg/dl, IQR: In fig only
(n = NR)
   
Postpartum: 24
weeks (75 µg)
Median:
78 μg/L,
25th 75th
%: 50,126
(n = 18)
Median: 34 μg/L, 25th 75th %: 26,
57 (n = 21)
   Mulrine
2010
Dunedin,
New
Zealand
Postpar-
tum
Iodine: daily 75 or 150 µg/d
iodine, control: placebo
Postpartum: 24
weeks (150 µg)
Median:
84 μg/L,
25th-75th
%: 60,157
(n = 19)
Median: 34 μg/L, 25th 75th %:
26,57 (n = 21)
In figure
only
In figure
only
Iodine: daily oral 150 µg ele-
mental iodine and micronutri-
ent supplement, control: mi-
cronutrient supplement no
iodine
Pregnancy: 35
weeks
Median: 86
μg/24 h,
25th-75th
%: 66–147
(n = 22)
pregnancy
and post-
partum
Median: 88 μg/24 h, 25th 75th %:
68-123 (n = 24)
   
    Median: 83
μg/24 h,
25th 75th
%: 54–145
(n = 20)
pregnancy
only
     
Nohr 2000 Aalborg,
Denmark
Pregnan-
cy or preg-
nancy and
postpar-
tum
    Median: 50
μg/L, 25th
75th %:
35-101 (n
= 22) preg-
nancy and
postpar-
tum
Median: 51 μg/L, 25th 75th %: 30–
80 (n = 20)
   
Table 1.   Urinary iodine concentration and breast milk iodine concentration following prepregnancy, pregnancy or postpartum iodine
supplementation  (Continued)
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    Median: 52
μg/L, 25th
75th %:
36–81 (n =
20) preg-
nancy only
     
Pregnancy: 37
weeks
Median:
106 μg/L,
95 %: NR
(n = 28)
Median: 54 μg/L, 95 %: NR (n = 26)    
Postpartum: 12
months
Median: 56
μg/L, 95
%: NR (n =
NR)
Median: 54 μg/L, 95 %: NR (n = NR) Median: 41
μg/L, 95
%: 31-74
(n = 27)
Median: 28
μg/L, 95
%: 19-46
(n = 26)
Pedersen
1993
East Jut-
land, Den-
mark
Pregnancy Iodine: daily drops 200 μg io-
dine, control: no treatment
Neonatal: 5
days
Median: 64
μg/L, 95
%: 34-70
(n = 27)
Median: 27 μg/L, 95 %: 21-56 (n =
25)
   
Pregnancy:
15-40 weeks
Mean:
376 μg io-
dine/g cre-
atinine,
SD: 456 (n
= 36)
Mean: 56 μg iodine/g creatinine,
SD: 25 (n = 10)
   Silva 1981 Eastern
Greater
Santiago,
Chile
Pregnancy Iodine: daily drops approxi-
mately 300 µg iodine, control:
no intervention
Postpartum: at
delivery
Mean:
493 μg io-
dine/g cre-
atinine,
SD: 586 (n
= not spec-
ified)
Mean: 127 μg iodine/g creatinine,
SD: 94 (n = not specified)
   
Zhou 2015 Ade-
laide, New
Zealand
Pregnancy Iodine: daily tablet 150 μg io-
dine, control: placebo
Postpartum: 6
weeks
    Median
(IQR):
106.0
(84.0-146.0),
n = 19
Median
(IQR):
124.0
(76.0-155.0),
n = 22
Table 1.   Urinary iodine concentration and breast milk iodine concentration following prepregnancy, pregnancy or postpartum iodine
supplementation  (Continued)
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Pregnancy: 30
weeks
Median:
233.3 μg/
L, IQR:
140.0,
314.8 (n =
171)
Median: 154.6 μg/L, IQR: 107.9,
212.4 (n = 185)
   
Postpartum: 6
weeks
Median:
115.5 μg/
L, IQR:
73.0, 155.3
(n = 129)
Median: 93.6 μg/L, IQR: 60.3, 159.8
(n = 135)
   
Gowachi-
rapant
2014
Bangkok,
Thailand
Pregnancy Iodine: daily 200 µg iodine
and multivitamin-mineral
tablets, control: multivita-
min-mineral tablets with no
iodine
Neonatal: 6
weeks
Median:
168.7 μg/
L, IQR:
97.7, 305.7
(n = 83)
Median: 193.3 μg/L, IQR: 136.7,
303.5 (n = 76)
   
Table 1.   Urinary iodine concentration and breast milk iodine concentration following prepregnancy, pregnancy or postpartum iodine
supplementation  (Continued)
IQR: interquartile range
KI: potassium iodide
NR: not reported
SD: standard deviation
SEM: standard error of the mean
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Thyroid volume (mL)Study
Iodine No iodine
Brucker-Davis 20131 Median: 9.73, range: 5.4–15.5 (n = 30) Median: 10.13, range: 4.2–25.5 (n = 46)
Pedersen 19932 Median: 11.1 (n = 28) Median: 12.4 (n = 26)
Gowachirapant 20143 Median: 8.0, IQR: 7.0, 9.1 (n = 176) Median: 8.1, IQR: 7.1, 9.4 (n = 190)
Table 2.   Maternal thyroid volume - pregnancy  (Continued)
1Assessed in the 3rd trimester.
2Assessed at 37 weeks' gestation. Median estimated from figure. No estimate of range or distribution was provided. Total was not provided
so was assumed.
3Assessed at 30 weeks' gestation. Intention-to-treat analysis.
 
 
Thyroid volume (mL)Study
Iodine No iodine
Brucker-Davis 20131 Median: 8.5, range: 3.8–13.8 (n = 18) Median: 9.7, range: 6.6–18.9 (n = 18)
Liesenkotter 19962 Mean: 20.5, SD: 8.5 (n = 38) Mean: 20.0, SD: 10.5 (n = 70)
Pedersen 19933 Median: 10.2 (n = 25) Median: 10 (n = 24)
Gowachirapant 20144 Median: 7.3, IQR: 5.8, 9.0 (n = 129) Median: 7.2, IQR: 6.1, 8.4 (n = 135)
Table 3.   Maternal thyroid volume - postpartum  (Continued)
1Assessed at 3 months postpartum.
2Assessed by ultrasound on average at 11 days postpartum. Mean and SD extracted from figure.
3Assessed at 12 months postpartum. Median estimated from figure. No estimate of range or distribution was provided. Total was not
provided so was assumed.
4Assessed at 6 weeks postpartum.
 
 
Thyroglobulin (in µg/L)Study
Iodine No iodine
Brucker-Davis 20131 Median: 17.5, range: 2.5–56.2 (n = 30) Median: 19.6, range: 3.8–98.6 (n = 46)
Nohr 20002 Median: 14.1, IQR: 5.0, 21.5 (n = 42) Median: 19.4, IQR: 8.2, 33.5 (n = 24)
Pedersen 19933 Median: 9.2 (n = 28) Median: 16.7 (n = 26)
Gowachirapant
20144
Median: 9.78, IQR: 5.46, 18.10 (n = 176) Median 11.90, IQR: 6.35, 22.30 (n = 190)
Table 4.   Maternal thyroglobulin - pregnancy  (Continued)
1Assessed in the 3rd trimester.
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2Assessed at 35 weeks' gestation.
3Assessed at 37 weeks' gestation. Median estimated from figure. No estimate of range or distribution was provided. Total was not provided
so was assumed.
4Assessed at 30 weeks' gestation.
 
 
Thyroglobulin (in µg/L)Study
Iodine No iodine
Brucker-Davis 20131 Median: 11.5, range: 4.4–37 (n = 18) Median: 23.1, range: 3.0–45.5 (n = 18)
Liesenkotter 19962 Mean: 8.3, SD: 10.9 (n = 38) Mean: 13.5, SD: 19.3 (n = 70)
Pedersen 19933 Median: 4.7 (n = 24) Median: 10.3 (n = 24)
Gowachirapant 20144 Median: 7.94, IQR: 4.89, 15.30 (n = 129) Median: 9.51, IQR: 4.79, 15.90 (n = 135)
Table 5.   Maternal thyroglobulin - postpartum  (Continued)
1Assessed at 3 months postpartum.
2Assessed on average at 11 days postpartum.
3Assessed at 12 months postpartum. Median estimated from figure. No estimate of range or distribution was provided. Total was not
provided so was assumed.
4Assessed at 6 weeks postpartum.
 
 
Iodine ControlOutcome
Median IQR n Median IQR n
Habituation 7.0 (5.4, 8.3) 22 7.6 (6.8, 8.1) 18
Social-interactive 7.4 (6.4, 8.0) 66 6.9 (6.0, 8.1) 68
Motor system 6.0 (5.3, 6.6) 73 5.8 (5.2, 6.4) 72
State organization 3.8 (2.8, 4.0) 48 3.8 (3.0, 4.1) 53
State regulation 4.0 (3.3, 4.5) 38 4.0 (2.6, 4.7) 40
Autonomic system 6.7 (6.0, 7.3) 61 6.7 (5.3, 7.3) 71
Reflexes 3.0 (1.8, 4.0) 74 3.0 (2.0, 4.0) 75
Supplementary
items
6.7 (5.3, 8.3) 48 6.3 (5.1, 8.1) 55
Table 6.   Neonatal behavioural assessment scales scores assessed at 6 weeks postpartum (Zimmerman
2009)  (Continued)
IQR: interquartile range
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A P P E N D I C E S
Appendix 1. Search strategy and terms
Two review authors (JPR and KBH) searched the WHO International Clinical Trials Registry Platform (ICTRP) for unpublished, ongoing or
planned trials using the following terms (last search date: 17 November 2016): "iodine AND pregnancy", "iodine AND pregnant", "iodine
AND postnatal", "iodine AND postpartum", "iodine AND breastfeeding", "iodine and lactation"
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diAerent outcomes based on what was reported in the included studies, in order to avoid losing potentially important information. We
changed this outcome from: Any adverse eAect (for example iodine-induced hyperthyroidism) to:
• Adverse eAects* Elevated TPO-ab (as defined by trial authors)* Hyperthyroidism (as defined by trial authors)
We added subgroups for a given outcome only where there were at least four studies (previously we planned to do this if there were three
or more and to report subgroup analyses only if there were at least two studies per included subgroup category). We considered this
meaningful, otherwise we would be comparing single studies rather than characteristics of diAerent types of studies.
Methods/types of participants - we have clarified that the study participants were not restricted in terms of the iodine status of the study
population or setting.
Methods/measures of treatment eAect - in this section we have clarified how we handled data presented as medians.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Dietary Supplements  [adverse eAects];  Hyperthyroidism  [epidemiology];  Hypothyroidism  [epidemiology];  Infant, Newborn,
Diseases  [epidemiology];  Iodine  [*administration & dosage]  [adverse eAects]  [deficiency];  Perinatal Mortality;  Postpartum Period;
  Preconception Care  [*methods];  Pregnancy Complications  [epidemiology];  Premature Birth  [epidemiology];  Prenatal Care
 [*methods];  Randomized Controlled Trials as Topic;  Thyroid Hormones  [blood];  Thyrotropin  [blood]
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
Iodine supplementation for women during the preconception, pregnancy and postpartum period (Review)
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